Edited Book

Advanced Nanostructured Phytosome–Chitosan Hydrogels for Targeted Dermatological Therapy





Editors

Nicky Kumar Jaiswal

Anil Kumar Sah

Rimpy

Jannat ul Firdaus

Savneet Kaur

Mantra Publication

(An International Publication)

Book title

Advanced Nanostructured Phytosome–Chitosan Hydrogels for Targeted Dermatological Therapy

Editors Details

1. **Nicky Kumar Jaiswal**

   Founder and CEO at The Article Architecture and Assistant Professor, School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab 147301, drnickyjaiswalpharmd@gmail.com, https://orcid.org/0009-0001-4841-0960

2. **Anil Kumar Sah**

   School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab dranil108@zohomail.in

3. **Rimpy**

   PhD research scholar at Institute of Pharmaceutical Sciences, Kurukshetra University, Thanesar, Kurukshetra, Haryana, India, 136119, hoodarimpy@gmail.com

4. **Jannat ul Firdaus**

   Assistant Professor, School of Pharmacy, Sharda University, Plot No. 32,34, Knowledge Park-III, Greater Noida–201310, https://orcid.org/0000-0002-1520-5864

5. **Savneet Kaur**

   Associate Professor in the Department of Applied Sciences at Desh Bhagat University, Mandi Gobindgarh Email:-kailleysavneet@gmail.com, https://orcid.org/0009-0006-4331-5012

Mantra Publication

Published, marketed, and distributed by:
Mantra Publication
An International Publisher
www.mantrapublicationservices.com
editorbooks@mantrapublicationservices.com
Whatsapp: +91 9236371090

ISBN: 978-81-686599-8-8

E-ISBN: 978-81-686599-0-2

Citation:

Jaiswal, N. K., Sah, A. K., Rimpy, Firdaus, J. ul, & Kaur, S.(2026). Advanced Nanostructured Phytosome–Chitosan Hydrogels for Targeted Dermatological Therapy . Mantra Publication.

Acknowledgment

I would like to express my sincere gratitude to all those who contributed to the successful completion of this chapter in the book *Advanced Nanostructured Phytosome–Chitosan Hydrogels for Targeted Dermatological Therapy*. I am deeply thankful to the editors for providing me with this valuable opportunity and for their constant guidance, encouragement, and support throughout the entire process. Their expertise and vision have significantly contributed to shaping the quality and direction of this work. I extend my heartfelt appreciation to my mentors, colleagues, and academic peers whose valuable suggestions, insightful discussions, and constructive feedback greatly enhanced the scientific depth and clarity of this chapter. I would also like to acknowledge the contributions of numerous researchers and scholars whose published literature and pioneering work laid the foundation for this study and inspired its development.

I am sincerely grateful to my institution for providing the necessary academic resources, research facilities, and a conducive environment that enabled the successful completion of this work. Special thanks are also due to all contributors, collaborators, and supporting staff involved directly or indirectly in this project for their cooperation and assistance. Furthermore, I would like to acknowledge the continuous advancements in the field of pharmaceutical and nanotechnology research, which have provided a strong scientific base for this work.

Finally, I express my deepest gratitude to my family and friends for their unwavering support, patience, and encouragement during this journey. Their constant belief in me has been a source of strength and motivation. This work stands as a reflection of collective effort, continuous learning, and academic dedication, and I remain truly thankful to everyone who has supported me in this endeavor.

Editors-

- Nicky Kumar Jaiswal
- Anil Kumar Sah
- Rimpy
- Jannat ul Firdaus
- Savneet Kaur

Preface

The field of dermatological drug delivery has undergone remarkable transformation over the past few decades, driven by continuous advancements in pharmaceutical sciences, nanotechnology, and biomaterials. The growing prevalence of skin disorders, coupled with the limitations of conventional topical formulations, has necessitated the development of more efficient, targeted, and patient-friendly therapeutic approaches. This book, *Advanced Nanostructured Phytosome–Chitosan Hydrogels for Targeted Dermatological Therapy*, is an effort to present a comprehensive and updated overview of emerging strategies that combine natural bioactives with advanced nanotechnological systems to enhance drug delivery through the skin.

The integration of phytosomes and chitosan-based hydrogels represents a promising approach in modern dermatology, offering improved bioavailability, enhanced skin permeation, controlled drug release, and reduced systemic side effects. This book has been carefully structured to cover fundamental concepts, including skin anatomy, drug delivery routes, and conventional systems, followed by detailed discussions on novel carriers, nanostructured hydrogels, formulation strategies, and advanced evaluation techniques. It also highlights recent innovations, translational challenges, and future perspectives in the field of nano dermatology.

Each chapter has been contributed by experts and researchers with significant experience in their respective domains, ensuring scientific accuracy, depth, and practical relevance. The aim of this book is to serve as a valuable resource for students, researchers, academicians, and industry professionals seeking to understand and explore advanced dermatological drug delivery systems.

We hope that this work will inspire further research, innovation, and collaboration in the development of safe, effective, and sustainable therapies for various skin disorders, ultimately contributing to improved patient care and clinical outcome.

Editors-

- Nicky Kumar Jaiswal
- Anil Kumar Sah
- Rimpy
- Jannat ul Firdaus
- Savneet Kaur

Chapter 1: Introduction to Dermatological Drug Delivery Systems

Dr. Nicky Kumar Jaiswal*, Shivani Pannu[1], Dr. Priyanka Singh[2],Apurva[3]

*Founder, The Article Architecture, India, Email-dr.nickyjaiswalpharmd@gmail.com

[1]Assistant Professor, Gateway College of Pharmacy, Sonipat, Email-shenupnnu70@gmail.com Orcid id- (https://orcid.org/0000-0002-0929-7862

[2]Adesh Institute of Dental Sciences, Desh University, Bathinda, Punjab 151101, Email-priyankasingh1427@gmail.com

CSJMU, Kanpur University, Department of Dental Sciences, Kanpur, India Email-singhapurva445@gmail.com

Abstract

Dermatology drug delivery systems have come out as a critical and developing branch of the pharmaceutical sciences with both local and systemic treatment advantages through skin. The skin possesses a unique structure which becomes a major obstacle in the permeation of drugs, especially the stratum corneum which has been a cause of the design of enhanced delivery methods. The traditional preparations like creams, gels and ointments have been common but they are constrained due to low penetration and retention. The current developments in nanotechnology such as liposomes, nanoparticles, phytosomes, and chitosan-based hydrogel have made a lot of progress in terms of drug solubility, stability and targeted delivery. These systems can allow the controlled and sustained release of drugs, increase bioavailability, and reduce side effects on the system. The development of such new technologies as microneedles, stimuli-responsive systems, and bioengineered carriers additionally helps to improve the results of therapy. On the whole, the contemporary dermatological drug delivery systems offer innovative and patient-friendly methods of effective cure of different skin disorders and offer the perspective of future study and clinical use.

Keywords:

Transdermal systems, Nanotechnology, Phytosome, Skin permeation, Controlled release, Nanocarriers, Dermatological drug delivery.

1. Introduction

Dermatological drug delivery systems have become a crucial and quickly developing area in both pharmaceutical and biomedical research, which deals with the application of therapeutic agents onto or through the skin, to provide the effects that are local or systemic. The skin is the largest organ of the human body, and it is a highly accessible and patient-friendly route through which drugs are delivered, but it is a very complex organ that acts as an obstacle to drug delivery, especially to hydrophilic and high molecular weight drugs, due to its complex structure, especially the outer layer, stratum corneum. This notwithstanding, skin possesses several important benefits as a route of delivery system, which include non-invasive administration, no gastrointestinal degradation, no hepatic first-pass, sustained drug delivery, and enhanced patient compliance, making it an interesting alternative to oral and parenteral delivery. The latter has made dermatological drug delivery systems

more important than ever because of the increased incidence of skin-related diseases like psoriasis, eczema, acne, fungal infections, and skin cancers as well as the increased need to provide effective systemic treatments through transdermal delivery. Topical delivery systems are mainly formed to perform on local level in the skin layers, thus offering a localized therapy with low systemic exposure where transdermal drug delivery systems allow the drugs to penetrate deeper through the skin layers and provide a controlled and lasting therapeutic effect, decreasing the frequency of administration and enhancing bioavailability. Dermatological drug delivery has evolved at a very high rate over the years with the use of old-aged formulations like ointments, pastes and herbal preparations giving way to high- engineered and sophisticated systems. Traditional dosage types, such as creams, gels, and lotions, increased the stability of drugs and their acceptability by patients but were still limited in their penetration ability. The recent developments have brought new carrier-based platforms including liposomes, noisome, ethosomes, solid lipid nanoparticles, nano emulsions and polymeric nanoparticles which improves drug solubility, stability, and skin permeation in addition to providing targeted and controlled drug delivery. Additionally, new technologies (microneedles, hydrogels and stimuli-responsive systems) have transformed the sphere and provided better penetration, location-specific delivery and responsiveness to physiological situations. The use of these innovations is especially important in the creation of nanostructured systems such as Phyto some-chitosan hydrogels, which are biocompatible and have superior therapeutic efficacies. Generally, dermatological drug delivery systems have been changing their basic form of a simple topical application towards complex, multi-purpose systems based on the ongoing research to conquer the skin barrier barrier and maximize therapeutic effects of a localized and systemic treatment.

2. Anatomy and Physiology of Skin

The skin being a multifunctional organ, and the main line of defense of the body, and as a critical point of dermatological drug delivery, and the anatomy and physiology of the skin is decisive in determining the absorption and activity of the drugs. The epidermis, the dermis, and the hypodermis are the three main layers that constitute the structure of the skin, each with a specific contribution to the role of the skin in defense against infections and in transporting various drugs. The outermost layer is the epidermis, which is the most important in the provision of the barrier properties of the skin; the epidermis is composed of a number of sublayers i.e. stratum basale, stratum spinosum, stratum granulosum and the outermost layer, stratum corneum. The stratum corneum consists of dead, keratinized cells (corneocytes) that hold together in a lipid matrix to create a compact brick-and-mortar structure and prevent most exogenous substances, thus controlling water loss and the entry of substances. It is the layer of epidermis which is covered with a dense layer of fibrous tissue of collagen and elastin which gives the skin its mechanical strength and elasticity and contains blood vessels, lymphatics and nerve endings. The hypodermis or subcutaneous layer is primarily adipose tissue, an energy storage site, thermal resistant and shock absorbing and though plays a lesser part in barrier resistance; may affect the distribution and retention of lipophilic drugs. The stratum corneum is the primary controller of the barrier effect of the skin and is also a selective permeability barrier through which only some of the molecules can pass through the stratum corneum in consideration of their physicochemical properties such as size, polarity and lipophilicity.Three major routes of drug molecules into the skin, namely, intercellular (diffusion through lipid domains) and transcellular (direct penetration through corneocytes) and appendageal (hair follicles and sweat glands) routes are well exemplified in Figure 1: Structure of Skin and Drug Penetration Pathways: All three routes are illustrated and their contribution to transdermal transport are also provided. Along with these routes, other skin appendages such as hair follicles, sebaceous glands and sweat glands are also involved in augmenting the drug delivery by providing alternative routes to bypass the stratum corneum barrier to

a greater extent; hair follicles are more specifically involved in augmenting the drug delivery by providing alternative routes to bypass the stratum corneum barrier to a greater extent. Sebaceous glands increase the rate of lipophilic drugs transportation in sebum rich conditions and sweat glands contribute to low rates of drug transportation under physiological conditions. Overall, the success of such a dermatological drug delivery system will depend, in turn, on the multifaceted interaction of the structural organization of the layers that make up the skin, the protective action of the stratum corneum, and the availability of appendageal pathways, which, in turn, requires a full understanding of the anatomy and physiology of the skin in order to develop more sophisticated and specific therapeutic compositions.



Figure 1: Structure of Skin and Drug Penetration Pathways

3. Routes of Dermatological Drug Delivery

Dermatological drug delivery involves various routes that aim to provide localized or systemic therapeutic response using through the skin with each route having a unique benefit depending on the disease and drug characteristics. The most widely used method is topical drug delivery that is mostly aimed at local treatment in the layers of skin, which is very effective in psoriasis, eczema, acne, and fungus treatment. Under this technique, topical agents including creams, ointments, gels and lotions are applied to the skin surface whereby the drug can operate on the epidermis or dermis without extensive drug systemic absorption, which will decrease side effects and enhance patient safety. The topical delivery method is however commonly limited by the barrier effect of stratum corneum that limits drug penetration particularly in the case of hydrophilic compounds or those compounds with high molecular weight. Transdermal drug delivery systems (TDDS) by contrast are meant to deliver drugs into the systemic circulation across the skin providing a controlled and prolonged release. The route has a number of benefits, such as evading the first-pass metabolism, increasing the bioavailability, reducing dosing frequency and increasing the patient compliance, which makes it especially useful in chronic diseases, like hypertension, hormonal therapy, pain treatment. Transdermal systems are normally designed to use the high technology like patches, microneedles, iontophoresis and chemical penetration enhancers in order to penetrate the skin barrier and carry drug regularly. Together with topical and transdermal methods, specific dermal delivery systems have attracted considerable interest over the past several years, to the effect of specifically targeting drugs to specific skin layers or appendages, either to hair follicles or sebaceous glands, to increase

therapeutic effect, without increasing systemic exposure. Such systems typically use newer carriers, such as liposomes, niosomes, nanoparticles, and nanostructured hydrogels, which can enhance drug solubility, stability and penetration, and control and site-specific delivery. Local delivery is particularly helpful in the treatment of local skin disorders, wound healing, and cosmetic use, in which it is essential to have specific localization of drugs. In general, the choice of a suitable route of dermatological drug delivery is contingent to a number of variables, such as physicochemical characteristics of the drug, the required effect, and the condition of the skin, and in the current dermatological treatment, the effectiveness and diversity of the route of drug delivery are constantly improved through the rise in new formulation technologies.

4. Types of Dermatological Drug Delivery Systems

The main types of dermatological drug delivery systems are categorized as conventional, novel, and nano-based system based drug delivery systems wherein each system has its unique properties and therapeutic benefits regarding its application in clinical use and properties of the drug being applied. The traditional drug delivery is a decades-old approach that incorporates such dosage forms as ointments, creams, lotions, gels, and pastes, the main aim of which is the topical application of the drug to produce a local effect of therapy. Such systems are relatively cheap and simple to develop, but commonly have disadvantages including low skin penetration, reduced drug retention, and fluctuating drug release, as well. Table 1: Classification of Conventional Dermatological Drug Delivery Systems, summarizes the classification and the features of these traditional systems, their composition, positive and negative features of such systems and it is easy to see that they remain relevant even after the appearance of the technology. In order to address the shortfalls of the traditional systems, new drug delivery systems have been invented employing sophisticated formulation techniques to increase drug permeability, stability and therapeutic actions. Such systems are liposomes, niosomes, transferosomes, ethosomes and microemulsions, which are vesicular and carrier-based methods of enhancing drug delivery across the skin barrier.

Table 1: Classification of Conventional Dermatological Drug Delivery Systems

S.No.	Dosage Form	Composition	Characteristics	Advantages	Limitations
1	**Ointments**	Hydrocarbon bases (petrolatum, paraffin), oils	Greasy, occlusive, semi-solid	Excellent hydration, enhances drug penetration	Sticky, poor patient compliance, difficult to wash
2	**Creams**	Emulsion systems (oil-in-water or water-in-oil)	Smooth, non-greasy, easily spreadable	Good patient acceptability, suitable for moist lesions	Less occlusive, may require preservatives
3	**Lotions**	Liquid emulsions with low viscosity	Fluid, easy to apply on large areas	Suitable for hairy areas, cooling effect	Low retention time, frequent application required

4	**Gels**	Water-based systems with gelling agents (carbopol, cellulose derivatives)	Transparent, non-greasy, fast drying	High patient compliance, easy application	Limited drug loading for hydrophobic drugs
5	**Pastes**	High solid content (zinc oxide, starch) in ointment base	Thick, stiff, protective layer	Protective barrier, good for exudative lesions	Difficult to spread, less aesthetic appeal
6	**Transdermal Patches (Conventional)**	Polymer matrix, drug reservoir, adhesive layer	Controlled drug release through skin	Sustained release, improved bioavailability	Skin irritation, limited drug types suitable
7	**Dusting Powders**	Finely divided powders (talc, starch)	Dry, absorbent, free-flowing	Reduces moisture, prevents friction	Poor adhesion, limited drug delivery capability

The novel systems are especially beneficial in improving the targeting of drugs, lowering the number of dosages per patient, and enhancing patient adherence through controlled and prolonged drugs release. Over the past few years the nano-based drug delivery systems have become a revolutionary approach in the field of dermatology, taking advantage of the nanotechnology to develop a better drug delivery system. These systems are nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, nano emulsions, dendrimers, and nanohydrogels, which in them provide a greater surface area, higher drug solubility, and deeper skin penetration. Nano-based systems particularly achieve targeted delivery of drugs or molecules to distinct skin layers or appendages thereby reducing systemic exposure that is fundamental in the treatment of chronic skin diseases and in cosmetic products. Moreover, the incorporation of bio-compatible polymers and natural products into nano-based technology, including phytosome-chitosan hydrogels has added an even greater potential in combining therapeutic efficacy with the safety, and sustainability of phytosome-chitosan hydrogels. In general, the development of traditional through innovative and nano-based dermatological drug delivery systems is a process of constant struggle to surmount the natural obstacle properties of the skin and to enhance the delivery of drugs to better clinical results.

5. Factors Affecting Drug Permeation Through Skin

The process of drugs permeating through the skin is a complex process that is dependent on a number of convergent factors that can be classified into two categories of factors which include: physicochemical properties of the drug, biological properties of the skin and environmental and formulation factors. Physicochemical properties of a drug are important in determining its ability to penetrate stratum corneum which is the most significant barrier to transdermal transport; optimal drug candidates to penetrate the skin should be moderately lipophilic, with low molecular weight (usually

less than 500 Da), and balanced aqueous-lipid solubility. Very hydrophilic or lipophilic drugs are those that are poorly permeable since they do not readily partition between the lipid-rich stratum corneum and the underlying layers of aqueous solution. Also, the concentration of drugs, their ionic state, as well as partition coefficient are other factors that greatly contribute to the rates of diffusion across the skin. Other biological factors of the skin also contribute significantly to drug permeability since the skin thickness, water content, lipid profile, and the integrity of stratum corneum might change and ultimately result in changes in permeability. An example is that, a broken or ill skin, such as one in eczema or psoriasis, can be more permeable whereas the more resistant areas of the skin, e.g. the palms and the soles are thicker. Skin characteristics are also dependent on age, gender and location of the anatomy that impacts on the drug absorption pattern. In addition, the skin appendages, hair follicles and the sweat gland might also be utilized as alternative routes of drug delivery particularly when one is handling nanoparticle systems. The environmental and formulation factors are also critical in controlling the drug permeation; the exterior conditions of temperature and humidity could have influence on the skin hydration and consequently, permeability. The increasing temperatures are more likely to increase the diffusion rates and the high humidity will more likely moisturize the stratum corneum so as to easily deliver the drugs. Formulation-related factors, including type of dosage form, penetration enhancers, pH, viscosity and drug releasing properties, play a crucial role in optimization of delivery. Advanced formulations have been specifically developed such as gels, emulsions and nanocarriers which are formulations that ought to increase the solubility of drugs, their stability, and the penetration efficacy. All these physicochemical, biological and environmental factors are taken together to ensure that dermatological drug delivery systems is effective and thus, should be put into perspective in designing effective and targeted therapeutic formulative.

6. Advantages and Limitations of Dermatological Drug Delivery

Dermatological drug delivery system has a lot of benefits that render the system an alluring alternative to the traditional routes of drug delivery like oral and parenteral administration whereas, it has some constraints and challenges that need to be overcome in order to achieve the best therapeutic results. Among the main benefits is the non-invasiveness of drug administration, which contributes to the increased compliance of the patients and does away with the pain of injections. Also, such systems avoid gastrointestinal breakdown and hepatic first-pass excretion thus, enhancing drug bioavailability and decreasing systemic side effects. Topical administration provides local therapy with high drug level in the action area with minimal systemic delivery, which is especially useful with skin diseases like psoriasis, eczema, and infections. Transdermal systems also offer regulated and continuous drug delivery, which lessens the number of times a drug is taken, as well as the consistency of the plasma drug levels. Moreover, dermatological preparations are typically easily applicable and can be developed to treat and cosmetically apply, this makes dermatological preparations more versatile. Nonetheless, in spite of these benefits, there are a number of constraints and difficulties. The main barrier is the stratum corneum which limits the penetration of most of the drugs, particularly those with high molecule weight or undesirable physicochemical characteristics. Patient acceptability can be affected by skin irritation, allergic reactions and sensitization caused by some formulations or excipients. Further, the difference in skin permeability associated with various age, hydration, anatomical site, and disease condition may result in irregular drug absorption. Poor drug loading capacity and challenges of delivery of hydrophilic or large biomolecules are also a major challenge. Moreover, the implementation of sophisticated dermatological systems also implies complicated formulation strategy and increased expenses. Altogether, even though dermatological drug delivery

systems have considerable therapeutic advantages, it is one of the priorities of current research and development to eliminate the limitations these systems have.

7. Emerging Trends in Dermatological Drug Delivery

New trends in the delivery of dermatological drugs are swiftly changing the sphere as they introduce the advanced technologies and innovative practices to eliminate the drawbacks of the traditional system and improve the therapeutic effects. Most of them nanotechnology-based systems have become very eminent because of their capacity to enhance the solubility of the drugs, stability, and skin permeation. Liposomes, niosomes, solid lipid nanoparticles, nanostructured lipid carriers, and nano emulsions are nanocarriers which offer greater surface area and allow the targeting of a specific layer or appendage of the skin, as well as increasing drug bioavailability and decreasing systemic side effects. These have found special use in management of chronic skin diseases and also in the release of drugs in controlled and sustained manner. In the meantime, non-toxic, biocompatible delivery systems are gaining momentum, in which therapeutic application of bioactives of plant origin (flavonoids, alkaloids, polyphenols) is used. When incorporated into the sophisticated carriers like phytosome and nanohydrogels, it enhances the stability, bioavailability and skin permeation of these phytoconstituents and therefore makes them highly suitable in dermatological and cosmeceutical applications. Furthermore, intelligent and sensitive drug delivery systems are a new-generation innovation in this field that is capable of responding to some physiological or environmental conditions, such as pH, temperature, enzymes, or light, to enable the delivery of drugs to the target site in a controlled and selective way. Such systems use stimuli-responsive hydrogels, microneedle and bioengineered polymer arrays capable of varying their sensitivity to dynamic skin states and improve precision of therapy. These novel technologies are also being incorporated as evident in Figure 2: Emerging Advanced Drug Delivery Systems in Dermatology, which demonstrates how conventional preparations have been substituted with multifunctional, targeted, and intelligent delivery systems. All these changes are revolutionizing dermatological therapy because the provision of drugs becomes more efficient, patient compliance is increased, and the outcome of the treatment is improved. The continued research in the field of nanotechnology, natural product-based delivery and responsive materials will probably give an expanded spectrum on the dermatological drug delivery, resulting in personalized and precision medicine delivery in the treatment of skin related diseases.



Figure 2: Emerging Advanced Drug Delivery Systems in Dermatology

8. Applications in Dermatology

The therapeutic agents to the skin have been implemented with precision and effect, therefore, making possible a broad array of clinical and cosmetic applications due to the ability to deliver the drug to the skin. Such systems can be used when treating inflammatory skin diseases such as psoriasis, eczema, acne and dermatitis, in which case the drug is concentrated at the site of inflammation and as a result, the disease is minimized, inflammation is reduced, irritation is reduced and microbial load is reduced, as well as the systemic exposure of the drug and its side effects are minimized. The enhanced formulations that include the nano-carrier and the controlled-release systems contribute to the penetration and retention of drugs further leading to better therapeutic effects and adherence to treatment by the patient. Dermatological delivery systems are instrumental regarding skin regeneration, wound healing since they aid in the timing of tissue regeneration, and in restoration of skin integrity. The systems which ensure the healing process occurs are hydrogel, nanofibrous scaffolds, and bioactive dressings as they ensure that the necessary humidity is maintained, oxygen permeability is increased, and the regular release of antimicrobial agents, growth factors, and bioactive compounds occurs. The methods are particularly effective in the management of chronic wounds, burns and diabetic ulcers as a result of which the traditional types of treatment do not appear effective. Outside therapeutic uses, the dermatological drug delivery systems are widely applied in cosmetic and cosmeceutical preparations to enhance the look and action of the skin. The recent delivery technologies have helped in the enhancement of penetration and stability of active ingredients like antioxidants, vitamins and herbal extracts, thus benefiting the skin brightening, pigmentation disorders, anti-aging and anti-aging applications. The carrier systems of liposomes, nano emulsions, phytosomes, etc. ensure further penetration of the products into the skin, and prolonged activity, and increase the products efficacy. Table 2: Applications of Dermatological Drug Delivery

Systems with focus on the versatility and growing importance of such systems is tabulated methodically with respect to the applications and advantages of the various systems in therapeutic and cosmetic fields. All these uses substantiate the growing sphere of the dermatological drug delivery systems in the modern healthcare and skincare industries with the constant innovation and demand of the effective and targeted treatment approaches.

Table 2: Applications of Dermatological Drug Delivery Systems

S.No.	Application Area	Condition/Use	Drug/Active Agents	Delivery Systems Used	Therapeutic Outcome
1	**Inflammatory Skin Disorders**	Psoriasis, Eczema, Dermatitis	Corticosteroids, NSAIDs, Immunomodulators	Creams, Gels, Liposomes, Nanoparticles	Reduced inflammation, itching, and redness
2	**Acne and Skin Infections**	Acne vulgaris, Bacterial & Fungal infections	Antibiotics, Antifungals, Retinoids	Gels, Nanoemulsions, Niosomes	Improved drug penetration, reduced microbial load
3	**Wound Healing**	Burns, Cuts, Ulcers	Antimicrobials, Growth factors, Herbal extracts	Hydrogels, Nanofibers, Bioactive dressings	Faster healing, reduced infection risk
4	**Skin Regeneration**	Tissue repair, Chronic wounds	Stem cells, Peptides, Biomolecules	Hydrogels, Scaffolds, Nanocarriers	Enhanced tissue regeneration and repair
5	**Transdermal Therapy**	Pain, Hormonal therapy, Cardiovascular diseases	Analgesics, Hormones, Antihypertensives	Transdermal patches, Microneedles	Sustained drug release, improved bioavailability
6	**Cosmetic Applications**	Anti-aging, Skin whitening, Anti-wrinkle	Vitamins (A, C, E), Antioxidants	Liposomes, Nanoemulsions, Creams	Improved skin texture and appearance
7	**Sun Protection**	UV protection, Photodamage prevention	Sunscreens, UV filters	Creams, Lotions, Nanocarriers	Protection against UV radiation
8	**Hyperpigmentation Treatment**	Melasma, Dark spots	Hydroquinone, Kojic acid, Herbal	Gels, Nanoformulation	Reduced pigmentation

			extracts	s	and even skin tone

9. Regulatory and Safety Issues.

The use of dermatological drug delivery systems and its quality, efficacy and safety are new issues of concern that involve regulatory and safety concerns in the development and approval of dermatological drug delivery systems. The regulations that are attracted by the different authorities such as the US FDA, EMA and other global authorities have provided a systematic platform on the evaluation of the topical and transdermal formulations such as formulation stability, manufacturing practices, labeling and clinical performance. These suggestions highlight the need to ensure that drug delivery systems are strictly characterized, especially when using developed drug carriers such as nanoparticles and hydrogels, in which complexity can influence safety profiles. An essential part of this is safety and toxicity assessment which requires in vitro and in vivo tests to assess skin irritation, sensitization, cytotoxicity and possible systemic exposure. Patch testing, dermal toxicity testing and permeation testing are some of the tests that are widely used to evaluate how formulations react to the skin. Moreover, biocompatible and non-toxic excipients should be used to reduce the adverse reactions and provide the long-term safety. The focus is placed especially on the nano-based systems because they are small and have higher penetration capacity, which can be perceived as a point of concern in terms of accumulation and toxicity. Altogether, compliance with regulatory requirements and a thorough safety assessment form the key to successful construction and commercialization of dermatological drug delivery systems.

10. Conclusion

The field of dermatological drug delivery systems has experienced massive developments whereby the traditional topical-based formulations have been upgraded into the highly advanced and targeted drug delivery systems. The peculiarities of the skin structure and barrier character are the challenge and the opportunity of a successful drug delivery, and the ongoing innovation in the sphere of formulation design and delivery serves as the motivation. The recent technologies, such as nanotechnology-based carriers, herbal and phytochemical delivery systems, and smart responsive materials have significantly improved drug penetration, stability, and therapeutic efficacy with minimum side effects on the organism. Such systems have proven to be widely applicable in treating inflammatory skin disorders and wound healing, transdermal therapy and cosmetic uses, in which they have shown versatility in either clinical or commercial use. Although these innovations were made, variability in permeability of the skin, toxicity of a new carrier and regulatory complications are some of the issues that are still being studied. The prospective trends will be oriented at the individualized and accuracy-based dermatological treatments, which will combine the advanced material, biotechnology, and digital health-related technologies to enhance treatment results. On the whole, the dermatological drug delivery systems are a dynamic and promising sphere that will continue to contribute to the modern healthcare to provide innovative methods of safe, effective and patient friendly treatment of a broad spectrum of skin diseases.

References

1. Barry, B. W. (2001). Novel mechanisms and devices to enable successful transdermal drug delivery. *European Journal of Pharmaceutical Sciences, 14*(2), 101–114.

2. Benson, H. A. E. (2005). Transdermal drug delivery: Penetration enhancement techniques. *Current Drug Delivery, 2*(1), 23–33.

3. Brown, M. B., Martin, G. P., Jones, S. A., &Akomeah, F. K. (2006). Dermal and transdermal drug delivery systems: Current and future prospects. *Drug Delivery, 13*(3), 175–187.

4. Prausnitz, M. R., & Langer, R. (2008). Transdermal drug delivery. *Nature Biotechnology, 26*(11), 1261–1268.

5. Kalia, Y. N., Guy, R. H., &Prausnitz, M. R. (2004). Mechanisms of transdermal drug delivery. *Advanced Drug Delivery Reviews, 56*(5), 619–658.

6. Williams, A. C., & Barry, B. W. (2012). Penetration enhancers. *Advanced Drug Delivery Reviews, 64*(Suppl), 128–137.

7. Hadgraft, J. (2001). Skin, the final frontier. *International Journal of Pharmaceutics, 224*(1–2), 1–18.

8. Honeywell-Nguyen, P. L., &Bouwstra, J. A. (2005). Vesicles as a tool for transdermal and dermal delivery. *Drug Discovery Today: Technologies, 2*(1), 67–74.

9. Verma, D. D., Fahr, A., Syed, M. A., & Pathak, K. (2003). Liposomes as drug carriers for the transdermal delivery of drugs. *Drug Development and Industrial Pharmacy, 29*(7), 743–758.

10. Cevc, G., & Blume, G. (2001). New, highly efficient formulation of diclofenac for the topical, transdermal administration. *Biochimica et Biophysica Acta, 1514*(2), 191–205.

11. Patel, R. P., Patel, G., & Baria, A. H. (2009). Formulation and evaluation of transdermal patch of aceclofenac. *International Journal of Drug Delivery, 1*(1), 41–51.

12. Paudel, K. S., Milewski, M., Swadley, C. L., et al. (2010). Challenges and opportunities in dermal/transdermal delivery. *Therapeutic Delivery, 1*(1), 109–131.

13. Dragicevic, N., & Maibach, H. I. (Eds.). (2015). *Percutaneous penetration enhancers chemical methods in penetration enhancement*. Springer.

14. Elsayed, M. M., Abdallah, O. Y., Naggar, V. F., & Khalafallah, N. M. (2007). Lipid vesicles for skin delivery of drugs. *International Journal of Pharmaceutics, 332*(1–2), 1–16.

15. Mehta, R. C., & Chawla, J. S. (2004). Nanoparticles in drug delivery. *Pharmaceutical Technology, 28*(3), 44–54.

16. Souto, E. B., & Müller, R. H. (2008). Lipid nanoparticles: Effect on bioavailability and pharmacokinetic changes. *Handbook of Experimental Pharmacology, 197*, 115–141.

17. Müller, R. H., Radtke, M., & Wissing, S. A. (2002). Nanostructured lipid matrices for improved microencapsulation. *International Journal of Pharmaceutics, 242*(1–2), 121–128.

18. Baspinar, Y., Üstündağ Okur, N., Karasulu, H. Y., &Karasulu, E. (2019). Herbal bioactives in skin care. *Pharmaceutical Development and Technology, 24*(8), 1046–1057.

19. Goyal, R., Macri, L. K., Kaplan, H. M., & Kohn, J. (2016). Nanoparticles and nanofibers for topical drug delivery. *Journal of Controlled Release, 240*, 77–92.

20. Boateng, J. S., Matthews, K. H., Stevens, H. N. E., & Eccleston, G. M. (2008). Wound healing dressings and drug delivery systems. *Journal of Pharmaceutical Sciences, 97*(8), 2892–2923.

21. Ahmed, T. A., Aljaeid, B. M., & Jabbari, E. (2016). Chitosan-based hydrogels for drug delivery. *Carbohydrate Polymers, 146*, 25–39.

22. Peppas, N. A., & Khare, A. R. (1993). Preparation, structure, and diffusional behavior of hydrogels. *Advanced Drug Delivery Reviews, 11*(1–2), 1–35.

23. Patel, S., & Shah, V. (2017). Nanocarrier-based drug delivery systems for skin applications. *Journal of Drug Delivery Science and Technology, 41*, 67–75.

24. Gupta, P., Vermani, K., & Garg, S. (2002). Hydrogels: From controlled release to pH-responsive delivery. *Drug Discovery Today, 7*(10), 569–579.

25. Bouwstra, J. A., Honeywell-Nguyen, P. L., Gooris, G. S., &Ponec, M. (2003). Structure of the skin barrier and its modulation. *International Journal of Pharmaceutics, 259*(1–2), 1–13.

26. Mbah, C. J., Builders, P. F., &Attama, A. A. (2014). Nanotechnology-based topical drug delivery systems. *Journal of Pharmaceutical Investigation, 44*(3), 205–219.

27. Singh, R., & Lillard, J. W. (2009). Nanoparticle-based targeted drug delivery. *Experimental and Molecular Pathology, 86*(3), 215–223.

28. Lademann, J., Richter, H., Teichmann, A., et al. (2007). Nanoparticles—An efficient carrier for drug delivery into the hair follicles. *European Journal of Pharmaceutics and Biopharmaceutics, 66*(2), 159–164.

29. Rai, M., Ingle, A. P., Birla, S., Yadav, A., & Santos, C. A. (2016). Strategic role of selected noble metal nanoparticles in medicine. *Critical Reviews in Microbiology, 42*(5), 696–719.

30. Vyas, S. P., & Khar, R. K. (2012). *Targeted and controlled drug delivery: Novel carrier systems*. CBS Publishers.

Chapter 2: Pathophysiology of Inflammatory Skin Disorders

***Dr Nagarjuna D, [1]Dr RS Meghasri, [2]Dr Shivaraj DR, [3]Dr Savanthi Chitrahasini**

Assistant Professor, Akshaya Institute of Pharmacy, Tumkur, Karnataka, India, Emil-damarlanagarjuna83@gmail.com

Assistant Professor, Akshaya Institute of Pharmacy, Tumkur, Karnataka, India, Emil-meghasri229@gmail.com

Assistant Professor, Akshaya Institute of Pharmacy, Tumkur, Karnataka, India, Emil-Shivaraj.dr27@gmail.com

Assistant Professor, TVM College of Pharmacy, Ballari, Karnataka, India, Email: chitrahasini2138@gmail.com

Abstract:

The inflammatory skin disorders are a heterogeneous group of immune-mediated diseases that can be marked by the appearance of redness, itching, swelling, and chronic inflammation, and that have a great impact on the quality of life of patients. Complicated interplay of genetic predisposition, environmental factors, immune malregulation and microbial imbalance cause these conditions, which include but are not limited to psoriasis, atopic dermatitis, acnes and contact dermatitis. The skin is a dynamic immune apparatus where coordination of the immune responses occurs via the keratinocytes, immune cells and cytokine networks. Oxidative stress, signal pathways (NF- -KB, MAPK, JAK-STAT), and the pro-inflammatory cytokines play significant roles in the disease progression. Additionally, the intensity of the disease is based on the microbiome of the skin and other external factors like pollution, diet and lifestyle. The creation of the diagnostic instruments and the particular treatment, including the biologic and small-molecule inhibitors, helped to manage the disease. The mechanisms play an important role in the development of personalized and effective therapeutic approaches towards the management of inflammatory skin disorders.

Keywords: Dermatologic inflammations, Cytokines, Immune response, Oxidative stress, Skin microbiome, Psoriasis, Atopic dermatitis, Targeted therapy.

1. Introduction

Inflammatory skin disorders are a heterogeneous cohort of diseases, which is classified by immune-mediated inflammation of the skin, which produces symptoms of redness, itching, swelling, scaling, and discomfort and is known to be very susceptible to both physical well-being and quality of life. These diseases are caused by complicated interplay of genetic factors predisposition, environmental factors, and maladjusted immune mechanisms leading to inflammation of the skin in chronic or repeated system. Typical examples are psoriasis, atopic dermatitis (eczema), acne vulgaris, and contact dermatitis, which have diverse pathophysiological pathways but all have shared inflammatory pathways. The skin is an active immune organ; it is important in the process of bringing forth and regulating immune responses, and there are several types of cells involved in the process of immune responses that include the keratinocytes, Langerhans cells, dendritic cells, and T lymphocytes, all of which contribute to the onset and progression of these disorders. Inflammatory skin diseases represent

a significant issue in terms of global public health, with millions of people around the world having the disease and millions more being affected by it. Diseases such as atopic dermatitis and psoriasis are extremely common at all ages, with rising prevalence being seen in both developed and developing nations, and partially because of urbanization, pollution, and changing lifestyles. Besides imposing physical suffering, they cause serious psychological and social impact as they cause stress and anxiety, as well as depression and low self-esteem, which makes them clinically important. Moreover, cardiovascular diseases, metabolic syndrome, and immune-related disorders are comorbidities that have regularly been linked to chronic inflammatory skin conditions and thus should be managed effectively and early on. Inflammatory skin diseases may be classified widely depending on the etiology, presentation, and immune pathophysiology. Amongst the common classifications are immune-mediated diseases like psoriasis and atopic dermatitis that involve impairment of T-cell responses and cytokine signalling pathways; infectious or microbial related diseases like acnes vulgaris that involve bacterial colonisation and immune activation; and allergic or contact related diseases like dermatitis, which is caused by exposure to irritant or allergens that provoke hypersensitivity. Also, these disorders can be classified as acute or chronic, local and systemic and mild to severe depending on the clinical features and course of disease. Further development of molecular biology and immunology has further narrowed down the classification by defining the specific cytokine profiles and signaling pathways including Th1, Th2, and Th17-mediated responses, which are important in disease pathogenesis. Overall, inflammatory skin disorders represent a complicated group of illnesses with both clinical and social implications that need a thorough investigation of the pathophysiology, worldwide burden, and codes of classification to come up with an effective treatment strategy and improve the patient outcome.

2. Skin Immune System and Inflammation

Skin is an active immunological organ which plays an important role in the innate and adaptive immune responses; it is the first line of defense against the pathogens and also it is involved in the inflammatory mechanisms in various skin diseases. The innate immune system of the skin is rapid and non specific and involves not only physical obstacles, which involve stratum corneum, but also cellular components that involve keratinocytes, macrophages, dendritic cells and neutrophils. Keratinocytes are not mere structural cell, they are also actively engaged in immune response through secretion of antimicrobial peptide, cytokines and chemokine to injury or infection, hence induce inflammation and bring the immune cells to the location of insult. Furthermore, microbial remnants are detected through pattern recognition receptors such as toll-like receptors (TLRs) which trigger intracellular signaling pathways that amplify the action of inflammation. The adaptive immune response on the contrary is highly specific and it involves activation of the T and B lymphocytes which recognize specific antigens and generate a specified immune response. It has been known that T helper (Th) cells and more specifically, Th1, Th2 and Th17 cells play a significant role in mediating inflammatory skin conditions through the secretion of cytokines such as interferon- 7, interleukins (IL-4, IL-6, IL-17), and tumor necrosis factor- alpha (TNF- 7) known to mediate the communication and inflammation in the immune cells. Cytokine network dysregulation has been implicated in several chronic inflammatory diseases such as psoriasis and atopic dermatitis. The interaction between these two forms of immunity forms a web of signal transduction that sustains and continues inflammation in the skin. As shown in Figure 1: Skin Immune Response and Inflammatory Pathways, the interactions between various cell types and cytokines are also needed to maintain the immune surveillance and the response to external stimulus, thus, any disruption in the relationship between the two may result in the appearance of the state of excessive or prolonged inflammation. Overall, the joint action of

keratinocytes, immune cells, and cytokine networks is important to skin homeostasis and the information above can be useful to develop specific interventions to the inflammatory skin disease.



Figure 1: Skin Immune Response and Inflammatory Pathways

3. Molecular Mechanisms of Inflammation

The molecular processes of skin inflammation are complicated interplay of pro-inflammatory cytokines, oxidative stress and intracellular signaling pathways, which interact to ultimately regulate both the pathogenesis and progression of the inflammatory responses. Proinflammatory cytokines and mediators play a central role in the coordination of immune responses in the skin, and some of the key molecules, tumor necrosis factor-alpha (TNF- 6) interleukins (IL-17, IL-23, IL-6, IL-17), and interferon- gamma (IFN- 6) play a role in the interaction of immune cells, including T lymphocytes, macrophages, and neutrophils. These cytokines help in increasing the intensity of inflammation by increasing the proliferation and differentiation of cells and the secretion of more inflammatory mediators. The essentials of each of these cytokines to the pathogenesis of the disease are summarized in Table 1: Key Cytokines and Molecular Mediators in Skin Inflammation: Table 1 is an introduction to the importance of each of these cytokines to the pathogenesis of the disease. In addition to cytokine activity an oxidative stress is also a major determinant in inflammatory skin disease and is the consequence of the imbalance between the production of the reactive oxygen species (ROS) and the antioxidant protection mechanisms of the skin. ROS are radicals of superoxide, hydrogen peroxide and hydroxyl radical that can cause damage to cellular components, such as lipids, proteins and DNA, leading to cell dysfunction and the initiation of other inflammatory pathways. Oxidative stress has not only increased tissue damages; it has heightened the production of cytokines in a vicious cycle that continues to fuel chronic inflammation. In addition, the presence of intracellular signal transduction signals such as nuclear factor kappa B (NF- 00B), mitogen-activated protein kinase (MAPK) and Janus kinase signal transducer and activator of transcription (JAK-STAT) signals play a critical role in regulating the genes of inflammation. NF-kB leads to the transcription of a number of pro-inflammatory genes in its activation and NF-kB and MAPK pathways in cell responses to stress and cytokines. JAK-STAT pathway is a major player particularly in the signaling of cytokines and

differentiation of immune cells. They are normally associated with long-term inflammatory disease of the skin such as psoriasis and atopic dermatitis. Overall, one can speak about cytokines, oxidative stress, and signaling pathways as a highly coordinated network that regulates the inflammatory response in the skin and are the goals of therapeutic intervention.

Table 1: Key Cytokines and Molecular Mediators in Skin Inflammation

S.No.	Mediator	Function	Associated Disorders
1	TNF-α	Promotes inflammation	Psoriasis
2	IL-1β	Initiates immune response	Acne, Psoriasis
3	IL-6	Enhances inflammation	Chronic skin disorders
4	IL-17	Recruits neutrophils	Psoriasis
5	IL-23	Maintains inflammation	Psoriasis
6	IFN-γ	Activates immune cells	Vitiligo
7	ROS	Causes oxidative stress	Acne, Aging
8	Histamine	Induces itching	Allergic dermatitis

4. Pathophysiology of Major Inflammatory Skin Disorders

Interaction between immune dysregulation, genetic background, exposure to environmental factors and microbial factors leading to chronic inflammation and impaired skin homeostasis complicates the pathophysiology of significant inflammatory skin diseases. Psoriasis is a persistent immune-mediated illness, which is characterized by excessive growth of keratinocytes and aberrant differentiation, this is mainly caused by the activation of the immune pathways of Th1 and Th17 cells. The central role in enhancing the inflammatory process is played by such cytokines as TNF-a, IL-17 and IL-23 that lead to thick scaly plaques and erythema. In contrast, atopic dermatitis (eczema) is more likely to be associated with Th2-mediated immunity, which is the presence of cytokines (e.g., IL-4, IL-5 and IL-13) and the inability of skin barriers to act properly, which is caused by structural protein defects, e.g., filaggrin. This leads to increased transepidermal water loss, allergic and irrepressible itch and inflammation. Acne vulgaris is a multifactorial disease and is characterized by additional factors, which include overproduction of sebum, hyperkeratinization of the follicles, colonization by Cutibacterium acnes and inflammatory reactions. The expression of natural immune pathways, and release of pro-inflammatory mediators, are involved in the pathogenesis of comedones, papules, and pustules. In its turn, contact dermatitis is caused by irritants or allergens, and can be further classified as irritant or allergic. Direct destruction of the skin barrier causes irritant contact dermatitis and allergic contact dermatitis is a T cell-mediated delayed hypersensitivity reaction to antigens following exposure. Under all these circumstances, all of the factors are bringing together the immune cells, cytokines and the environment to torment normal skin functionality and keep the inflammation going. Figure 2: Pathophysiological Mechanisms of Major Skin Disorders demonstrates that each of the disorders has certain and overlapping molecular and cellular pathways, which have a role in the development and progression of the disease. These mechanisms need to be understood to develop specific therapies that can be used to control the immune responses and reinstatement of skin barrier, which in turn would help patients with inflammatory skin diseases have better clinical outcomes.



Figure 2: Pathophysiological Mechanisms of Major Inflammatory Skin Disorders

5. Role of Microbiome in Skin Inflammation

Skin microbiome is a significant component of skin homeostasis and inflammatory system regulation, and its balance and composition are also central in the pathogenesis of inflammatory skin diseases. The skin microbiota is a heterogeneous assembly of microorganisms such as bacteria, fungi, viruses, mites, among others which live on various regions of the skin depending on various factors like moisture, sebum secretion, and environmental exposure. The Staphylococcus, Cutibacterium, and Corynebacterium common bacteria are known to aid in maintaining a healthy balance in the microbial ecosystem by preventing the colonization of harmful organisms and aiding in immune functions. Nevertheless, the development and course of several inflammatory skin diseases are strongly linked to dysbiosis or an imbalance of the normal microbial balance. As an example, Staphylococcus aureus overgrowth is typical in atopic dermatitis, which causes inflammation due to the production of toxins and immune activation, whereas Cutibacterium acnes contributes to acne by promoting the action of inflammatory responses in hair follicles. The causes of dysbiosis may include antibiotic use, environmental variation, disruption of skin pH and barrier function, which is associated with a high predisposition to infection and inflammation. Host-microbiome interactions are very dynamic and entail complicated signaling pathways, which control immune tolerance and defense. Interaction of skin-resident microbes and keratinocytes and immune cells occurs via pattern recognition receptors and affects the synthesis of cytokines, antimicrobial peptides, and inflammatory mediators. Such interactions between the host and the microbe are important in the maintenance of immune homeostasis but when impaired may cause over stimulation of immune response and chronic inflammation. Also, the microbiome may affect the effectiveness of dermatological treatment due to the impact on drug metabolism and permeability of the skin. Recent studies show promise in microbiome-specific therapy (including probiotics, prebiotics, and microbial transplantation) in the restoration of microbial balance and the treatment of inflammatory skin diseases. On the whole, the microbiome of the skin is one of the crucial points of the pathophysiology of skin inflammation, and a

more comprehensive understanding of its structure, dysregulation, and interplay with the host immune system is necessary to create new therapeutic options.

6. Genetic and Environmental Factors

A complex combination of genetic predisposition and environmental factors promotes the development and progression of inflammatory skin disorders and determines the level of individual predisposition and the severity of the disease. Genetic predisposition is the cornerstone in the identification of risk of other diseases like psoriasis, atopic dermatitis, and acne, and there are several genes that control immune response, skin barrier, and inflammatory signaling pathways. As an illustration, structural protein genes, that encode filaggrin, are strongly linked with dysfunctional skin barrier in atopic dermatitis, which results in elevated transepidermal water loss and penetration of allergens. Similarly the genetic variation in the production of cytokines and immune responses including Th1, Th2 and Th17 also contribute to the chronic state of inflammation in psoriasis and other skin diseases. Nevertheless, the genetic determinants are not enough to cause a disease, and the environmental stimuli play an important role in inducing and promoting the inflammatory reactions. The skin homeostasis and the immune pathways can be disrupted by factors like air pollution, exposure to allergens, ultraviolet (UV) radiation, microbial infections as well as climate conditions. Irritants and pollutants have the potential to cause oxidative stress and inflammation, whereas allergens can cause hypersensitivity reactions, which result in such conditions as contact dermatitis. The influence of the UV radiation is twofold, as it enhances and suppresses immune reactions with the amount of its exposure. Lifestyle and dietary factors play an important role in influencing the skin health and inflammatory processes besides the genetic and environmental factors. Having more inflammation and worsening of diseases like acne and psoriasis has been linked to high carbohydrates content of processed foods, high glycemic index and unhealthy fats, although, high contents of antioxidants, vitamins and omega-3 fatty acids have been linked with protective effects in the diet. Unhealthy lifestyle choices such as stress, poor sleep, smoking and poor hygiene can also contribute towards aggravation of inflammatory responses by altering immune response and skin barrier integrity. The combination of these genetic and environmental factors is summarized in Table 2: Genetic and Environmental Risk Factors in Inflammatory Skin Disorders which attracts the attention to the key factors that led to the emergence and progression of the disease. Overall, the combination of the personal genetic factor and the modifiable environmental and lifestyle factors demonstrates the multifactorial nature of inflammatory skin diseases and the importance of applying the individual approach to the prevention and treatment intervention development.

Table 2: Genetic and Environmental Risk Factors in Inflammatory Skin Disorders

S.No.	Factor Type	Specific Factors	Impact on Skin Disorders
1	**Genetic Factors**	Filaggrin mutation, Cytokine gene variations	Impaired barrier, chronic inflammation
2	**Environmental Factors**	Pollution, UV radiation, Allergens	Oxidative stress, immune activation
3	**Microbial Factors**	*S. aureus*, *C. acnes*	Infection, inflammation aggravation
4	**Lifestyle Factors**	Stress, Smoking, Sleep disorders	Immune imbalance, flare-ups

5	**Dietary Factors**	High glycemic diet, Low antioxidants	Increased inflammation, acne severity

7. Clinical Manifestations and Diagnosis

The clinical presentation of inflammatory skin disorders is different in relation to the type of illness but in general, it is characterized by the appearance of multiple lesions, a feeling of pain, and a functional disability of the skin. It is commonly associated with erythema (redness), pruritus (itching), edema (swelling), scaling, dryness and in others, burning or painful sensations. The nature of the lesions in various disorders varies; an example is psoriasis which occurs through thick, very scaly, and well-defined, silvery plaques whereas atopic dermatitis occurs with poorly defined, erythematous, and highly itchy white patches that are usually related to dry and sensitive skin. The acnes vulgaris is characterized by existence of comedones, papules and pustules and in some cases nodules mainly in sebaceous gland areas such as face and upper trunk. Contact dermatitis on the other hand can be either localized reddening, vesicles, or blistering due to irritant or allergenic agents. These conditions can only be accurately diagnosed by a combination of a clinical assessment, history, and in some instances laboratory tests. Visual examination and dermatoscopy are done by dermatologists to determine morphology and patterns of distribution of the lesions and patch testing is practiced to determine the allergen in suspected contact dermatitis. This is because skin biopsy and histopathological analysis can be used in complicated or atypical cases to ascertain diagnosis and distinguish between similar cases. The mechanisms of diseases can be explained as well through the identification of some biomarkers, such as elevated levels of cytokines (e.g. IL-17 in psoriasis, IgE in atopic dermatitis) and they can be used to guide a specific therapy. The molecular diagnostics has also improved to enhance disease-specific markers of the detection and response to treatment prediction. Severity assessment scales are essential in the determination of the disease progression and the choice of treatment used, the most frequently used scales are; Psoriasis Area and Severity Index (PASI), Eczema Area and Severity Index (EASI), and Global Acnes Grading System (GAGS). These measures provide normative values regarding the degree of the lesion, its size, and the impact it makes on the well-being of life and through them, clinical workers can observe the success of the treatment and adjust therapeutic strategies on that. Overall, the adequate treatment of inflammatory skin diseases should be a complex process that would entail clinical observation, diagnostic tests, and severity assessment.

8. Therapeutic Beginnings and Prospects.

The progress in the study of the molecular and immunological pathways of inflammatory skin diseases has resulted in the discovery of new therapeutic targets and creating more specific treatment patterns. An immune process and cytokine attacks have found their way into modern dermatological therapy especially in chronic diseases, e.g., psoriasis and atopic dermatitis.A. Above all, significant cytokines such as TNF-a, IL-17, IL-23 and IL-4/IL-13 have been soundly established as cause of inflammation and treatment to inhibit these compounds have been proven to be very effective in clinical practice. These specific therapies have the capacity to reduce inflammation and normalise the functions and homeostasis of the keratinocytes and the skin including the regulation of specific immunological responses such as the Th1, Th2 and Th17 responses. New biological therapies include monoclonal antibodies and fusion protein, which have brought about a revolution in the treatment of inflammatory skin diseases since they are highly specific and more effective than the traditional one. Biologics, which inhibit IL-17 or IL-23 pathways have shown impressive results in reducing the severity of the disease and improving the quality of life of the patients, yet, long-term safety, cost, and availability remain to be a problem. Intracellular signaling pathway inhibitors that are small molecule inhibitors have also been of interest as biologics to regulate immune responses at a molecular scale. In

the future, the application of the techniques of personalized medicine in dermatology is likely to be a transformative development of the field by tailoring the treatment to the genetic, molecular and clinical profile of a particular patient. Recent advances in genomics, discoveries of biomarkers, and artificial intelligence are making it possible to predict disease progress and treatment response with much greater accuracy and assist clinician to select the most effective, least informative treatment option in each patient. Overall, the application of targeted therapies, biologics and personalized medicine is a promising future of the management of inflammatory skin disorder to offer a superior therapeutic effect and shift to a more precise and personalized treatment.

9. Conclusion

The inflammatory skin disorders are a complex and multidimensional group of the diseases significantly affecting the quality of life and health of the affected patients, and its mechanisms should be completely comprehended so as to be able to manage it effectively. These conditions develop in a complicated interaction of a genetic predisposition, environmental factors, immune imbalances and microbial influence in which they preserve inflammation. The progress of research in dermatology has given us useful knowledge about the role of cytokines, oxidative stress, and signaling pathways in the development of diseases, which allows the creation of specific and innovative treatment methods. The development of drug delivery systems especially the introduction of nanotechnology and biologically active compounds has increased the effectiveness and accuracy of treatment methods even more. There has also been the growth in the supply of more accurate diagnostic processes and severity assessment tools that have enhanced the early detection, accurate categorization and enhanced follow up of the disease progression. Despite the developments, the problem of inconsistent patient response, potential existence of undesirable drug activities, the need to employ cost-effective treatment procedures are problematic areas of concern. Possibly, it will be possible that the future investigation will focus on uniting personalized medicine, the application of sophisticated biomaterials and digital health technologies to simplify the effects of treatment and improve patient care. Overall, it is relevant that the scientific breakthrough should be complemented with clinical experience to be able to cope with the growing burden of inflammatory skin disorders and to come up with safe, effective, and sustainable treatments.

References

1. Nestle, F. O., Kaplan, D. H., & Barker, J. (2009). Psoriasis. *New England Journal of Medicine, 361*(5), 496–509.
2. Lowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. (2014). Immunology of psoriasis. *Annual Review of Immunology, 32*, 227–255.
3. Guttman-Yassky, E., Nograles, K. E., & Krueger, J. G. (2011). Contrasting pathogenesis of atopic dermatitis and psoriasis. *Journal of Allergy and Clinical Immunology, 127*(5), 1110–1118.
4. Bieber, T. (2008). Atopic dermatitis. *New England Journal of Medicine, 358*(14), 1483–1494.
5. Weidinger, S., & Novak, N. (2016). Atopic dermatitis. *Lancet, 387*(10023), 1109–1122.
6. Kupper, T. S., &Fuhlbrigge, R. C. (2004). Immune surveillance in the skin. *Nature Reviews Immunology, 4*(3), 211–222.
7. Pasparakis, M., Haase, I., & Nestle, F. O. (2014). Mechanisms regulating skin immunity. *Nature Reviews Immunology, 14*(5), 289–301.
8. Sabat, R., Wolk, K., Loyal, L., Döcke, W. D., &Ghoreschi, K. (2019). T cell pathogenesis of psoriasis. *Nature Reviews Immunology, 19*(12), 701–712.
9. Di Meglio, P., Villanova, F., & Nestle, F. O. (2014). Psoriasis. *Cold Spring Harbor Perspectives in Medicine, 4*(8), a015354.

10. Kim, J., & Krueger, J. G. (2015). The immunopathogenesis of psoriasis. *Dermatologic Clinics, 33*(1), 13–23.
11. Akdis, C. A., &Akdis, M. (2011). Mechanisms of immune tolerance. *Journal of Allergy and Clinical Immunology, 127*(4), 1023–1031.
12. Brandt, E. B., &Sivaprasad, U. (2011). Th2 cytokines in allergic disease. *Journal of Clinical Immunology, 31*(4), 450–457.
13. Eyerich, K., Dimartino, V., & Cavani, A. (2015). IL-17 and IL-22 in skin inflammation. *European Journal of Immunology, 45*(6), 1555–1565.
14. Grice, E. A., & Segre, J. A. (2011). Skin microbiome. *Nature Reviews Microbiology, 9*(4), 244–253.
15. Byrd, A. L., Belkaid, Y., & Segre, J. A. (2018). Human skin microbiome. *Nature Reviews Microbiology, 16*(3), 143–155.
16. Sanford, J. A., & Gallo, R. L. (2013). Functions of the skin microbiota. *Seminars in Immunology, 25*(5), 370–377.
17. Belkaid, Y., & Segre, J. A. (2014). Skin microbiome and immune regulation. *Science, 346*(6212), 954–959.
18. Nestle, F. O., Di Meglio, P., Qin, J. Z., & Nickoloff, B. J. (2009). Skin immune responses. *Nature Reviews Immunology, 9*(10), 679–691.
19. Krueger, J. G., & Bowcock, A. (2005). Psoriasis pathophysiology. *Nature Reviews Immunology, 5*(9), 699–711.
20. Papp, K. A., Langley, R. G., Lebwohl, M., et al. (2008). Efficacy of biologics in psoriasis. *Lancet, 371*(9625), 1675–1684.
21. Blauvelt, A. (2018). IL-23/IL-17 axis in psoriasis. *Journal of Investigative Dermatology, 138*(1), 13–16.
22. Ghoreschi, K., Balato, A., Enerbäck, C., & Sabat, R. (2021). Therapeutics targeting IL-23 and IL-17. *Immunity, 54*(3), 489–501.
23. Tan, J. K. L., & Bhate, K. (2015). Acne pathophysiology. *British Journal of Dermatology, 172*(Suppl 1), 3–12.
24. Langan, S. M., Irvine, A. D., & Weidinger, S. (2020). Atopic dermatitis. *Lancet, 396*(10247), 345–360.
25. Kong, H. H., & Segre, J. A. (2012). Skin microbiome in dermatology. *Journal of Investigative Dermatology, 132*(3), 933–939.
26. Dainichi, T., Hanakawa, S., Kabashima, K. (2014). Role of immune regulation in skin diseases. *Journal of Dermatological Science, 76*(3), 179–185.
27. Armstrong, A. W., & Read, C. (2020). Pathophysiology and treatment of psoriasis. *JAMA, 323*(19), 1945–1960.

Chapter 3: Herbal Bioactives in Dermatological Therapy

Kabhi Khanna*, Mohammed Shaik Fahad[2]

*Adesh Institute of Pharmacy and Biomedical Sciences Bathinda Punjab.

[2]Department of Pharmacology, Rajiv Gandhi University of Health Sciences (RGUHS)E-mail - msfahad1310@gmail.comOrcid- https://orcid.org/0009-0004-5094-4197

Abstract

The reason why Herbal Bioactives are of great interest in dermatological therapy is their natural origin, therapeutic efficacy, and good safety profile. These natural products, which are alkaloids, flavonoids, terpenoids and polyphenols, have different pharmacological properties like anti-inflammatory, antioxidant, antimicrobial and healing properties of wounds, and can thus be used in the management of different skin conditions. The idea of using herbs as a form of medicine is not new to traditional systems of medicine and the current scientific discoveries have reaffirmed their medicinal value. Herbal Bioactives are important in the therapy of such conditions as psoriasis, acne, atopic dermatitis, and wounds through the modulation of inflammatory pathways, oxidative stress reduction and tissue regeneration. Innovations in the formulation methods and especially the use of nanotechnology in delivery systems, like phytosomes, liposomes and nanogels have increased their stability, bioavailability, and penetration into the skin. Herbal Bioactives are a prospective and sustainable, patient friendly therapeutic method in modern dermatological practice although there are issues concerning standardization and clinical validation.

Keywords:

Herbal Bioactives, Dermatological therapy, Phytochemicals, Nanotechnology, Skin disorders, Antioxidant, Anti-inflammatory, Drug delivery

1. Introduction

The therapeutic potential, safety profile and traditional medicine experience of herbal bioactives have all made it a very popular product in dermatological therapy. Herbal medicine, used in dermatology, is comprised of plant-based compounds, including: alkaloids, flavonoids, terpenoids, polyphenols, which are applied in treating various skin diseases, such as inflammation, infections, pigmentation disorders, and wound healing. These natural products have diverse pharmacological effects including anti-inflammatory, antioxidant, antimicrobial and immunomodulatory effects and therefore are very ideal to be applied on the skin. Relative to synthetic drugs, in general, herbal bioactives have been linked to fewer side effects, as well as enhanced patient acceptability and this has been contributing to their growing use in the development of modern dermatological preparations and cosmeceuticals. The utilization of herbal products in skin care is a tradition, which has a history of thousands of years and has been integrated in the traditional medicine systems, including Ayurveda, Traditional Chinese medicine, and Unani. Use of the plant extracts such as neem (Azadirachtaindica), turmeric (Curcuma longa), aloe vera (Aloe barbadensis), and teas tree oil (Melaleuca alternifolia) in treating a skin ailment are documented in ancient texts and practices. The modern herbal dermatological products were based on empirical knowledge and natural resources as the basis of these folk remedies to treat wounds, infections and inflammatory diseases. However, over time most of these traditional claims and active phytoconstituents that led to their therapeutic effect have been confirmed by scientific innovations. It has also been augmented with the proliferation of the necessity to have safer,

environmental friendly and sustainable treatment methods. The herbal bioactives do not simply treat the symptoms of diseases but also contribute to the process of tissue regeneration by enhancing the barrier properties, reducing the oxidative stress, and facilitating the process of tissue regeneration. They are also commonly utilized in cosmetic preparations as anti-aging agents, skin lightening agents and as environmental harmful protection agents. However, there are still unresolved concerns of a lack of clinical standardization, variability of plants, and stability issues. The limitations notwithstanding, the current studies and the use of sophisticated delivery mechanisms including phytosomes, nanocarriers, and hydrogels are greatly enhancing the efficacy and bioavailability of herbal substances. Overall, the field of herbal bioactives is a prospective opportunity in the dermatological care, a synthesis of traditional wisdom with the modern science and modern technology in order to present a solution to a wide range of skin diseases in an efficient and patient friendly manner.

2. Classification of Herbal Bioactives

All these factors have made it a very popular product in dermatological therapy due to its therapeutic potential, safety profile and experience in traditional medicine. In dermatology, plant-based compounds such as alkaloids, flavonoids, terpenoids and polyphenols are contained in herbal medicine that is used in the treatment of several skin diseases, such as inflammation, infections, pigmentation disorders and wound healing. These natural products have varied pharmacological effects, such as anti-inflammatory, antioxidant, antimicrobial, and immunomodulatory effects, hence they are very ideal to be applied on the skin. Relative to synthetic drugs, herbal bioactives have generally been associated with fewer side effects and greater patient acceptability, and this has been prompting their increasing utilization in the modern day as a component of the modern dermatological preparation and cosmeceuticals. Use of herbal products in skin care practice is a practice that has a thousand-year old history and is entrenched within traditional medicine systems such as Ayurveda, Traditional Chinese Medicine and Unani. The application of the use of plant extracts such as neem(Azadirachtaindica), turmeric (Curcuma longa), aloe vera (Aloe barbadensis), and teas tree oil (Melaleuca alternifolia) in treating skin ailments are recorded in ancient texts and practices. The modern herbal dermatological products were founded on the empirical knowledge and natural resources of the folk remedies that form the basis of the treatment of wounds, infections and inflammatory diseases. Scientific innovations have however over time confirmed most of these traditional assertions and active phytoconstituents that caused their therapeutic action are isolated and characterized. Natural bioactives have also been shown to have relevance in the skin therapy by the escalation in the need to possess safer, environmental friendly and sustainable approaches of treatment. The herbal bioactives do not just have the ability to treat the symptoms of the diseases, but also enhance the health of the skin, enhancing the barrier capabilities, reducing oxidative stress, and promoting the process of tissue regeneration. In addition, they are widely used in cosmetic preparations as anti-aging agents, skin brighteners, and environmental damaging protection agents. Still, there is concern over a lack of clinical standardization, variability of plants and stability issues. The limitations notwithstanding, the current studies and the use of sophisticated delivery mechanisms including phytosomes, nanocarriers, and hydrogels are greatly enhancing the efficacy and bioavailability of herbal substances. In sum, herbal bioactives are an emerging and promising field in the dermatological treatment, a collage of traditional knowledge with the new science and contemporary technology to offer effective and patient friendly remedies to a myriad of skin ailments.

Table 1: Classification and Sources of Herbal Bioactive Used in Dermatology

S.No.	Class of Bioactives	Major Compounds	Plant Sources	Dermatological Activity
1	**Alkaloids**	Berberine, Vincristine	*Berberis*, *Catharanthus roseus*	Anti-inflammatory, Antimicrobial
2	**Flavonoids**	Quercetin, Catechins	*Camellia sinensis*, *Ginkgo biloba*	Antioxidant, Anti-inflammatory
3	**Terpenoids & Essential Oils**	Menthol, Limonene, Tea tree oil	*Mentha*, *Melaleuca alternifolia*	Antimicrobial, Wound healing
4	**Polyphenols**	Resveratrol, Catechins	Grapes, Green tea	Antioxidant, Anti-aging
5	**Tannins**	Gallic acid, Ellagic acid	*Terminalia*, Pomegranate	Astringent, Protective

3. Mechanisms of Action of Herbal Bioactives

Various interrelated processes in which the herbal bioactives have their therapeutic effects manifested as anti-inflammatory, antioxidant, antimicrobial and wound healing effects are involved in the process of restoring the skin health and functionality. Anti-inflammatory activity is one of the main mechanisms of action because bioactive compounds, including flavonoids, alkaloids, and terpenoids, regulate the main inflammatory processes by inhibiting the synthesis of pro-inflammatory cytokines, including TNF-alpha, IL-1 beta, and IL-6, and also reduce signaling cascades, like NF- kB and MAPK. This leads to the decrease of inflammation, erythema and tissue damage in various conditions like psoriasis, eczema and acne. Besides having anti-inflammatory properties, herbal bioactives are also highly antioxidant, and this is vital in safeguarding the skin against oxidative stress because of the reactive oxygen species (ROS). Polyphenols, tannins, flavonoids serve as free radical scavengers, which neutralize ROS and cannot cause damage to cellular components (lipid, proteins, and DNA) and minimize the role of inflammation in damaging the skin, slowing the aging process. Moreover, the presence of antimicrobial properties of herbal compounds also plays an important role in their dermatological effect of inhibiting the growth of pathogenic microorganisms, such as bacteria, fungi, and viruses, which can be the cause of skin infections and inflammatory diseases. Antimicrobial activity Antimicrobial activity of essential oils and plant extracts has been noted to be broad-spectrum but useful in the control of infections and to prevent the development of diseases. As far as wound healing is concerned, the herbal bioactives induce tissue regeneration by increasing collagen synthesis and promoting the proliferation of cells as well as the process of angiogenesis that hastens the process of repairing damaged skin. The compounds also assist to keep the wound environment moist and prevent secondary infections which further assist in the healing process. The combination of all these mechanisms is shown in Figure 1: Mechanisms of Action of Herbal Bioactives in Skin Disorders that shows how various bioactive compounds interact with cellular and molecular pathways to produce therapeutic effects. In general, herbal bioactives are very effective in treating various skin issues due to their multifunctional nature, and this provides an integrated approach to skin care treatment.



Figure 1: Mechanisms of Action of Herbal Bioactives in Skin Disorders

4. Herbal Bioactives in Major Skin Disorders

Herbal bioactives have been found to possess a great therapeutic potential in the treatment of major skin disorders owing to their multi-pharmacological effects such as anti-inflammatory, antioxidant, antimicrobial and regenerative effects. Other natural substances like curcumin (Curcuma longa), aloe (Aloe barbadense), and indigo naturalis have been found to be effective in the management of psoriasis, especially in the scaling and erythema of the skin by suppressing the pro-inflammatory cytokine production of TNF- α and IL-17. Chamomile (Matricaria chamomilla), licoricey (Glycyrrhiza glabra), and coconut oil, which have soothing, anti-inflammatory, and barrier-repairing effects, would be beneficial in the case of atopic dermatitis to lower itch, scale, and hypersensitivity reactions. Herbal agents with good antimicrobial properties as well as sebum-controlling properties are effective in the treatment of acne and other skin infections; tea tree oil (Melaleuca alternifolia), neem (Azadirachta indica), and green tea (Camellia sinensis) are also commonly studied to treat epidermal acne, swelling, and excessive oil secretion. Herbal bioactives per aloe vera, calendula (Calendula officinalis), and honey help in tissue repair and enhancing the process of collagen synthesis, epithelialization, and avoidance of microbial contamination of tissue in wound healing and skin repair, leading to improved healing in skin cuts and burns and chronic wounds. Natural compounds have the ability to not only address the underlying pathophysiological processes, but also are able to address the health of the skin in general with very few side effects. Table 2: Herbal Bioactives and their Therapeutic Applications in Skin disorders in Table 2: Summarization of the various therapeutic roles, major sources of herbs and how they can be used in different skin disorders reflects their relevance as effective and safer alternatives or even complementary to the conventional dermatological treatment methods. Altogether, the application of herbal bioactives to contemporary dermatological practices is still increasing because of the scientific evidence and the necessity to use natural and sustainable treatment methods.

Table 2: Herbal Bioactives and Their Therapeutic Applications in Skin Disorders

S.No.	Skin	Herbal Bioactive /	Key Activity	Therapeutic Effect

	Disorder	Source		
1	**Psoriasis**	Curcumin (*Curcuma longa*), Aloe vera	Anti-inflammatory, Immunomodulatory	Reduces scaling and inflammation
2	**Atopic Dermatitis**	Chamomile, Licorice, Coconut oil	Anti-inflammatory, Barrier repair	Reduces itching and dryness
3	**Acne & Infections**	Tea tree oil, Neem, Green tea	Antimicrobial, Sebum regulation	Controls bacteria and acne lesions
4	**Wound Healing**	Aloe vera, Calendula, Honey	Regenerative, Antimicrobial	Promotes healing and tissue repair

5. Formulation Approaches for Herbal Dermatological Systems

The development of the herbal dermatological system formulation methods has been developed to improve the stability, bioavailability and therapeutic efficacy of plant-derived bioactives when used in the skin. The use of conventional herbal formulations has been very rampant as it is easy, economical and it is not hard to prepare, the herbal formulation can be used in various forms like ointments, creams, gels, pastes, and herbal oils. Although they are mainly intended to be used topically, they are excellent in the delivery of bioactives to the deepest layers of the skin and benefit by moisturizing, relaxing, and the topical process of treating inflammation and infections locally. Nevertheless, the traditional systems are mostly limited by poor skin penetration, low stability of active compounds, and the inconsistency in the drug release, which may decrease the overall effectiveness of the system. To address these problems, superior delivery models have been designed, where modern pharmaceutical technologies are used to enhance the functionality of herbal bioactives. Phytosomes, liposomes, niosomes and nanogels are designed systems that are specifically used to increase the solubility, stability and permeability of plant-derived compounds. An example of this is called phytosomes which enhance the bioavailability of phytoconstituents through complexation with phospholipids, which enhances easier absorption by the skin. Bioactives are to be carried by vesicles that are liposomes and other vesicles and are encased by lipid bilayers that protect the bioactives and allow their release under control. Nanogels and nano emulsions also increase drug delivery by offering a high surface area, better penetration, and prolonged release characteristics, which makes them far more effective to target the deeper layers of the skin. These altered systems have a particular application in treatment of chronic skin diseases, in which a better delivery and longer action on the treatment is required. The transition to the advanced formulation methods may be illustrated in Figure 2: Herbal-Based Drug Delivery Systems for Skin Therapy, in which various delivery platforms and their mode of action are described to increase the rate of skin penetration and treatment. Overall, modern formulation technology coupled with the traditional understanding of herbs has provided the new prospects in the sphere of dermatological therapy that some more efficient, more stable,



and patient friendly herbs products could be developed in a wide range of skin diseases.

6. Safety, Toxicity, and Regulatory Aspects

The concerns of safety, toxicity, and regulations are the main issues regarding the development and use of herbal bioactives in dermatological treatment to make sure that these natural products are efficient and safe to use by the human population. The safety of herbal compounds is critically evaluated as a part of the systematic assessment carried by in vivo and in vitro studies to establish her capacity in causing skin irritation, sensitization, phototoxicity and allergic reactions. Though the herbal products are thought to be naturally safe, some of the plant-derived compounds can be harmful based on the levels of concentration, formulation, and sensitivity in a given patient. Hence, test procedures that are standardized like patch tests, dermal toxicity tests and biocompatibility tests are necessary to determine their safety profile prior to their clinical use. The identification of potentially dangerous constituents, contamination with heavy metals, pesticides or microorganisms, and the possibility of interaction with other drugs are all toxicological issues. In addition to this, the accumulative toxicity or unforeseen side effects of the long or excessive use of certain herbal compounds can also be observed and that is why controlled dosing and standard of the formulations should be considered. Regulatory policies play a great role in defining the quality, safety and effectiveness of herbal dermatological products. Several regulatory bodies like the World Health Organization (WHO), US Food and Drug Administration (FDA), and European Medicines Agency (EMA) have come up with guidelines on the evaluation, manufacture, labelling and marketing of the herbal products. These standards place emphasis on Good Manufacturing Practices (GMP), good labelling of sources of the plant, standardization and evidence-based justification of therapeutic claims. Most places classify herbal products differently compared to standard drugs and this may result in a difference in the regulatory requirements and approval procedure. However, there is also a tendency to devote more focus to the idea of control and scientific validation that would ensure the safety of consumers and their trust in the product. In totality, the successful development and acceptance of herbal dermatological treatments should be done in a holistic manner wherein stringent safety consideration, rigorous toxicological analysis and regulatory adherence are put into consideration.

7. Challenges and Limitations

Various challenges and limitations that can influence the effectiveness, safety, and common clinical usage are associated with the development and use of herbal bioactives in dermatological treatment. Stability and standardization is one of the main issues because most of the herbal compounds are relatively delicate to the environmental conditions including light, temperature, oxygen, and pH and are subject to degradation and decreased therapeutic effect with time. Since the active constituents and concentration of the actives may vary depending on the source plant, conditions during harvesting, and methods applied in the extraction process, it is hard to guarantee uniform quality and concentration of active constituents in herbal preparations. The non-standardization may cause variation in the performance of the product, as well as, lower reproducibility of the results. Moreover, there is a great difficulty in variability of bioactive compounds because chemical composition of herbal extracts may vary according to geographic location, soil conditions, climate, and methods of processing. This variability complicates the process of developing standard dosing, predictability of therapeutic effect, and even lot to lot consistency which is the main concern in pharmaceutical development in the contemporary world. Moreover, there is a limited clinical testing of herbal dermatological products with most of such formulations not being supported by solid scientific research through well-constructed clinical studies. Although the use is traditional and preliminary

research has furnished supportive evidence, large scale, randomized and controlled clinical trials are required to establish the efficacy, safety and long term effects. Scientific evidence is also important in the approval of regulatory acceptance and thus clinical validation is crucial in product approval and acceptance in the market. On the whole, it is very important to overcome these issues by use of better standardization method, better formulation methods and through better clinical research methods to ensure that the therapeutic potential of herbal bioactives in dermatology is achieved fully.

8. Future Perspectives and Innovations

The advancement of modern technologies, new ways of formulations, and individualized treatment are becoming the further trends of herbal dermatological treatment which can make the plant-based therapeutic means more effective and accurate. One of the most promising developments is the use of nanotechnology in delivery of herbal drugs whereby nanocarriers, such as phytosomes, liposomes, solid lipid nanoparticles and nanogels, are used in enhancing the solubility, stability, and skin penetration of herbal bioactives. These nanoscale systems allow delivery of active compounds to specific strata of the skin in a controlled and directed form thus improving the effect of the therapeutic process and reducing the side effects of the system. The principle of synergistic herbal formulations has also come into the limelight along with nanotechnology meaning the combination of multiple bioactive substances or plant extracts to achieve the higher therapeutic effect through the complementary mechanism of action. Personal equilibrium of pharmacological peculiarities of these ingredients may contribute to the effectiveness, reduce required dosages, and reduce potential side effects. The method is especially useful in the treatment of complicated skin diseases in which there are multiple pathological pathways. In addition, individualized herbal dermatology is a novel paradigm that is geared towards the personalization of treatment pattern in terms of genetic make-up of an individual, type of skin, microbiome composition, and specific disease features. The degree of advancement in genomics, biomarker profiling, and digital health technologies is allowing the development of custom herbal formulas to optimize therapeutic response and better patient outcomes.These innovations as shown in Figure 3: Future Trends in Herbal Dermatological Therapy point to the shift towards more specific, efficient, and patient-centered skin care. On the whole, nanotechnology, synergistic formulation approaches, and personalized medicine are predicted to make a breakthrough in herbal dermatological treatment, leading the way to more effective, scientifically-proven treatments, in which the traditional knowledge is mixed with new technological changes.

Figure 3: Future Trends in Herbal Dermatological Therapy

9. Conclusion

The herbal bio actives have become an exciting and evolving constituent of dermatological therapy and present a promising and patient-friendly modality of managing various skin ailments using a natural and effective modality. The pharmacological activities of the plant-derived compounds that can be used in the third generation of dermatology include anti-inflammatory, antioxidant, antimicrobial, and wound healing effects, which when combined together help to enhance the health of the skin and the management of diseases. The classification, mechanisms of action, and therapeutic uses of herbal bioactives, as observed in this chapter, have demonstrated that they have a huge potential in the treatment of diseases like psoriasis, atopic dermatitis, acnes, and wounds. Moreover, the development of formulation strategies especially the use of nanotechnology based delivery systems has overcome most of the old limitations that characterized herbal compounds, including lack of stability and low bioavailability. Regardless of these developments, the issues of standardization, variability of bioactive composition, and a lack of clinical validation are still critical aspects that have to be taken into account to guarantee the uniform efficacy and safety. There is a need to have regulatory structures and strict scientific scrutiny to facilitate the acceptance and commercialization of herbal dermatology products. In prospect, herbal dermatology will be the meeting point between traditional information and new scientific discoveries, such as nanotechnology, synergistic preparations, and customized medicine strategies. These advances will improve the accuracy, efficiency, and safety of herbal treatments, leading to an increased number of tailored and personalized treatments. In general, herbal bioactives are a promising and emerging field of knowledge in the dermatological field, and it may offer the future to offer sustainable and innovative solutions to present and future problems in skin health.

References

1. Mukherjee, P. K., Maity, N., Nema, N. K., & Sarkar, B. K. (2011). Bioactive compounds from natural resources. *Journal of Ethnopharmacology, 137*(3), 1125–1137.
2. Pandey, K. B., & Rizvi, S. I. (2009). Plant polyphenols as antioxidants. *Oxidative Medicine and Cellular Longevity, 2*(5), 270–278.

3. Gupta, S. C., Patchva, S., & Aggarwal, B. B. (2013). Therapeutic roles of curcumin. *Clinical and Experimental Pharmacology and Physiology, 40*(7), 431–442.
4. Subramanian, S., & Ramasamy, S. (2016). Herbal bioactives in dermatology. *Pharmacognosy Reviews, 10*(19), 1–10.
5. Kaur, C. D., & Saraf, S. (2010). Herbal photoprotective formulations. *Pharmacognosy Reviews, 4*(7), 82–87.
6. Draelos, Z. D. (2009). Botanicals in dermatology. *Dermatologic Clinics, 27*(1), 63–69.
7. Bisset, N. G., & Wichtl, M. (2001). *Herbal drugs and phytopharmaceuticals*. CRC Press.
8. Ali, B., Al-Wabel, N. A., Shams, S., et al. (2015). Essential oils used in dermatology. *Asian Pacific Journal of Tropical Biomedicine, 5*(8), 601–611.
9. Thring, T. S., Hili, P., & Naughton, D. P. (2009). Anti-collagenase activity of plant extracts. *BMC Complementary and Alternative Medicine, 9*, 27.
10. Chanchal, D., &Swarnlata, S. (2008). Novel approaches in herbal cosmetics. *Pharmacognosy Reviews, 2*(4), 222–227.
11. Kumar, S., Pandey, A. K. (2013). Chemistry and biological activities of flavonoids. *The Scientific World Journal, 2013*, 162750.
12. Cowan, M. M. (1999). Plant products as antimicrobial agents. *Clinical Microbiology Reviews, 12*(4), 564–582.
13. Reddy, B. S., & Reddy, P. S. (2015). Herbal treatment for dermatological disorders. *Journal of Pharmacy Research, 9*(2), 123–130.
14. Dharmananda, S. (2003). Herbal medicine in dermatology. *Institute for Traditional Medicine*.
15. Saewan, N., &Jimtaisong, A. (2015). Natural products as anti-aging agents. *Journal of Cosmetic Dermatology, 14*(1), 47–63.
16. Lin, T. K., Zhong, L., & Santiago, J. L. (2018). Anti-inflammatory effects of plant extracts. *International Journal of Molecular Sciences, 19*(1), 70.
17. Bhuyan, D. J., et al. (2021). Plant polyphenols in skin protection. *Molecules, 26*(21), 6489.
18. Shukla, A., Rasik, A. M., & Dhawan, B. N. (1999). Wound healing properties of herbal compounds. *Journal of Ethnopharmacology, 65*(1), 1–11.
19. Lodha, R., et al. (2013). Role of aloe vera in wound healing. *Journal of Dermatological Treatment, 24*(3), 205–208.
20. Hammer, K. A., Carson, C. F., & Riley, T. V. (2006). Antimicrobial activity of tea tree oil. *Clinical Microbiology Reviews, 19*(1), 50–62.
21. Subapriya, R., & Nagini, S. (2005). Medicinal properties of neem. *Current Medicinal Chemistry – Anti-Cancer Agents, 5*(2), 149–156.
22. Pazyar, N., et al. (2013). Review of turmeric in dermatology. *Phytotherapy Research, 27*(3), 321–329.
23. Surjushe, A., Vasani, R., &Saple, D. G. (2008). Aloe vera in dermatology. *Indian Journal of Dermatology, 53*(4), 163–166.
24. Bedi, M. K., & Shenefelt, P. D. (2002). Herbal therapy in dermatology. *Archives of Dermatology, 138*(2), 232–242.
25. Kumar, R., et al. (2017). Herbal nanocarriers for skin delivery. *Journal of Controlled Release, 261*, 62–78.
26. Jain, S., et al. (2010). Phytosomes: A novel drug delivery system. *International Journal of Pharmaceutical Sciences, 2*(4), 224–235.
27. Maiti, K., et al. (2007). Enhanced therapeutic potential of phytosomes. *International Journal of Pharmaceutics, 334*(1–2), 37–42.
28. Souto, E. B., & Müller, R. H. (2008). Nanostructured lipid carriers. *European Journal of Pharmaceutics and Biopharmaceutics, 68*(3), 513–525.

29. Goyal, R., et al. (2016). Nanotechnology in dermatology. *Journal of Controlled Release, 240*, 77–92.
30. Patel, A., et al. (2019). Herbal formulations in dermatology. *Pharmacognosy Reviews, 13*(25), 1–10.
31. Ekor, M. (2014). Safety and toxicity of herbal medicines. *Frontiers in Pharmacology, 4*, 177.
32. World Health Organization. (2013). *WHO guidelines on good agricultural practices for medicinal plants*. WHO Press.
33. EMA. (2017). *Guidelines on quality of herbal medicinal products*. European Medicines Agency.
34. U.S. Food and Drug Administration. (2020). *Botanical drug development guidance*. FDA.

Chapter 4: Phytosome Technology: Principles and Applications

*Dr. Vikas Kumar Pandey,[1]Jayprakash Soni

*Assistant Professor, Department of Pharmacy Practice, Pentium Point College of Pharmacy, Hardi, Rewa, (MP), Email-vptype2@gmail.com

[1]Assistant Professor, Department of Pharmaceutics, Awdhesh Pratap Singh Vishvidhyalaya, Rewa, (MP), Email- jaisoni1990@gmail.com

Abstract

Phytosom technology is a new and better mode of delivering herbal drugs which is directed at enhancing bioavailability, stability and therapeutic activity of bioactives obtained by plants. This technology involves the formation of a molecular complex between phytoconstituents and phospholipids that increase their lipid solubility and their interaction with biological membranes, in particular, the skin. Phytosomes address drawbacks of traditional herbal preparations, including, but not limited to, low absorption, low stability, and low skin penetration. This technology has the ability to obtain control and sustained release of the drug, high permeability to practical use, and direct delivery, which makes it very effective in dermatological practices. The phytosomes formulations have been found to have tremendous potential in the treatment of many skin disorders, such as inflammation, acne, eczema, and aging as they have better penetration and extended therapeutic effects. Nevertheless, despite the associated challenges associated with the complexity of formulations and their standards, phytosom technology provides an effective, efficient and biocompatible platform to be used in modern dermatological and cosmeceutical applications.

Keywords:

Phytosome technology, Herbal drug delivery, Phospholipids, Bioavailability, Skin penetration, Nanocarriers, Dermatology

1. Introduction

Phytosome technology is one such new technology in the area of herbal drug formulation, which attempts to overcome the limitations of the conventional herbal formulations by improving bioavailability and therapeutic efficacy of plant-derived bioactives. A phytosome is a complex, which involves a phytoconstituent, e.g. a flavonoid or polyphenol, with a phospholipid, usually phosphatidylcholine which results in a lipid-soluble complex of the active component. Phytosomes, unlike conventional herbal extracts, which are usually poorly absorbed since they are hydrophilic, enable the integration of bioactives more easily into the biological membrane, and thus, increase permeability of the skin and enhance systemic or local delivery. The necessity of the development of modern herbal delivery methods is predetermined by the fact that herbal compounds are characterized by low bioavailability and low bioactivity, quick degradation, and the inability to penetrate the biological barrier, including stratum corneum. The traditional dosage forms, including creams, ointments, extracts among others, usually cannot provide adequate levels of active compounds to the target site resulting in suboptimal therapeutic results. In that regard, the phytosome technology can provide a potential solution to the case as it will combine the advantages of natural bioactive with the latest approaches to drug delivery, which will provide a better stability, controlled release and an increase in the penetration. Among the main positive features of phytosomes compared to alternative systems is the fact that these systems allow much higher absorption and bioavailability of the herbal

compounds due to the formation of the stable lipid-compatible complex, which increases the affinity of biological membranes. Also, the phytosomes have enhanced ability to protect delicate phytoconstituents against environmental degradation including oxidation and hydrolysis, thus increasing their shelf life and therapeutic potentials. They also allow the targeted and sustained delivery of drugs, which decreases the rate of application and enhances patient compliance. In addition, phytosomes have superior skin permeation and hence, are better used in dermatology and cosmeceutical use. In general, phytosome technology can be noted as a major breakthrough in the field of herbal drug delivery, as it stands as a link between the traditional approach to the herbal medicine and the contemporary pharmaceutical science, and provides an efficient and trustworthy platform to increase the therapeutic potential of the natural compounds.

2. Fundamentals of Phytosome Technology

Phytoseme technology is a new and advanced technology in the delivery of herbal drugs, which is based on the establishment of a molecular complex between the plant-derived bioactive and phospholipids to improve their absorption and therapeutic efficacy. Phytosome was named based on the words phyto, which means plant, and some, which means cell-like structure, which describes a phytoconstituent complex attached to phosphatidylcholine, as a phospholipid, by hydrogen bond and HBA. This complexion makes the phytosomes different to the traditional herbal extracts since the active constituents are not only enclosed but chemically conjugated to the lipid component and gives them better incorporation into biological membranes. Phytosomes are structurally made up of phospholipid molecule comprising of the hydrophilic head and the hydrophobic tail in which the polar head of the phytoconstituent interacts with the phospholipid molecule of the phytosomes to form a stable lipid-compatible interaction. This unusual structure helps to increase the solubility of the hydrophilic plant compounds in the lipid environments thereby enabling the transport across the lipid rich biological barriers like that of the stratum corneum of the skin. Phytosomes are usually composed of standardized plant extracts with a high content of polyphenols or flavonoids and phospholipids of natural origins such as soy lecithin, which helps them to become biocompatible and safe. The phytosem formation process includes the interaction of the polar functional groups of the phytoconstituent with the polar head of the phospholipid forming an amphiphilic lipophilic complex. This bi-polar attribute enables the phytosome to blend effectively in cell membranes, and thus, improves the penetration and bioavailability of drugs. Formation is usually a solvent-based process in which the two components are dissolved and then allowed to mix under regulated conditions to enable the formation of complex. The structure of the phytoconstituent and the phospholipid complex as shown in Figure 1: Structure and Formation of Phytosomes is a vesicle-like complex which helps to deliver the active compound to the sites efficiently. In general, the basic concepts of the phytosome technology emphasize the possibility to overcome the shortcomings of traditional herbal preparations increasing stability, membrane penetration, and treatment efficacy, which makes it a worthwhile delivery system in contemporary dermatological and pharmaceutical practice.



Figure 1: Structure and Formation of Phytosomes

3. Preparation Methods of Phytosomes

A variety of advanced techniques are used to prepare phytosomes, which are aimed at supporting the formation of a stable complex between phytoconstituents and phospholipids to enhance the bioavailability and the therapeutic effects of herbal chemicals. Among the most popular of them are the solvent evaporation process that is mainly popular due to its simplicity and efficiency whereby the phytoconstituent and phospholipid are dissolved in an appropriate organic solvent and then dried under reduced pressure to form a thin film which, on rehydration, forms the phytosom complex. Another method which is of importance and is known as the anti-solvent precipitation method is where the phytoconstituent-phospholipid solution is added to non-solvent causing the precipitation of the phytosom complex due to decreased solubility, resulting in the fine particles with increased homogeneity. Very similar to solvent evaporation method is the thin film hydration method in which it is necessary to create the lipid film and then hydrate it with an aqueous phase under controlled conditions, to form vesicles structures with high encapsulation efficiency and stability. Also, the supercritical fluid technology is more advanced and environmentally friendly, which is based on supercritical fluids, such as carbon dioxide, to promote the formation of phytosomes without any other harmful organic solvents and, therefore, improve the purity and scalability of the products. These two techniques have their own merits and various demerits in terms of their ability to control the sizes of particles, the capability to encapsulate, scales and cost-efficacies. This is because the selection of an appropriate method of preparation depends on the nature of physicochemical properties of the phytoconstituent, formulation needs and intended use. Table 1: Methods of Phytosome Preparation and Characteristics summarizes the main characteristics, benefits, and shortcomings of these techniques of preparation and is a comparative presentation of the various methods to prepare phytosomes. Overall, the history of various forms of preparation has helped to develop phytoseme technology according to which effective and stable forms of the delivery of the herbs could be developed which could be used in both dermatological and in pharmaceutical practice.

Table 1: Methods of Phytosome Preparation and Their Characteristics

S.No.	Method	Principle	Advantages	Limitations
1	**Solvent Evaporation**	Formation of thin film by solvent removal	Simple, high encapsulation efficiency	Use of organic solvents
2	**Anti-solvent Precipitation**	Precipitation using non-solvent	Uniform particle size, easy process	Limited control over morphology
3	**Thin Film Hydration**	Hydration of lipid film to form vesicles	Stable vesicles, good drug loading	Time-consuming
4	**Supercritical Fluid Technology**	Use of supercritical CO_2 for complex formation	Solvent-free, high purity, scalable	Expensive, requires specialized equipment

4. Characterization of Phytosomes

The characterization of phytosomes is a significant procedure in determining its physicochemical properties, stability, and overall functionality as a drug delivery system to make sure that it can find application in the dermatological and pharmaceutical fields. Particle size and zeta potential are one of the main parameters measured and they play an important role on the stability, permeability and bioavailability of phytosomal preparations. The dimension of particles is often defined in a manner that smaller and well-spread particles are associated with increased penetration via the skin and enhanced therapeutic outcomes. Contrarily, Zeta potential provides the value of the surface charge of the particles which is an indicator of the stability of these particles in the suspension; the higher the absolute values the more stable such particles tend to be since they do not cluster. The other important parameter is entrapment efficiency since it determines the percentage of successfully incorporated phytoconstituent in the phospholipid complex.. A high entrapment efficiency is preferable because this guarantees the maximum drug loading and prolonged release, which is part of better therapeutic results. The structural aspects of phytosomes also require morphological analysis and it is normally conducted through advanced imaging platforms like the scanning electron microscopy (SEM) and transmission electron microscopy (TEM). These methods will give extensive data regarding the shape, surface features, and vesicular structure of phytosomes, verifying the formation of the complex of phytoconstituent-phospholipid. Besides this, in vitro drug release tests are also performed to measure the release characteristics of the encapsulated bioactive compounds with time that are useful in predicting their behavior at physiological conditions and also to determine their controlled release characteristics. These analyses are conducted in the form of diffusion studies and are essential in the process of maximizing the formulation parameters. The different methods of characterization and their uses in evaluating the phytosome systems are shown in Figure 2: Characterization Techniques of Phytosome Systems, and the need to utilize all these methods to fully determine the situation. In general, proper characterization would result in the production of stable, effective, and quality phytosomal preparations with greater therapeutic value.

5. Mechanism of Drug Delivery and Skin Penetration

The pharmacokinetic mechanism of drug delivery and skin penetration of phytosomes-based systems is mainly dictated by the lipid-compatible structure, which allows the system to effectively interact with the biological barriers of the skin and increases the results of the penetration of the phytoconstituents into the targeted sites. The interaction of phytosomes with skin lipids especially stratum corneum is one of the most important components of this mechanism as stratum corneum is the layer where a highly organized lipid matrix serves as the major barrier to penetration of a drug. The phospholipid molecule of phytosomes has structural similarity to lipid bi-layer of the skin and hence the complex is readily incorporated into the intercellular lipid domains. This contact breaks up the tight lipid structure, making the membrane more fluid and ensuring the diffusion of the bioactive compounds that are encapsulated by it further into the deeper layers of the skin. With this, phytosomes have a high effect on the permeability of hydrophilic phytoconstituents which otherwise would have little penetration ability through the skin. Phytosomes have also been reported to increase the bioavailability and absorption of herbal compounds besides better penetration. Stabilization of the phospholipid phytoconstituent complex raises the lipophilicity of the active molecules and enhances their partitions into the lipid-rich environment of the skin and their retention at the target site. This increases the levels of drugs in the area and also increases the duration of effect and does not require the frequent application. Moreover, the amphiphilic property of phytosomes enables it to pass through hydrophilic and lipophilic routes, which guarantee adequate delivery to various layers of the skin. The other key characteristic of phytosome-based delivery is that controlled and targeted drug delivery, which is necessary in ensuring constant therapeutic concentrations overtime. The phospholipid matrix also serves as a reservoir that continuously releases the bioactive compound that is encapsulated in it over a prolonged period, thus reducing changes in drug concentration and possible side effects. Also, the delivery can be targeted by altering the formulation parameters, i.e., the particle size, the surface charge, and composition, so that the drug can be concentrated at certain skin layers or in the impacted areas. It is a localized method that is especially useful in treating localized skin problems where it is feasible to deliver the medication more specifically. In general, lipid interaction, an improved absorption mechanism, and a controlled release mechanism combine synergistically to make phytosome technology a highly powerful system to enhance drug delivery and skin penetration in dermatological therapy.



6. Applications of Phytosomes in Dermatology

Phytoseme technology has had widespread use in dermatology since it improves herbal bioactive delivery, stability, as well as efficacy, which makes the technology very ideal in therapeutic as well as cosmetic applications. Anti-inflammatory and anti-aging applications are among the most significant ones, and phytosome-based preparations of curcumin, quercetin, and green tea polyphenols are utilized to impose an anti-inflammatory effect, neutralize free radicals, and safeguard the skin against oxidative damage. These recipes assist in reducing the aging indications including wrinkles, fine lines, along with the decrease in skin elasticity through stimulating collagen production and elevating skin hydration. Phytosomes have been shown to have a great potential in the treatment of several skin ailments like psoriasis, acne and eczema. Indicatively, curcumin phytosomes have been shown to prevent inflammatory cytokines in psoriasis, whereas tea tree oil and neem-based phytosom have good antimicrobial action against the acnes-causing bacteria. On the same note, flavonoids and herbs as phytosomal preparations are also efficient in the treatment of eczematous skin as they restore skin barrier function, decrease itching, and irritation in patients. The higher penetration and sustained release ability of phytosomes guarantee the increase of local drug concentration and higher treatment effect duration, improving the overall treatment effects. Other than as therapeutic agents, phytosomes find extensive use in cosmetic products such as cosmeceuticals because of their capacity to convey active ingredients effectively into the skin. They are included in skin brighteners, skin hydrators, skin UV protectors, and skin anti-aging in the form of creams and gels, serums, and lotions. The cosmeceuticals based on phytosomes are especially desirable because they have natural background, less toxicity and better bioavailability as compared to traditional formulations. Table 2: Phytosome-Based Herbal Formulations in Dermatology summarizes and provides an overview of the available and wide variety of herbal products in phytosome in terms of therapeutic effects and effectiveness in a variety of skin diseases and conditions. All in all, phytosome technology is an innovative and widely applicable technology in the field of dermatology due to its ability to combine herbal medicine with modern-day drug delivery systems, as well as provide efficient solution to the medical and cosmetic skin care requirements.

Table 2: Phytosome-Based Herbal Formulations in Dermatology

S.No.	Herbal Bioactive (Phytosome)	Application Area	Key Activity	Therapeutic Benefit
1	**Curcumin Phytosome**	Psoriasis, Inflammation	Anti-inflammatory, Antioxidant	Reduces redness and scaling
2	**Green Tea Phytosome**	Anti-aging	Antioxidant	Prevents wrinkles, protects skin
3	**Quercetin Phytosome**	Eczema	Anti-inflammatory	Reduces irritation and itching
4	**Tea Tree Oil Phytosome**	Acne	Antimicrobial	Controls bacterial growth
5	**Neem Phytosome**	Skin infections	Antibacterial, Anti-inflammatory	Promotes skin healing
6	**Aloe Vera**	Wound healing	Regenerative,	Accelerates tissue

	Phytosome		Moisturizing	repair

7. Advantages and Limitations of Phytosome Technology

Phytosomes technology has several notable benefits in the improved delivery and efficacy of herbal Bioactives, which are used to a large extent in the dermatological and pharmaceutical processes. However, it also comes with some limitations and challenges. Among the main benefits of phytosomes, the formation of a lipid-compatible complex with phospholipids that enhances the bioavailability of phytoconstituents deserves to be mentioned because it promotes the better absorption of phytoconstituents through biological membranes, and the skin is not an exception. This increased permeability results in high therapeutic efficacy and quick action of action in contrast to the traditional herb formulations. Phytosomes also, offer better stability to sensitive plant chemicals, as it shields them against environmental degradation, oxidation, hydrolysis, and photodegradation, which in turn increases shelf life and also preserves therapeutic properties. The second benefit is that they are capable of controlled and sustained drug release that allows sustaining steady levels of drugs at the target site and lessens the frequency of administration, thereby increasing patient compliance. Phytosomes are also characterized by high biocompatibility and low toxicity as natural phospholipids are used and therefore, they can be used in therapeutic and cosmetical products over a long period. Nevertheless, phytosome technology has some limitations and challenges despite having these advantages, which require to be addressed to be used more broadly. The difficulty of formulation and production is one significant constraint, as it demands a close control of the process parameters and might raise the production expenses. Stability, scalability, and environmental safety can also be problematic due to the fact that some methods used in the preparation require the use of phospholipids and organic solvents. Also, the quality and composition of herbal extracts can be variable making the phytosomal formulations less consistent and reproducible. Inadequate supply of standard protocols and regulatory measures to Phytosystem-based products also makes their development and commercialization even more challenging. Also, there is long-term stability and mass production, which need more research and streamlining. In general, although phytoseme technology offers a very promising method of enhancing the delivery of herbal drugs, all these drawbacks have to be overcome by more sophisticated formulation strategies and standardization of the technology to achieve all the potential of the technology in the modern dermatological practice.

8. Regulatory and Safety Considerations

The formulations should be of good quality, effective and safe to be used dermatologically, and this is possible only through regulatory and safety considerations during the development and application of the phytosome-based formulations. Pytosomal products are subjected to a detailed evaluation of their physicochemical characteristics, biocompatibility, and possibilities of their toxicological impact. Even though phytosomes can be regarded as safe because of the utilization of natural phospholipids and bioactive components of plants, it is important to check the parameters of the skin irritation, sensitization, cytotoxicity, and phototoxicity by means of standardized in vitro and in vivo experiments. Patch tests, dermal toxicity tests, and permeation tests are some of the tests that are usually used to determine the reaction of the phytosomal formulations on the skin and to make sure that they do not have any adverse effects when used over a long period. Also, the use of phytosomes due to their nanoscale structure requires special consideration of their penetration characteristics and possible systemic exposure because their increased permeability can result in unwanted concentration in more deep-seated tissues. The purity and quality of raw materials also fall under the toxicological consideration, since the purity of the materials can be contaminated with pesticides, heavy metals or even residual solvents, which can be of high health risk. This has led to the mandatory quality

management and Good Manufacturing Practices (GMP) to achieve safe and consistent products. Regulatory guidelines of phytosomal products might vary depending on the region but generally come under the banner of the world health organization (WHO), US food and drug administration (FDA), and European medicines agency (EMA). These recommendations highlight the importance of having accurate records of the sources of plants, standardizing active constituents, validity of manufacturing processes and scientific support of safety and effectiveness. In the majority of cases, phytosomal preparations may be either classified as herbal drug or dietary supplement or cosmeceutical depending on the intended use, which influences the control rules to give the product approval and make it available on the market. Nevertheless, a tendency to make the regulation and evidence-based assessment stricter in the interests of the consumer safety and the reliability of the product is on the increase. Altogether, the combination of a thorough safety assessment, quality control, and adherence to the regulations is the key to the successful creation and reception of the phytoseme-based dermatological products.

9. Future Perspectives and Innovations

The future of the phytosomes technology is geared towards enabling the system with better nanotechnology, combination delivery systems and targeted therapeutic plans to enhance the efficacy of the herbal drug delivery system. A key advancement is phytosome nanotechnology whereby phytosomal complexes have been produced at a nanoscale to improve drug loading, stability and local delivery. These are nano-phytosomes, which have increased penetration in the skin, surface area and contact to biological membrane, and an increased capacity to deliver phytoconstituents to deeper skin layers. They are also especially promising in the treatment of chronic dermatological conditions, in which controlled and sustained release is a necessity. Along with nanotechnology, there is also an emergence of hybrid delivery systems as a powerful methodological approach, which incorporates the use of phytosomes in combination with other advanced carriers such as liposomes, nanoparticles, hydrogel and microneedles. These hybrid systems use the benefits of more than one technology to accomplish a better encapsulation and stability of drugs and targeted delivery, in addition to allowing multifunctional therapeutic action. As an instance, phytosome-loaded hydrogels can be used to achieve a high penetration value, as well as extended retention at the point of application, which is why it is highly effective in wound healing and inflammation. In addition, personalized phytosomal therapy is a relatively novel idea that is set to tailor treatment regimens and details to factors affecting the individual patient, including genetic profile, skin type, bacterial composition, and severity of the disease.The innovations in genomics, the study of biomarkers and digital health technologies are allowing the creation of tailored phytosomal formulations to maximize therapeutic effects and reduce adverse effects. These novelties, as depicted in Figure 3: Emerging Trends in Phytosystem-Based Drug Delivery, point on the shift towards more specific, efficient, and personalized drug delivery systems. All in all, nanotechnology, hybrid systems and personalized medicine will make the next generation of phytoseme-based therapies to be more effective, safer and more adaptable in the dermatological field.



Figure 3: Emerging Trends in Phytosome-Based Drug Delivery

10. Conclusion

Phytoseme technology is one of the significant developments in the sphere of herbal drugs delivery and thus it offers a good solution between the past and the present that is shown in the field of pharmaceutical science. Phytosomes enhance the solubility, stability and bioavailability of herbal compounds by forming a stable complex of phytoconstituents and phospholipids and eliminate most of the limitations of conventional formulations. In the current chapter, the efficacy of phytosome systems in enhancing skin penetration, and delivery of drugs into the body have been expressed through the principles, the method of preparation, the techniques of characterization and the mechanisms of the delivery. Their versatility and clinical relevance is further exhibited in their broad use in dermatology such as anti-inflammatory, anti-aging, therapeutic and cosmeceutical applications. Despite these advantages, there are certain problems such as difficulty of herbal formulations, variability of herbal raw materials, and regulatory constraints, which must be considered as the key factors of large-scale growth and commercialization. However, with the constant research and technological advancement particularly in nanotechnology, hybrid formulations as well as personalized medicine, the prospects of phytosom-based preparations are constantly growing. It is hoped that the inventions will enhance the accuracy, effectiveness and patient outcomes of dermatological therapy. Generally speaking, phytosomes have an enormous potential to be used as a new breed of delivery system of herbal bioactives, which would help in advancing safer, more effective and sustainable therapeutic uses of a wide range of skin diseases.

References

1. Bombardelli, E., Curri, S. B., Della Loggia, R., Del Negro, P., Gariboldi, P., &Tubaro, A. (1989). Complexes between phospholipids and vegetal derivatives (phytosomes). *Fitoterapia, 60*(1), 1–9.
2. Semalty, A., Semalty, M., Rawat, B. S., & Singh, D. (2010). Phytosome technology: A review. *Journal of Pharmacy Research, 3*(6), 1387–1391.
3. Kidd, P. M. (2009). Bioavailability and activity of phytosome complexes. *Alternative Medicine Review, 14*(3), 226–246.

4. Maiti, K., Mukherjee, K., Gantait, A., Saha, B. P., & Mukherjee, P. K. (2007). Curcumin–phospholipid complex: Enhanced bioavailability. *International Journal of Pharmaceutics, 334*(1–2), 37–42.

5. Lu, M., Qiu, Q., Luo, X., Liu, X., Sun, J., Wang, C., & Deng, Y. (2019). Phytosome technology in drug delivery. *Drug Delivery, 26*(1), 214–224.

6. Patel, J., & Patel, R. (2009). Phytosomes: Emerging strategy in herbal drug delivery. *International Journal of Pharmaceutical Sciences Review and Research, 1*(2), 1–5.

7. Semalty, M., Semalty, A., Rawat, B. S., & Franceschi, F. (2013). Supramolecular phospholipid complexes of herbal drugs. *Current Drug Discovery Technologies, 10*(1), 62–69.

8. Jain, S., & Sharma, S. (2016). Phytosomes: A novel approach for herbal drug delivery. *International Journal of Pharmaceutical Sciences and Research, 7*(6), 2310–2320.

9. Kidd, P. M., & Head, K. (2005). A review of silybin phytosome. *Alternative Medicine Review, 10*(3), 193–203.

10. Gupta, N. K., Dixit, V. K. (2011). Development and evaluation of herbal phytosomes. *Journal of Drug Delivery, 2011*, 1–7.

11. Yue, P. F., Yuan, H. L., Zhu, W. F., et al. (2010). Preparation and characterization of phytosomes. *Drug Development and Industrial Pharmacy, 36*(9), 1023–1029.

12. Sharma, S., & Sikarwar, M. S. (2005). Phytosome: A review on formulation technology. *Pharmacognosy Reviews, 2*(4), 194–200.

13. Singh, D., Rawat, M. S. M., &Semalty, A. (2012). Phytosome: An emerging technology. *International Journal of Pharmaceutical Sciences and Nanotechnology, 5*(3), 1739–1745.

14. Kumar, S., Gupta, S., & Sharma, P. K. (2017). Phytosomes: A novel drug delivery system. *Journal of Drug Delivery and Therapeutics, 7*(4), 14–20.

15. Yadav, N. P., & Dixit, V. K. (2008). Recent approaches in herbal drug delivery. *Pharmacognosy Reviews, 2*(4), 197–203.

16. Manach, C., Scalbert, A., Morand, C., et al. (2004). Polyphenols: Bioavailability and health effects. *American Journal of Clinical Nutrition, 79*(5), 727–747.

17. Puglia, C., & Bonina, F. (2012). Lipid nanoparticles in skin delivery. *Advanced Drug Delivery Reviews, 64*(Suppl), 118–131.

18. Souto, E. B., & Müller, R. H. (2008). Lipid nanoparticles for topical delivery. *European Journal of Pharmaceutics and Biopharmaceutics, 68*(3), 513–525.

19. Goyal, R., Macri, L. K., Kaplan, H. M., & Kohn, J. (2016). Nanotechnology in dermatology. *Journal of Controlled Release, 240*, 77–92.

20. Patel, A., Patel, M., Yang, X., & Mitra, A. K. (2010). Recent advances in lipid-based delivery systems. *Drug Development and Industrial Pharmacy, 36*(10), 1231–1242.

21. Honeywell-Nguyen, P. L., &Bouwstra, J. A. (2005). Vesicles in skin delivery. *Drug Discovery Today: Technologies, 2*(1), 67–74.

22. Paudel, K. S., Milewski, M., Swadley, C. L., et al. (2010). Dermal/transdermal delivery challenges. *Therapeutic Delivery, 1*(1), 109–131.

23. Ekor, M. (2014). Safety and toxicity of herbal medicines. *Frontiers in Pharmacology, 4*, 177.

24. World Health Organization. (2013). *Guidelines on good agricultural and collection practices (GACP) for medicinal plants*. WHO Press.

25. European Medicines Agency. (2017). *Guidelines on herbal medicinal products*. EMA.

Chapter 5: Chitosan-Based Nanocarriers in Drug Delivery

Gautam Raj Puri[1], Dr. Seema Tomar*, Ravina Yadav [1], Gursimran Singh [2], ShehnazKhatoon[3], Simranjeet Kaur Lohat[1]

[1]Assistant Professor, School of Pharmaceutical Sciences, RIMT University, Mandi Gobindgarh, Punjab, India

*Professor, Faculty of Pharmaceutical Sciences, Motherhood University, Dehradun, India

[2]Assistant Professor, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India

[3]Assistant Professor, Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela, Punjab, India

Abstract

Drug delivery systems using chitosan nanoparticles has emerged as one of the promising fields of drug delivery systems due to the unique physicochemical and biological properties of such nanoparticles. Chitosan is produced using natural derivatives; thus, biocompatible, biodegradable and a good mucoadhesive, with antimicrobial properties and is therefore very appropriate in dermatology. These nanocarriers include: nanoparticles, nanogels and hybrid systems and allow the drugs to be more stable, increase bioavailability, targeted delivery and enable the drugs to be controlled and release steadily. They are better in their interactions with biological membranes, which increases the skin penetration and retention, which improves the therapeutic effects of wound healing, inflammatory skin disorders, and antimicrobial therapy. With the problems of standardization, scalability, and regulatory approval, the current evolution of nanotechnology, stimuli-responsive systems, and customized medicine are expanding their possibilities. Overall, we can speak about chitosan-based nanocarriers as a new and efficient way to create next generation drug delivery systems in the sphere of dermatology and beyond.

Keywords Chitosan, Nanocarriers, Drug Delivery, Dermatology, Nanotechnology, Controlled Release, Targeted Delivery.

1. Introduction

Due to their physicochemical and biological characteristics, chitosan-based nanocarriers have become a promising and flexible system in the modern drug delivery systems that are highly applicable in pharmaceutical and dermatological uses. Chitosan is a biodegradable, biocompatible and natural polysaccharide that is made of chitin and chitin is produced primarily by the exoskeleton of the crustaceans like shrimp and crabs. It is structurally β-(14)-linked D-glucosamine and N-acetyl-D-glucosamine, and can be used with parameters altered by altering its degree of deacetylation and molecular weight to create a wide range of structures with varying characteristics. Different chitosan derivatives have been produced such as carboxymethyl chitosan, trimethyl chitosan, and thiolated chitosan, to enhance the solubility, permeability and functional performance of chitosan, and therefore broaden its use in the drug delivery system. The significance of chitosan in pharmaceutical delivery is based on the outstanding properties, including mucoadhesiveness, positive charge, and forming

nanoparticles, hydrogels, and nanocomposites. Cationic properties of chitosan allow a high level of interaction with negatively charged biological membranes and mucosal surfaces to improve drug retention and absorption. Moreover, chitosan has a natural antimicrobial and wound healing effect, which is especially useful in the dermatological preparations. Nanocarriers made of chitosan have the capacity to entrap a broad spectrum of therapeutic agents, small molecules, proteins, and herbal bioactives, and prevent their degradation, as well as allow them to be released in a controlled and sustained manner. Among the significant benefits of chitosan based nanocarriers is the enhancement of drug bioavailability and targeted delivery; in particular, across biological barriers like the skin and mucosal tissues. Their small size (in the nano size regime) enables greater penetration and distribution and an easy surface modification makes them able to associate with targeted delivery and stimuli-responsive capabilities. More so, these systems are less toxic, more stable, and have better therapeutic effects than the traditional methods of drugs delivery. Regardless of these benefits, current studies are still aimed at streamlining methodology to formulate and addressing scalability and reproducibility issues. Altogether, nanoparticles made of chitosan can be discussed as a new and promising solution in the field of drug delivery, as natural biopolymers are intertwined with the latest nanotechnology innovations to create more efficient, safer, and patient-friendly drug delivery systems.

In addition to these properties, chitosan-based nanoparticle is gaining momentum as an attractive focus in regards to more advanced and targeted therapeutic solutions in particular in transdermal drug delivery and dermatology. Their ability to create transient apertures in tight junctions augments paracellular transport which consequently leads to enhanced penetration of drugs that are typified by low permeability. Further, chitosan systems can be engineered to respond to a specific stimulus e.g. pH, temperature or enzymes so as to enable site-selective drug delivery and to suppress systemic side effects. Another way in which the versatility of chitosan can be employed is by combining it with other nanocarriers, such as liposomes and nanoparticles to come up with hybrid systems that are more functional and therapeutic. The sustainable and environmental friendliness nature of chitosan is also in line with the increased demand to utilise green and biocompatible pharmaceutical substances. With the ever-evolving nanotechnology and material science, chitosan-based nanocarriers will become the key to the next generation drug delivery systems that will introduce a more precise, safer and more effective clinical delivery system.

2. Physicochemical Properties of Chitosan

Chitosan is a versatile biopolymer that has many physicochemical characteristics, and thus it is an ideal biopolymer in drug delivery systems particularly in dermatology where the structure, composition and functional characteristics of chitosan play an important role in defining its efficacy. Chitosan is a linear polysaccharide, chemically; it is a polysaccharide composed of 2-deoxyglucosamine and N-acetyldeoxyglucosamine (2-deoxy-4-glucosamine and 2-deoxy-4-glucosamine), made by deacetylation of chitin and found in the cell walls of cells of fungi, shrimp, crabs, and lobster, as well as crustaceans. The positive charge which appears as a result of the presence of free amino groups in its structure under the conditions of acid enables the establishment of strong electrostatic interaction with negatively charged biological membranes, mucosal surfaces and biomolecules. One of the factors that make this cationic is the reason behind its mucoadhesive and permeation-enhancing characteristics. Figure 1: Structure and Properties of Chitosan will show that the characteristic of the polymer in drug delivery systems is because the polymer backbone and utility groups are present. The magnitude of deacetylation (DD) and molecular weight (MW) are important parameters, which indeed have a considerable impact on the physicochemical and biological properties of chitosan. The higher the deacetylation, the greater the number of the free amino groups that increases the solubility, the density of charges, or the ability to interact with the

biological tissues, and the molecular weight determines the viscosity, mechanical strength, and the ability to interact with the biological tissues. It is common that the lower molecular weight chitosan has a higher tendency to solubility and permeability and that higher molecular weight forms exhibit a greater prowess of film-forming and supporting properties. The other property that is relevant to chitosan is the solubility of chitosan since chitosan can be dissolved in dilute acidic solution due to the protonation of chitosan to its amino groups but not the alkaline acidic pH that may limit its use with some formulations. To overcome this shortcoming, various derivatives e.g. carboxyl methyl chitosan and trimethyl chitosan have been prepared in order to improve its water solubility and functionality over a wider range of pH. Chitosan has been highly renowned in the context of biocompatibility in that it is non-toxic, biodegradable and bioadhesive making it most suitable in the biomedical and pharmaceutical sectors. Biological well-toleration of this compound and low immunogenicity of the biodegradation products of this compound (non-toxic oligosaccharides) also add to the safety profile of this compound. In addition to this, chitosan per se has antimicrobial and wound-dressing properties which augment its application in dermatological preparations. Finally, the usefulness of chitosan as a versatile and working material in the advanced drug delivery systems depends on the physicochemical properties of the material such as its structure, level of deacetylation, molecular weight, solubility and biocompatibility.

Figure 1: Structure and Properties of Chitosan

3. Types of Chitosan-Based Nanocarriers

Nano carriers made of chitosan, are a friendly and broad-based type of drug delivery system in that it has enhanced stability, bioavailability, and targeting of therapeutic agents, particularly in the field of dermatology as well as biomedical application. Some of them include chitosan nanoparticles; they have been extensively studied due to their easy preparation, biocompatibility and high mucoadhesive properties. They are in most cases produced by ionic gelation processes or cross-linking processes and have a positive charge on their surface that enables them to interact with the negatively charged biological membranes thus augmenting drug penetration and retention. They can entrap various different drugs, both small molecules and proteins as well as herbal bioactives, and can offer

protection against degradation as well as controlled release. Another category of significant interest is chitosan nanogels, cross-linked polymeric networks of high water content, and great swelling capacity. These systems have excellent drug-loading capacity and they can also respond to environmental stimuli like pH and temperature hence the systems are ideal in controlled and sustained delivery of drugs. They place them better upon the surface of the skin through their soft and flexible structure increasing drug residence time and improving therapeutic performance in topical therapy. Chitosan-coated liposomes and nano emulsions are hybrid delivery systems, which are hybrids of lipid-based delivery systems and the functionality of chitosan. Chitosan is used in such systems as surface modifier, which enhances stability, prevents aggregation, and increases the permeability of biological barriers. The coating is also said to be beneficial in the sustained release and enhanced contact with skin and mucosal surfaces, and these systems are therefore quite effective in the delivery of hydrophilic and lipophilic drugs. Moreover, chitosan-based hybrid nanocarriers, a type of nanocarriers that are made by combining chitosan with other nanomaterials, including polymers, lipids, or inorganic nanoparticles, have the ability to work in multifunctional niche: they combine targeted delivery, increased stability, and stimuli-responsiveness. Such sophisticated facilities can be designed to deliver medication in site specific ways, which decreases adverse reactions and increases treatment effectiveness. Table 1: Types of Chitosan Nanocarriers and Their Characteristics summarizes the diverse nature of the chitosan-based nanocarriers and their functional benefits and application features. On the whole, these nanocarrier systems have a great potential in enhancing the overall drug delivery system and increasing the number of applications of chitosan in contemporary medicine.

Table 1: Types of Chitosan Nanocarriers and Their Characteristics

S.No.	Type of Nanocarrier	Key Characteristics	Advantages	Applications
1	Chitosan Nanoparticles	Nanosized, positively charged, high surface area	Enhanced penetration, controlled release	Drug delivery, wound healing
2	Chitosan Nanogels	Hydrophilic, swelling network, stimuli-responsive	High drug loading, sustained release	Topical and transdermal delivery
3	Chitosan-Coated Liposomes/Nanoemulsions	Lipid core with chitosan coating	Improved stability, permeability	Delivery of hydrophilic & lipophilic drugs
4	Chitosan-Based Hybrid Nanocarriers	Combination with polymers/lipids/nanomaterials	Targeted delivery, multifunctional	Advanced drug delivery, nanotherapy

4. Preparation Methods of Chitosan Nanocarriers

Chitosan-based nanocarriers can be prepared using a gamut of methods that allow producing stable, nanosized systems with a defined drug loading and release profiles, which is why they are applicable to various pharmaceutical and dermatological applications. The ionic gelation technique is one of the

most common techniques and is carried out on the premise of the electrostatic bond between the positively charged chitosan and the negatively charged cross-linking reagents like sodium tripolyphosphate (TPP). It is easy, gentle and does not necessitate the use of strong chemicals or extreme temperatures thus ideal in encapsulating sensitive biomolecules like proteins, peptides and herbal bioactives. The resulting nanoparticles are also normally homogenous in size and are stable and biocompatible. The next technique is the emulsion cross-linking method where cross-linking is performed in an oil in which the chitosan is dissolved in the aqueous mixture and dispersed in the organic one, then the cross-linking is carried out with the help of the agents (such as glutaraldehyde). It is possible to create nanoparticles with a size and morphology controlled by this method, but the solvents and cross-linking agents used might be of concern in terms of toxicity and environmental effects. Another popular method is polyelectrolyte complexation, in which the chitosan and the opposite charged polymers, e.g., alginate or dextran sulfate, are interacted to create nanocarriers by electrostatic interactions. The technique is beneficial because it is simple, toxic chemicals are not used, and stable and biodegradable complexes of the drug are being formed. More than these traditional approaches, novel techniques like spray drying, supercritical fluid processing, microfluidics etc. are also being investigated as a way of enhancing scalability, reproducibility, and uniform products. An example of this is spray drying, which allows converting chitosan solutions into dry powders of nanoparticles of controlled size and enhanced stability and, thus, large-scale manufacturing. Also, these sophisticated techniques enable further manipulation of the characteristics of particles and profiles of drug release. As shown in Figure 2: Preparation Methods of Chitosan Nanocarriers, the approaches used in the preparation of the nanocarrier system have certain procedures and conditions, which also affect the ultimate characteristics of the system. The choice of suitable preparation technique is determined by the characteristics of the drug, required particle size, stability necessities as well as intended use. All in all, the existence of various methods of preparation gives the flexibility in the selection of the chitosan-based nanocarriers with specific qualities, which increase their efficacy as drug delivery systems in contemporary therapeutics.



Figure 2: Preparation Methods of Chitosan Nanocarriers

5. Mechanism of Drug Delivery and Release

The drug delivery and release mechanism of chitosan-based nanocarriers is dictated by their own peculiar physicochemical characteristics, in particular, their cationic character, mucoadhesiveness, and their capability to form multifunctional nanoscale systems, which altogether allow improving the retention, penetration, and regulation of drug release. Mucoadhesion and skin contact is one of the most important mechanisms in which the positively charged amino group of chitosan electrostatically reacts with the negatively charged components of biological membranes, i.e. mucin and skin lipids. This interaction enhances good adhesion on the skin surface or mucosal tissues, which prolongs the residence of drug delivery system and provides time to remain in contact with the target site. This can be used in dermatology to increase the penetration of the stratum corneum by the drug temporarily breaking through its tight junctions and lipid organization in order to increase diffusion of the encapsulated drug. Moreover, chitosan is able to develop a coat of skin, which is a protective layer that promotes moisture and increases the absorption of drugs. The other significant characteristic of chitosan-based nanocarriers is the controlled and sustained drug release, which is done via its polymeric matrix structure. Chitosan nanoparticles or nanogels have the ability to release drugs that have been encapsulated inside them in a slow process that can occur by diffusion, polymer swelling and degradation. The rate at which drugs are released has been found to be influenced by the level of cross-linking, chitosan molecular weight, and the environmental factors, including pH and temperature. An example is chitosan, which has a pH-sensitive property, i.e., it swells and is more soluble in acidic environments, and hence this can be used to release drugs in response to a particular condition. This slow absorption system allows the dose to be maintained at the desired target site so that the drug is not used as often and the drug has minimal side effects. Moreover, targeting drug delivery by altering the surface of chitosan nanoparticle can be done by attaching appropriate ligands, antibodies or functional groups which identify and bind to target tissues or cells. This facilitates localized delivery thus enhancing the efficacy of treatment whilst mitigating systemic exposure and toxicity. Chitosan based systems may also be designed to react to external stimuli including temperature, enzymes or even magnetic fields and this increases targeting ability. All in all, the combination of good mucoadhesion, controlled release attribute and the potential to attain targeted delivery attribute gives chitosan-based nanocarriers a great potential drug delivery platform, especially in dermatological and transdermal delivery.

6. Applications in Dermatological Drug Delivery

Nanocarriers made of chitosan have received enormous interest in the dermatology drug delivery system because of its multifunctional characteristics such as biocompatibility, biodegradability, antimicrobial activity, and improved drug penetration, which means that it is highly applicable in a broad spectrum of skin uses. The chitosan has been found to be one of the most vital in wound healing and skin regeneration because of the ability to achieve hemostasis, cellular proliferation and faster wound healing. The use of chitosan nanoparticles and hydrogel is able to maintain a wet environment which facilitates the healing of the wound as well as shield the site against microbial infection. They are also known to increase the deposition of collagen and angiogenesis contributing to the rapid and efficient healing of damaged tissues on the skin. Chitosan nanocarriers have been used as effective delivery vehicles of anti-inflammatory drugs and herbal bioactives in the management of inflammatory skin diseases like psoriasis, eczema and dermatitis. Their mucoadhesive and permeation and enhancement characteristics enhance drug retention and penetration to the deeper layers of skin to enable a better control of inflammation and minimizing of symptoms like redness, itching and swelling. Also, the fact that chitosan can regulate immunity is another factor that makes chitosan have therapeutic value in the treatment of chronic inflammatory disorders. The other major use of chitosan based nanocarriers is in antimicrobial and anti-acne therapies. Chitosan also has inherent

antimicrobial effect on a broad spectrum of microorganisms including acnes causing microorganisms like Cutibacterium acnes. In the form of nanoparticle or nanoemulsion, chitosan increases the penetration of antimicrobial agents, which increases their effectiveness and reduces bacterial resistance. Such systems also assist in regulating the sebum production and minimizing inflammation thus highly effective in the management of acne. All uses of chitosan-based nanocarriers in dermatology, their respective functions and therapeutic advantages are listed in Table 2: Chitosan-Based Nanocarriers in Dermatological Applications, and it demonstrates the wide range of applications of chitosan-based nanocarriers due to their wide range of applications in treating different dermatological conditions. All in all, chitosan nanotechnology can be used in the development of dermatological formulations, which can be considered a promising solution to enhance the results of treatment, minimize side effects, and patient adherence.

Table 2: Chitosan-Based Nanocarriers in Dermatological Applications

S.No.	Application Area	Chitosan-Based System	Key Activity	Therapeutic Benefit
1	**Wound Healing**	Chitosan nanoparticles, Hydrogels	Regenerative, Hemostatic	Accelerates tissue repair
2	**Skin Regeneration**	Chitosan nanogels	Collagen stimulation	Enhances skin repair
3	**Inflammatory Disorders**	Chitosan nanoparticles	Anti-inflammatory	Reduces redness and irritation
4	**Acne Treatment**	Chitosan nano emulsions	Antimicrobial	Controls acne-causing bacteria
5	**Skin Infections**	Chitosan-coated systems	Antibacterial, Antifungal	Prevents microbial growth

7. The strengths and weaknesses of Chitosan Nanocarriers.

Nanocarriers based on chitosan have many benefits which make them very attractive to drug delivery especially in the field of dermatology and biomedicine, despite the limitations and problems that should also be taken into account. One of the major strengths is their good biocompatibility and biodegradability since chitosan is a natural polysaccharide with good tolerance to biological systems, and breaks down into non-toxic products. This renders it appropriate in the therapeutic use in the long term with minimal chances of adverse effects. The other vital strength is its cationic nature that enables it to have high electrostatic interactions with negatively charged biological membranes resulting in an increase in mucoadhesion and enhanced absorption and retention of drugs at the target site. Chitosan nanocarriers inherently possess some antimicrobial and wound healing properties and this further adds some additional therapeutic value to the use of the particles in particular to skin-based applications. Furthermore, they are highly versatile and have the capability of trapping a wide variety of therapeutic agents such as small molecules, proteins, nucleic acids as well as herbal bioactives. They also have been reported to produce controlled and extended release of drugs, aids in maintaining therapeutic levels of drugs, reduces dosing schedules and increases patient adherence. With the assistance of surface modification of chitosan nanocarriers which would further increase the therapeutic efficacy of chitosan nanocarriers, the targeted delivery of drugs and the stimuli-responsible nature of chitosan nanocarriers could be achieved. Despite these advantages, there exist a

great number of limitations and difficulties that chitosan nanocarriers can be faced with, which may impact their usage in practice. Their low solubility under neutral and alkaline conditions is one of the major shortcomings as it might limit their application in some formulations. The chemical modification could raise solubility, but there are possibilities that the processes will become prolific and expensive. Depending on the difference in the physicochemical properties of chitosan, such as degree of deacetylation and molecular weight may not be uniformly reliable. Further, mass-scale production and standardization are not as simple as the preparation processes are delicate, and the factors formulating it should be as precise as possible. Some of the methods that they use in preparing the cross-linking agents and organic solvents can also be questioned in terms of its toxicity and safety. Moreover, the aggregation and degradation with time may be some stability problems that influence the shelf life of chitosan-based systems. Overall, although chitosan nanocarriers have high potential in drug delivery, the shortcomings discussed in this paper need to be addressed by considering advanced formulation considerations and standardization of chitosan nanocarriers in order to achieve success in clinical conversion.

8. Safety, Toxicity, and Regulatory Aspects.

The toxicity, safety and regulatory performance of the chitosan based nanocarriers is a significant variable that determines the development, clinical realisation and commercialisation of the material in drug delivering systems. Chitosan is generally considered a safe, biocompatible biomaterial due to its natural origin and biodegradability, in which the results of degradation are not toxins, and are readily excreted into the body. It has been shown that biocompatibility studies of chitosan have proven it to be with low immunogenicity and cytotoxicity, and thus can be used in a number of biomedical tasks, such as topical drug delivery, transdermal drug delivery and mucosal drug delivery. Nevertheless, molecular weight, degree of deacetylation, concentration, and formulation properties can affect the chain of being able to influence the safety profile of chitosan nanocarriers. Thus, extensive toxicity data is required to assess the possible negative impact, such as skin irritation, sensitisation, cytotoxicity, and inflammatory reactions. They are usually tested in vitro with cell cultures, and in vivo with animal models in order to evaluate the safety and tolerability of these systems. Also, the size of chitosan-based carriers is small, and thus the penetration, biodistribution, and possible accumulation in tissues should be critically considered since improved penetration facilitated by the increased permeability can result in unwanted systemic exposure. The residual solvents, cross-linking agents, and impurities are also regarded as toxicological considerations and need to be kept at a minimum with the use of strict quality control measures. The regulatory issues of chitosan made nanocarriers vary based on the purpose of their application, the nature of the product, and the area. These systems may be categorized as pharmaceuticals, medical devices or cosmeceuticals, all of which are regulated under various models. According to the regulatory authorities such as World Health Organization (WHO), the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), there is a need to implement a Good Manufacturing Practices (GMP), standardization of raw materials, validation of manufacturing processes, and extensive documentation of safety and efficacy data. Assessment and standardized testing protocols are being given more importance to ensure the quality of products and safety of patients. However, no standard model of guidelines on nanocarrier-based systems exists and this presents challenges in regulatory approval and commercialization. Overall, the key to safe and effective usage of chitosan-based nanocarriers in drug delivery lies in a powerful strategy in terms of a thorough toxicity analysis, high quality control, and compliance with regulatory measures.

9. Future Perspectives and Innovations

The use of smart technologies in the integration of hybrid systems and personalized practice of medicine is an emerging trend in the future of chitosan-based nanocarriers to enhance the accuracy, efficiency and versatility of drug delivery systems. The most promising development is the design of smart and stimuli-responsive chitosan systems which release drugs in response to a specific internal or external stimulus; pH, temperature, enzymes or light. These systems take advantage of the pH-sensitive characteristic of chitosan which enables the release of drugs in a controlled manner in the environment like inflated or infected tissues in which pH changes are usual. Responsiveness in this form implies site-specific delivery of drugs, decreased side effects of the system, and better therapeutic effects. In addition to the smart systems, the chitosan-based hybrid nanotechnology is also receiving a lot of interest as it involves the incorporation of chitosan with other nanomaterials such as liposomes, nanoparticles, hydrogels and inorganic carriers to form multifunctional delivery platforms. These hybrid systems have been described to have better stability, increased capacity to deliver drugs and synergistic therapies and hence deliver the lipophilic and hydrophilic drugs at a higher efficiency. Nanoparticles or nanogels that are chitosan-coated and in combination with metallic or polymeric acids could be used to deliver therapeutic agents, act as antimicrobials, and serve as a sustaining system. In addition, the trend of individualized drug delivery methods can be regarded as a radical trend in the use of chitosan nanocarriers, according to which the treatment is determined by the characteristics of the patients, their genetic profile, skin type, severity of the disease, and the structure of their microbiomes. The emerging opportunity of designing customized formulations to maximize drug action but minimise the chances of side effects is creating the opportunity of designing tailored formulations. Collectively, these inventions are indicative of the shifting trend in chitosan-based nanocarriers towards smarter, more versatile, and patient-centered drug delivery systems as represented in Figure 3: Emerging Trends in chitosan-based nanocarriers toward smarter, more versatile, and patient-centered drug delivery system. Altogether, the interplay between smart materials, hybrid nanotechnology, and personalized medicine promises a lot of improvement of the capabilities of chitosan-based nanocarrier, and the next-generation solutions in the field of dermatology and many others will become possible.



Figure 3: Emerging Trends in Chitosan-Based Nanocarriers

10. Conclusion

The synergistic biocompatibility and biodegradability and versatility in functionality have seen chitosan-based nanocarriers become a highly promising and versatile platform in the modern use of drug delivery, and especially in dermatological delivery. Due to their ability to augment drug stability, improve bioavailability and permit the regulation and target discharge, they are superior to the majority of the traditional delivery systems. The number of chitosan nanocarriers and the current methods of preparation and characterization are the factors suggesting that they could be used to deliver an impressive number of therapeutic agents. Moreover, their nature, such as mucoadhesion, antimicrobial activity and wound healing capacity, further expand their area of application in the treatment of the skin disorders, infections, and wound healing capacity. Despite these advantages, the issues of standardization of formulations, scalability and regulatory permission are significant drawbacks to the widespread clinical use of them. However, the latest research that is being steered towards smart stimuli-responsive, hybrid nanotechnology and the use of personalized drug delivery is believed to counter these inefficiencies and the practice of the personalized drug delivery will see an enhancement in their functionality. With the continuous improvement of nanotechnology and material science, chitosan nanocarriers will play a significant role in the development of the next generation systems of therapeutic therapies with better safety, efficacy and patient specific delivery of a therapeutic system that will generate improved patient outcomes.

References

1. Rinaudo, M. (2006). Chitin and chitosan: Properties and applications. *Progress in Polymer Science, 31*(7), 603–632. https://doi.org/10.1016/j.progpolymsci.2006.06.001
2. Ravi Kumar, M. N. V. (2000). A review of chitin and chitosan applications. *Reactive and Functional Polymers, 46*(1), 1–27.
3. Dash, M., Chiellini, F., Ottenbrite, R. M., & Chiellini, E. (2011). Chitosan—A versatile biomaterial. *Progress in Polymer Science, 36*(8), 981–1014.
4. Agnihotri, S. A., Mallikarjuna, N. N., &Aminabhavi, T. M. (2004). Recent advances in chitosan-based drug delivery systems. *Journal of Controlled Release, 100*(1), 5–28.
5. Grenha, A. (2012). Chitosan nanoparticles: A survey of preparation methods. *Journal of Drug Targeting, 20*(4), 291–300.
6. Mohammed, M. A., Syeda, J. T. M., Wasan, K. M., & Wasan, E. K. (2017). An overview of chitosan nanoparticles. *International Journal of Nanomedicine, 12*, 765–782.
7. Bernkop-Schnürch, A., &Dünnhaupt, S. (2012). Chitosan-based drug delivery systems. *European Journal of Pharmaceutics and Biopharmaceutics, 81*(3), 463–469.
8. Khor, E., & Lim, L. Y. (2003). Implantable applications of chitosan. *Biomaterials, 24*(13), 2339–2349.
9. Calvo, P., Remuñán-López, C., Vila-Jato, J. L., & Alonso, M. J. (1997). Novel hydrophilic chitosan-polyethylene oxide nanoparticles. *Journal of Applied Polymer Science, 63*(1), 125–132.
10. Illum, L. (1998). Chitosan and its use as a pharmaceutical excipient. *Pharmaceutical Research, 15*(9), 1326–1331.

11. Sarmento, B., Ferreira, D., Veiga, F., & Ribeiro, A. (2006). Characterization of insulin-loaded chitosan nanoparticles. *European Journal of Pharmaceutics and Biopharmaceutics, 63*(1), 1–8.

12. Csaba, N., Garcia-Fuentes, M., & Alonso, M. J. (2009). Nanoparticles for nasal vaccination. *Advanced Drug Delivery Reviews, 61*(2), 140–157.

13. Mao, S., Sun, W., & Kissel, T. (2010). Chitosan-based formulations for drug delivery. *European Journal of Pharmaceutics and Biopharmaceutics, 75*(2), 133–141.

14. Sogias, I. A., Williams, A. C., &Khutoryanskiy, V. V. (2008). Chitosan-based mucoadhesive systems. *Biomacromolecules, 9*(7), 1837–1842.

15. Thanou, M., Verhoef, J. C., &Junginger, H. E. (2001). Oral drug absorption enhancement by chitosan. *Advanced Drug Delivery Reviews, 52*(2), 117–126.

16. Uchegbu, I. F., & Schatzlein, A. G. (2006). Polymers in drug delivery. *International Journal of Pharmaceutics, 307*(1), 1–2.

17. Kean, T., & Thanou, M. (2010). Biodegradation and toxicity of chitosan. *Advanced Drug Delivery Reviews, 62*(1), 3–11.

18. Jayakumar, R., Prabaharan, M., Sudheesh Kumar, P. T., et al. (2011). Biomaterials based on chitin and chitosan. *Biotechnology Advances, 29*(3), 322–337.

19. Kumar, A., Vimal, A., & Kumar, A. (2020). Chitosan-based nanocarriers in biomedical applications. *Materials Science and Engineering: C, 108*, 110389.

20. Panyam, J., &Labhasetwar, V. (2003). Biodegradable nanoparticles for drug delivery. *Advanced Drug Delivery Reviews, 55*(3), 329–347.

21. Patel, M. P., & Patel, R. R. (2019). Chitosan mediated targeted drug delivery. *Journal of Drug Delivery Science and Technology, 49*, 191–205.

22. Ahmed, S., Ikram, S. (2016). Chitosan based scaffolds and nanocarriers. *International Journal of Biological Macromolecules, 82*, 287–295.

23. World Health Organization. (2013). *WHO guidelines on good manufacturing practices (GMP)*. WHO Press.

24. U.S. Food and Drug Administration. (2020). *Guidance for industry: Drug products*. FDA.

25. European Medicines Agency. (2018). *Guideline on nanotechnology-based medicinal products*. EMA.

Chapter 6: Nanostructured Hydrogels for Topical Applications

Dr. Nicky Kumar Jaiswal*, Kabhi Khanna[1]

*Founder, The Article Architecture, India, Email-dr.nickyjaiswalpharmd@gmail.com

*Adesh Institute of Pharmacy and Biomedical Sciences Bathinda Punjab.

Abstract

Nanostructured hydrogel has come as a new platform of topical drug delivery with improved therapeutic potential due to its unique three-dimensional polymer structure and nanoscale structure. These systems have the ability to develop a high degree of retention, biocompatibility, and encapsulation of an array of bioactive agents, which make it possible to regulate and maintain the release of drugs. Nanotechnology incorporated into the pharmaceutical industry increases absorption, stability, and targeted delivery of extremely effective drugs in treating wounds, inflammatory skin diseases, and transdermal therapies. Besides this, site-specific release of drugs in stimulus-responsive hydrogels can be responsive to environmental factors, e.g. pH and temperature, and this results in an enhanced outcome of the therapy. Nevertheless, since the existing problems in regard to stability, scalability and regulatory approval remain, the further development of nanocomposites systems and personalized medicine still continues to expand their opportunities. Altogether, nanostructured hydrogel displays a promising and novel way of treating the skin and the currently existing drug delivery methodologies.

Keywords: Nanostructured hydrogels, Topical drug delivery, Controlled release, Nanotechnology, Dermatology, Wound healing, Stimuli-responsive systems.

1. Introduction

Hydrogels have received a lot of interest in drug delivery systems because they are one of the few polymers that are hydrophilic and form three dimensional polymer networks that have the potential to hold high volumes of water without structural degradation thus being highly biocompatible with biological tissues. Hydrogels have been extensively used as carriers of a wide variety of therapeutic agents, including small molecules, proteins, peptides and herbal bioactives in drug delivery because of the ability to tune their physicochemical properties, such as porosity, swelling behavior and mechanical strength. The properties allow regulated and prolonged release of drugs, enhanced stability of encapsulated drugs and adherence to therapy. Over time, the traditional hydrogel has been upgraded and giving rise to the nanostructured hydrogel which has incorporated nanoparticles, nanofibers or nano crosslinked network as part of its performance enhancement features. It has been shown that the development of nanostructured hydrogels has addressed most of the inefficiencies of the conventional systems including low mechanical strength, low drug loading capacity and lack of control of the drugs release profile. The introduction of nanotechnology has resulted in new types of hydrogel being identified to have a higher surface area, higher bio release capacity and compatibility with biological membranes resulting in higher therapeutic efficacy. In addition, nanostructured hydrogels with stimuli responsive behavior that can release drugs based on environmental conditions such as pH, temperature or enzyme activity can be designed to enable targeted and site specific delivery of drugs. Of particular importance is the use of nanostructured hydrogel in topical therapy

since nanostructured hydrogel can be utilized to deliver therapeutic agent to the skin in a localized and sustained manner. High water content guarantees a moist environment that promotes wound healing and skin regeneration and their soft and flexible nature is that of ensuring better adhesion and comfort on the usage. These systems enhance the penetration of drugs across the skin barrier, which enhances bioavailability and therapeutic efficacy in the treatment of various dermatological issues such as wounding, burning, infection and inflammatory diseases. Nanostructured hydrogel is also widely used in cosmetic and cosmeceutical preparations (skin hydration, anti-aging, rejuvenating, etc.) due to its ability to deliver deep into skin an active ingredient of the formulation. Even though promising as they are in regard to their benefits, issues of formulation complexity, stability and scalability remain research items. Altogether, nanostructured hydrogels constitute an important contribution to the topical drug delivery offering a flexible and efficient platform to enhanced therapeutic performance and patient outcome.

2. Structure and Properties of Nanostructured Hydrogels

The combination of structural and functional characteristics of nanostructured hydrogel is distinctly related to their topical drug delivery application through multiple reasons, and firstly, their three dimensional polymeric network and nanoscale structure. These hydrogels are based on polymer network structure and are comprised of cross-linked polymer chains that form a porous structure and can be used to entrap therapeutic agents. These polymers can be natural like chitosan, alginate and gelatin or synthetic like polyvinyl alcohol and polyethylene glycol which add certain mechanical and chemical properties. The structuring of the hydrogel at the nanoscale increases surface area and leads to better interaction of the hydrogel with the biological tissues and hence effective loading and release of drugs. The interlocked polymer network enables the hydrogel to serve as a reservoir of drug molecules; this is due to the fact that polymer network provides structural stability as well as functional versatility as demonstrated in Figure 1: Structure and Functional Properties of Nanostructured Hydrogels. The swelling nature and water holding ability of the nanostructured hydrogel are one of the most crucial aspects of the gel as it is controlled by the hydrophilic character of the polymer chains. Now these hydrogels are able to take up large volume of water or biological fluids thus swelling up and forming channels in the network to allow diffusion of drugs. The property is particularly applicable in the topical application as it allows moistening the environment that leads to the active release of therapeutic agents and increased the level of hydration of the skin. The degree of swelling can be controlled by the density of cross-linking, polymer composition and environmental factors such as pH and temperature which provides a fine control over the profile of drug release. The mechanical and rheological properties of nanostructured hydrogels are also important in defining their performance and applicability besides swelling properties. Such properties are elasticity, viscosity and gel strength that determine whether the hydrogel will stick to the skin and hold up to the external force, as well as hold together when used externally. Rheology behavior and in particular viscoelasticity offers that the hydrogel can be easily deposited on the skin without any loss of its shape and consistency. The effectiveness of nanomaterials to enhance mechanical strength and stability further enhances these properties to the extent that the hydrogel becomes more resistant to deformation and degradation. All in all, a very specific polymer network, a high swelling ability, and a maximized mechanical strength allow nanostructured hydrogels to be an incredibly useful and versatile system of topical drug delivery, where therapeutic compounds can be successfully controlled and delivered.



Figure 1: Structure and Functional Properties of Nanostructured Hydrogels

3. Types of Nanostructured Hydrogels

The wide range of nanostructured hydrogels can be classified in terms of the type of polymers used in their preparation with each category offering various physicochemical properties and therapeutic effects which is one of the reasons why they are effective in the topical drug delivery systems. Natural hydrogels are polymer based hydrogels which are naturally found through the biopolymers of chitosan, alginate, gelatin, hyaluronic acid and collagen which are widely known to exhibit excellent biocompatibility, biodegradability and low toxicity. These hydrogels are very similar to the extracellular matrix and hence they are highly applicable in wound healing, tissue regeneration and skin repairs. Their inherent bioactivity, such as antimicrobial and anti-inflammatory properties, further enhances their therapeutic potential. It is, however, possible to have natural hydrogels that are restricted with regards to mechanical strength and stability; this can constraint their long-term performance. Synthetic polymer based hydrogel on the other hand are developed using polymers, which are superior in mechanical strength, controlled composition and reproducibility, such as polyvinyl alcohol (PVA), polyethylene glycol (PEG) and polyacrylamide and poloxamers. These hydrogel systems may be custom-designed with very specific physicochemical properties, including tunable swelling properties, degradation rate and kinetics of drug release making them very versatile in terms of a variety of drug delivery applications. Synthetic hydrogels, also, can be more structurally stable and can be engineered to be stimuli-responsive to allow controlled and targeted release of drugs under some condition, such as pH, or temperature changes. Although they have these benefits, they might not have the inherent bioactivity of natural polymers and may need to be further modified to improve their biological compatibility. Hybrid and composite hydrogels Hybrid and composite hydrogels are an advanced form of nanostructured systems which contain natural and synthetic polymers or include nanoparticles, nanofibers or other nanomaterials to achieve synergistic behaviour. These systems are meant to overcome the drawbacks of single types of polymers by combining the biocompatibility of natural polymers, the mechanical strength and versatility of synthetic materials. By combining the characteristics of both gels, hybrid hydrogels hold a better loading capacity of drugs, enhanced mechanical stability and enhanced control of drug release profile, and are, therefore, highly appropriate in complex dermatological uses. Moreover, it can be loaded with nanomaterials to be given other functionalities that include antimicrobial effect, response to stimuli and targeted delivery. The following Table 1: Types of Nanostructured Hydrogels and Their Characteristics,

summarizes the key features and benefits of thesenanostructured hydrogel, classifying them and describing their properties and applications. Overall, the broad spectrum of nanostructured hydrogels forms a flexible platform with the help of which the effective and advanced topical drug delivery systems can be created.

Table 1: Types of Nanostructured Hydrogels and Their Characteristics

S.No.	Type of Hydrogel	Common Polymers	Key Characteristics	Applications
1	**Natural Polymer-Based Hydrogels**	Chitosan, Alginate, Gelatin, Hyaluronic acid	Biocompatible, biodegradable, bioactive	Wound healing, tissue regeneration
2	**Synthetic Polymer-Based Hydrogels**	PVA, PEG, Polyacrylamide, Poloxamers	High mechanical strength, controlled properties	Drug delivery, transdermal systems
3	**Hybrid/Composite Hydrogels**	Natural + Synthetic polymers, Nanoparticles	Enhanced stability, multifunctional, stimuli-responsive	

4. Preparation Methods of Nanostructured Hydrogels

Following a series of steps to prepare nanostructured hydrogels is necessary to achieve stabilized, three dimensional polymer networks with nanoscale properties that enhance drug loading capabilities, mechanical stability and release properties to be developed into topical applications. These techniques can be broadly divided into physical cross-linking, chemical cross-linking and radiation or advanced fabrication techniques with each having its own unique strengths based on the properties of the final hydrogel system that is required. Methods of physical cross-linkage are based on non-covalent forces, such as hydrogen bonding, ionic interactions, hydrophobic forces and crystallization to form hydrogel networks without necessarily using potentially toxic cross-linking reagents. Popular in this category are such methods as freeze-thaw cycling, ionic gelation, and self-assembly that give rise to hydrogels that can be combined with biocompatible molecules and sensitive drugs.These systems are also reversible and environmentally responsive thus making them suitable in application that need stimuli-responsive behavior. They can however have reduced mechanical strength when compared to chemically cross-linked systems. Chemical cross-linking methods, in their turn, imply an establishment of covalent bonds between polymer chains with the help of cross-linking reagents, including glutaraldehyde, genipin, or carbodiimide. The method leads to hydrogels that are more stable in terms of structure, have superior mechanical strength, and have a better control of degradation and drug release characteristics. The cross-linking is also performed using chemicals, thereby enabling control of network density and porosity to be precisely tuned and greatly affecting swelling and diffusion rates of drugs. In spite of these benefits, the application of cross-linkers that are made of chemicals must be optimized to reduce toxicity, and to make them safe when used in biomedical studies. Secondly, besides traditional approaches, radiation and new fabrication tools have attracted interest to the fabrication of new nanostructured hydrogel with desirable characteristics. Other radiation-based techniques, gamma irradiation and electron beam irradiation, allow cross-linking to be achieved without using chemical agents, which results in sterile and very stable hydrogel that can be used in medicine. The development of hydrogel with specific structures, regulated pore dimensions, and customized drug release properties is achieved through advanced methods (3D printing, electrospinning, and microfluidics). The technologies allow developing the patient-specific

and customized hydrogel-based systems of targeted therapy. As shown in Figure 2: Preparation Techniques of Nanostructured Hydrogels, all the methods have different mechanisms and processing conditions affecting the structural and functional properties of the hydrogel. Choice of a suitable preparation method is determined by the nature of polymer, nature of drug, desired mechanical characteristics and desired use. Altogether, these versatile preparation techniques offer a versatile and potent design resource of designing nanostructured hydrogels with ideal outcomes in topical drug delivery systems.



5. Drug Loading and Release Mechanisms

The drug loading and release processes in nanostructured hydrogels are the most important in dictating the efficiency of these systems as topical drug delivery systems because these processes create a way through which therapeutic molecules are integrated into the hydrogel structure and their release at the target site. There are a number of different methods by which drug loading in hydrogels can be accomplished, such as by physical entrapment, chemical conjugation and adsorption to the porous polymer network, depending on the drug and hydrogel composition. When loaded, drugs dissociate out of nanostructured hydrogels via well-established mechanisms, and the most common ones include diffusion-controlled, swelling-controlled and stimuli-responsive processes. In diffusion-controlled delivery, the drug molecules progressively move out of the hydrogel structure into the immediate surroundings along concentration gradients. Pore size, polymer network density, and drug solubility are some of the factors that have a significant effect on this mechanism. Smaller molecules have a higher rate of diffusion whereas larger molecules have a low rate of release because they are hindered by sterics within the polymer network. Such release is used especially in keeping the drug concentration constant and predictable with time. Swelling-controlled release, however, is controlled by the capacity of hydrogel to absorb water or bio-fluids, which causes the polymer network to expand. The network structure of the hydrogel becomes more relaxed as it swells, and, therefore, encapsulated drug molecules can more easily diffuse out. Swelling depends on aspects like polymer composition, cross-linking density, as well as environmental factors, such as pH and temperature. The

mechanism is particularly beneficial in the topical practice, as it offers long-term drug release and maintains a humid condition, which helps keep the wound healing and skin hydrated. Besides these traditional processes, stimuli-responsive release systems are a superior system in nanostructured hydrogel-based drug delivery. These systems are created to react to certain internal or external stimuli like pH, temperature, enzymatic activity or light and allow the targeted and controlled release of drugs. An example is the pH-sensitive hydrogel that is able to release drugs at a faster rate in inflamed or infected tissues when the pH is not normal (when compared to the skin), whereas temperature-sensitive hydrogels can react to body heat and release drugs. This localized and regulated delivery reduces side effects in the system and improves therapeutic effectiveness. In general, the effective drug loading and release that is highly adaptable, coupled with the versatility of nanostructured hydrogels, renders nanostructured hydrogel an ideal and highly versatile medium of topical drug delivery, which can offer a better control of drug release profiles and patient outcomes.

6. Applications in Topical Drug Delivery

The nanostructured hydrogels have emerged as very useful in topical drug delivery because it can offer localized, controlled, and sustained delivery of therapeutic agents and also offer a moist and protective environment to the skin. These hydrogels are highly significant in wound healing and tissue regeneration because they enhance cell proliferation, collagen formation and angiogenesis which contribute to effective tissue repair. They also contain a lot of water that enables them to keep the site of the wound hydrated to eliminate dehydration, which in turn promotes quick healing. Also, antimicrobial agents, growth factors or herbal bioactives can be incorporated into nanostructured hydrogels, which further increases their infection prevention and regeneration promoting properties. They are soft and flexible and therefore can conform to the surface of the wound making the patients comfortable and delivering evenly spread drugs. Nanostructured hydrogel can be used as an effective carrier of anti-inflammatory and immunomodulatory drugs in the treatment of inflammatory skin condition which includes psoriasis, eczema and dermatitis. Their nanoscale structure increases drug penetration across the stratum corneum and active compounds reach deeper into the skin where inflammation remains. This leads to better treatment effect and minimization of the symptoms of redness, itchiness, and swelling. In addition, the slow delivery of drugs through these hydrogels is controlled, which means that high rates of drug delivery do not require the frequent use of these hydrogels, and side effects are also minimized. Nanostructured hydrogel is also commonly utilized in transdermal and cosmetic uses, where they are used to deliver active ingredients across the skin barrier. In transdermal systems, they allow the systemic delivery of drugs by increasing permeability and constant levels of drugs with time. These hydrogels are applied in the cosmetic and cosmetical sector to hydrate and anti-age the skin, as well as brighten the skin, because they can be used to deliver vitamins, antioxidants, and other bioactive agents deeper into the skin. The effectiveness and practicality of nanostructured hydrogels in these use cases are as follows: Table 2: Applications of Nanostructured Hydrogels in Topical Therapy and clearly show the therapeutic advantages and the broad applicability of the product. All in all, advanced hydrogel systems potential lies in the area of enhancing topical drug delivery, improving the outcome of the treatment, and introducing innovative solutions to the field of dermatology and skincare.

Table 2: Applications of Nanostructured Hydrogels in Topical Therapy

S.No.	Application Area	Hydrogel Type	Key Activity	Therapeutic Benefit
1	**Wound Healing**	Nanostructured hydrogels	Regenerative,	Accelerates tissue

		(natural/synthetic)	Moisturizing	repair
2	**Tissue Regeneration**	Nanocomposite hydrogels	Collagen stimulation	Enhances skin regeneration
3	**Inflammatory Disorders**	Drug-loaded hydrogels	Anti-inflammatory	Reduces redness and irritation
4	**Transdermal Delivery**	Stimuli-responsive hydrogels	Controlled drug release	Improves systemic drug delivery
5	**Cosmetic Applications**	Hydrogel-based cosmeceuticals	Hydration, Anti-aging	Improves skin texture and elasticity

7. The merits and demerits of Nanostructured Hydrogels.

The nano structured hydrogels possess more benefits that make them be very effective in topical drug delivery primarily due to their structural and functional properties. The most significant is their high water content that makes them a moist environment that is needed in the healing of wounds, skin hydration and improved diffusion of drugs. Their polymeric network of three dimensions allows the effective encapsulation of a wide range of therapeutics such as small molecules, proteins and herbal bioactives to enable controlled and sustained delivery of drugs. This nanoscale structure enhances surface area and contact with the biological tissues leading to a greater effectiveness of the drugs with penetration and retention in the skin layers. Other than this, nanostructured hydrogel is biocompatible, biodegradable and non-toxic which means it can be used over a long period with minimal side effects. Their elasticity and low consistency make them more comfortable to the patient, and enhance the adhesion to the skin surface. Furthermore, it is possible to design such systems to be stimuli responsive which enables application of site and targeted drug delivery. Although these are positive, there are some limitations and challenges that have to be taken into consideration. Nanostructured hydrogel can have a low mechanical strength and stability especially in physically cross-linked systems that can influence their viability in the course of usage. Formulation and optimization processes may be very expensive and cause the cost of production to increase and no longer be scalable to industrially relevant objects. In addition, large-scale manufacturing is also a problem in terms of uniformity and reproducibility. Possible issues related to drug leakages, premature release and drug storage stability should also be taken into account. In addition, nanomaterials may give rise to safety and environmental issues, in the long run, its use. Overall, it can be concluded that nanostructured hydrogels are high potential solutions, but these constraints should be overcome to allow them to be applied in practice in clinics and commercially as well.

8. Safety, Toxicity and Regulatory Aspects.

The safety and regulatory considerations are critical in the development and utilization of nanostructured hydrogels in topical drug delivery systems. The biocompatibility and biodegradability nature of these hydrogels are normally deemed as safe especially when made with the use of natural or well established synthetic polymers. Biocompatibility and safety testing entails thorough testing by in vitro and in vivo experiments to establish cytotoxicity, skin irritation, sensitization, and possible inflammatory reactions. It is expected that the hydrogel will not cause any irritation or harm to the skin tissues and therefore can be used in the topical region on a long term basis. However, when the nanomaterials are incorporated into the hydrogel matrix, interaction between the nanomaterials and the biological systems should be taken into consideration since the increased penetration may lead to the increased exposure to the tissue or a systemsic absorption. Toxicological research also needs to

take into account the existence of the remaining cross-linking agents, solvents or impurities that can impact safety. Stability and degradation behavior over a prolonged period of time is also important to ensure that the degradation products are safe and non-toxic. The regulatory requirements of nanostructured hydrogels are different based on the purpose of the hydrogel, be it pharmaceutical, medical device, or cosmeceutical. The composition of formulations, manufacturing procedures, quality control and safety and efficacy data are documented and necessary according to the regulations of the regulatory authorities such as the WHO, FDA and EMA. In manufacturing, there should be good manufacturing practice (GMP) to ensure that there is consistency and quality of the product. However, no uniform regulatory principles are specifically to nanostructured systems, which leads to problems with the acceptance and commercialization. Generally, the appropriate and cautious attitude towards the safety assessment and the strict adherence to the requirements of regulations are the key to the safe and useful application of nanostructured hydrogels.

9. Future Prospects and Innovations.

The future of nanostructured hydrogel in topical drug delivery has a great potential due to the continuous development of nanotechnology, material science and customized medicine. The most important innovation that requires mention is the creation of intelligent and stimuli-responsive hydrogels, which are developed to deliver drugs in reaction to a particular environmental action due to pH, temperature, light or enzyme presence. These systems allow accurate and regulated drug delivery, which enhances the efficacy of the therapy and reduce side effects. Indicatively, pH-responsive hydrogels have the ability of selectively releasing drugs in an inflamed or infected area of the skin where the pH is not normal. The other significant development is nanocomposite hydrogel systems, which are hydrogels that are intertwined with nanoparticles, nanofibers or other nanomaterials in order to raise their mechanical strength, drug loading capacity and multifunctional characteristics. Such systems may have other advantages like antimicrobial effect, enhanced stability and target delivery. In addition, topical treatment in the form of hydrogel is also becoming a revolutionary treatment whereby hydrogel preparations are tailored based on some specific patient factors, such as skin type, genetic makeup and severity of disease. The biomarker analysis and digital health technologies, along with artificial intelligence, can be used to create a treatment based on the patient, which facilitates a more positive treatment outcome. Hopefully, these innovations will significantly enhance performance and versatility of nanostructured hydrogel in dermatology. In the long run, the use of intelligent technologies, nanocomposites, and customized solutions will become the future of hydrogel-based drug delivery solutions.

10. Conclusion

One of the most developed and versatile systems of topical drug delivery with significantly improved results relative to the traditional systems in the areas of drug loading, controlled release and therapeutic efficacy. Their three dimensional polymer network with nanoscale dimensions enable them to be effectively encapsulated and provide a wide range of therapeutic agents including small molecules, proteins and herbal bioactives. These hydrogels can provide a non-turbid, moist and protective microclimate, which enhances wound healing, high skin hydration, and increased penetration of drugs through the skin barrier. They are also biocompatible, biodegradable and low toxic making them also suitable in long-term dermatological use. Also, stimuli-responsive and targeted delivery engineering nanostructured hydrogel has created a way into precision medicine and enhanced treatment outcomes. Along with the achievement of these advantages, the formulation, scalability, stability and regulatory approval are also high-profiling issues that should be taken into consideration in order to secure their wide clinical use. With some luck, however, the recent scientific

research, and technological progress, will be able to counter these shortcomings by creating a more stable, robust and customizable system of hydrogel. As nanotechnology, intelligent materials and custom therapeutic systems are integrated there is probable to be a more effective performance and an even more applicable therapeutic system. Overall, nanostructured hydrogels have a tremendous potential as the new generation drug delivery systems that can provide new innovative, efficient and patient friendly ways of treating different skin disorders and others.

References

1. Peppas, N. A., Bures, P., Leobandung, W., & Ichikawa, H. (2000). Hydrogels in pharmaceutical formulations. *European Journal of Pharmaceutics and Biopharmaceutics, 50*(1), 27–46.
2. Hoare, T. R., &Kohane, D. S. (2008). Hydrogels in drug delivery. *Polymer, 49*(8), 1993–2007.
3. Caló, E., &Khutoryanskiy, V. V. (2015). Biomedical applications of hydrogels. *European Polymer Journal, 65*, 252–267.
4. Li, J., & Mooney, D. J. (2016). Designing hydrogels for drug delivery. *Nature Reviews Materials, 1*(12), 16071.
5. Ahmed, E. M. (2015). Hydrogel: Preparation and applications. *Journal of Advanced Research, 6*(2), 105–121.
6. Hoffman, A. S. (2012). Hydrogels for biomedical applications. *Advanced Drug Delivery Reviews, 64*(Suppl), 18–23.
7. Gupta, P., Vermani, K., & Garg, S. (2002). Hydrogels in drug delivery. *Drug Discovery Today, 7*(10), 569–579.
8. Tiwari, G., & Tiwari, R. (2012). Bioadhesive drug delivery systems. *International Journal of Pharmaceutical Investigation, 2*(1), 2–11.
9. Annabi, N., Tamayol, A., Uquillas, J. A., et al. (2014). 3D hydrogels in regenerative medicine. *Advanced Materials, 26*(1), 85–124.
10. Drury, J. L., & Mooney, D. J. (2003). Hydrogels for tissue engineering. *Biomaterials, 24*(24), 4337–4351.
11. Koetting, M. C., Peters, J. T., Steichen, S. D., & Peppas, N. A. (2015). Stimuli-responsive hydrogels. *Materials Science and Engineering: R, 93*, 1–49.
12. Qiu, Y., & Park, K. (2001). Environment-sensitive hydrogels. *Advanced Drug Delivery Reviews, 53*(3), 321–339.
13. Buwalda, S. J., Boere, K. W. M., Dijkstra, P. J., et al. (2014). Hydrogels in a historical perspective. *Journal of Controlled Release, 190*, 254–273.
14. Thakur, V. K., & Thakur, M. K. (2014). Hydrogels: Smart materials. *ACS Sustainable Chemistry & Engineering, 2*(12), 2637–2652.
15. Seliktar, D. (2012). Designing cell-compatible hydrogels. *Science, 336*(6085), 1124–1128.
16. Boateng, J., Matthews, K., Stevens, H., & Eccleston, G. (2008). Wound healing dressings. *Journal of Pharmaceutical Sciences, 97*(8), 2892–2923.
17. Moura, L. I. F., Dias, A. M. A., Carvalho, E., & de Sousa, H. C. (2013). Wound healing mechanisms. *Journal of Tissue Engineering and Regenerative Medicine, 7*(9), 704–718.
18. Kamoun, E. A., Kenawy, E. R. S., & Chen, X. (2017). Smart hydrogels for drug delivery. *Arabian Journal of Chemistry, 10*(5), 1463–1474.
19. Ruel-Gariépy, E., & Leroux, J. C. (2004). In situ-forming hydrogels. *European Journal of Pharmaceutics and Biopharmaceutics, 58*(2), 409–426.
20. Langer, R. (1998). Drug delivery and targeting. *Nature, 392*(6679), 5–10.
21. Torchilin, V. P. (2006). Nanocarriers in drug delivery. *Nature Reviews Drug Discovery, 5*(2), 145–160.

22. Patel, A., Cholkar, K., Agrahari, V., & Mitra, A. K. (2013). Ocular drug delivery systems. *Journal of Controlled Release, 192*, 349–361.
23. World Health Organization. (2013). *Guidelines on good manufacturing practices (GMP)*. WHO Press.
24. U.S. Food and Drug Administration. (2020). *Guidance for industry: Drug delivery systems*. FDA.
25. European Medicines Agency. (2018). *Guideline on nanotechnology-based medicinal products*. EMA

Chapter 7: Formulation Strategies for Phytosome–Chitosan Hydrogels

***Johny lakra, Jasmine Gill[1], Tehreen Parveen[2]**

*Research Scholar, MM College of Pharmacy, Maharishi Markandeshwar Deemed to be University, Mullana-Ambala, Haryana, India Email-lakrajohny@gmail.com ORCID ID: 0009-0006-3704-5247

[1]Research Scholar (Pharm D PB), I.S.F College of Pharmacy, Moga, India, Email-Ajassgill@gmail.com

[2]Assistant Professor, School of Pharmaceutical Sciences, RIMT University, Mandi Gobindgarh, Punjab Email-tehreen.parveen26@gmail.com

Abstract

Phytosom-chitosan hydrogels have also been developed as a new hybrid drug delivery system to combine the bioavailability-enhancing property of phytosomes with the biocompatibility and mucoadhesive characteristic of chitosan hydrogels. These systems have been discovered to increase solubility of herbal bioactives, stability of herbal bioactives, and skin penetration of herbal bioactives as well as control continuous and sustained release of drugs used topically. Their multifunctional nature is what makes them useful in the treatment of wound healing, anti-inflammatory effect and this can also be used to treat chronic skin conditions such as psoriasis and eczema. Nanotechnology has also been included which adds to drug loading, targeted delivery and efficacy of the therapy. Moreover, these hydrogels provide a moist environment which leads to the regeneration of tissues and increases patient compliance. Although some issues with the complexity and the stability of the formulations may arise, the potential of smart and personalized delivery systems is widening due to the continuous innovations. On the whole, phytosome-chitosan hydrogels are a viable platform of the present-day dermatological care approach and drug delivery methods.

Keywords: Phytosome, Chitosan hydrogel, Topical drug delivery, Herbal bioactives, Nanotechnology, Controlled release, Dermatology.

1. Introduction

Phytosome-chitosan hydrids Phytosome- chitosan hydrogel system represents a novel hybrid drug delivery system, which combines the benefits of phytosome technology with the functionality features of chitosan hydrogels, and provides a highly effective platform in topical use. Phytosomes are phospholipid complexes, which can increase the bioavailability and permeability of bioactives of plant origin due to their ability to improve lipid compatibility, and chitosan hydrogel, which is a three-dimensional, biocompatible, and mucoadhesive hydrogel with the ability to release drugs sustainably and exhibit the ability to improve their skin retention. The joint use of the two systems leads to a synergistic formulation that counters the shortcomings of each constituent, including low degree of solubility and stability of phytoconstituents, insufficient drug penetration and retention of conventional hydrogels. The reason why phytosomes are used together with hydrogels is because there is necessity to establish a delivery system that enhances the solubility and stability of the herbal bioactives besides seeking a controlled, localized and sustained drug delivery at the target site.

Phytosomes aid further penetration of active components into the skin as a result of interplay with lipid membranes and the chitosan hydrogel structure promotes adherence to the skin surface and a moist environment to promote drug penetration and therapeutic effect. This dual process enhances greatly the bioavailability and therapeutic action of drugs especially in dermatological diseases including inflammation, infections and wound healing. Also, chitosan provides antimicrobial and wound remedial attributes, which contributes to the overall formulation performance further. The significant benefits of phytosomechitosan hydrogels in topical drug delivery are that it offers a controlled and slow release of bioactive compounds, which decreases the number of applications and enhances patient compliance. They are also biocompatible and biodegradable, therefore, less toxic and irritating and can be used in the long term. Moreover, these hybrid systems can also be designed to demonstrate stimulus-responsive behavior, which means that they can release drugs in a particular environmental parameter, e.g. pH or temperature. These properties of phytosomes at the nanoscale are enriched with the gel network that increases drug loading capacity, stability, and targeted delivery which leads to a better therapeutic outcome. In general, phytosome - chitosan hydrogels are a prospective and novel strategy of dermatological drug delivery, which can close the gap between herbal medicine and modern pharmaceutical technologies to offer effective therapeutic approaches that are safe and convenient to the patient.

2. Components of Phytosome–Chitosan Hydrogels

Phytoseme-chitosan hydrogels are complicated hybrid systems which consist of various functional units that interactively work together to amplify drug delivery performance, especially in topical use. These systems mainly consist of the phytoconstituent which consists of plant-derived bioactive compounds like flavonoids, polyphenols, alkaloids and terpenoids possessing therapeutic properties including anti-inflammatory, anti-oxidative and antimicrobial effects. Nevertheless, these compounds tend to be insoluble and less bioavailable and this is overcome by formation of phytosome complexes. The phytoconstituents in the phytosomes are complexed with the phospholipids, usually phosphatidylcholine, to form a lipid-compatible structure and improve the solubility, stability and permeability of phytoconstituents through biological membranes. This complexation is an important means of enhancing the penetration of herbal bioactives into deeper skin layers. Chitosan is another crucial ingredient, which is a natural, biodegradable, and biocompatible polymer made out of chitin that is the hydrogel structure. The most common usage of chitosan and its derivatives including carboxymethyl chitosan and trimethyl chitosan is that they have great mucoadhesization capabilities, positive surface charge and can form flexible and stable gel networks. These properties allow good contact with the skin surface, high retention of the drug and increase penetration. Moreover, chitosan has the intrinsic antimicrobial and wound healing effects, which also lead to the therapeutic efficacy of the formulation even more. The agents and additives that form cross-links in the hydrogel contribute to stabilizing the hydrogel structure and regulating its physicochemical characteristics. To create a stable three-dimensional network within which polymer chains are cross-linked by using sodium tripolyphosphate, glutaraldehyde, or genipin should achieve increased mechanical strength, stability and control of drug release. Plasticizers, penetration enhancers, stabilizers etc are added to give the best possible properties like flexibility, spreadability and drug permeation. As an illustration, glycerol can be considered a plasticizer to increase the flexibility of the gel, whereas the drug can be improved to penetrate the skin by the use of essential oils or surfactants. In a manner depicted in Figure 1: Components and Structure of Phytosome–Chitosan Hydrogels, the incorporation of phytosome complexes into the chitosan hydrogel structure with the help of suitable cross-linkage and auxiliary cares leads to a well-organized system that has the ability to facilitate effective encapsulation and release of drugs. On the whole, the effective combination and careful selection of these

ingredients is the key to the designing of an efficient and stable phytosome-chitosan hydrogel formulation with improved therapeutic functionality.



3. Formulation Design Strategies

The design approaches of phytosome-chitosan hydrogel are pivotal in dictating the overall performance, stability and therapeutic effectiveness of the ultimate delivery system ex specially in topical applications. One of the overriding constructs that should be considered is the choice of proper polymers and lipids since the choice of appropriate polymers and lipids directly affect the structural integrity and functional behaviour of the hydrogel. The preference of chitosan is normally based on its biocompatibility, biodegradability and mucoadhesion which encourages the adhesion of the skin and adhesion of drugs. The solvability and permeability of the compound can be increased as well through the choice of chitosan derivatives i.e. carboxymethyl and trimethyl chitosan. Phospholipids like phosphatidylcholine are important on the lipid surface of the phytosome complex formation as it enables the encapsulation of phytoconstituents and increase its lipid solubility, which can improve percutaneous absorption and bioavailability of skin. The percentage makeup of polymer and fatty acids must be aligned so as to come up with a stable and efficient hybrid system. The other dimension that plays a crucial role in designing a formulation is how to maximize drug loading and encapsulations. Top level encapsulation will be done to ensure that the maximum amount of bioactive compound is encapsulated in the phytosom complex and then entraped in the hydrogel matrix. Other variables such as drug- lipid ratio, polymer concentration and mode of preparation have a tremendous influence on the efficiency of entrapment and distribution of the drug in the system. High level of encapsulation not only enhances the therapeutic efficacy, but also contributes to the long term and controlled release of drugs. Moreover, the phytosomes should be uniformly distributed in the hydrogel to provide a uniform delivery of the drug in the area of application. Viscosity and gel strength too should be manipulated so as to generate a good topical formulation. Viscosity of the hydrogel is a factor that defines the spreadability, ease of application and the time the hydrogel remains on the skin whilst the gel strength is a factor that defines the structural integrity and the resistance to deformation

of the hydrogel. These types of properties can be varied by focusing on the polymer, increasing or decreasing the density of cross-linking of the polymer and adding other materials such as plasticizers or stabilizers. The optimum ratio between the viscosity and gel strength is one that will enable the hydrogel to be stable and yet flexible and comfortable to apply. We can observe that types of polymers, lipid composition, cross-linking conditions, and the processing methods have all an impact on the physicochemical and functional properties of the formulation as can be seen in Table 1: Formulation Variables and Their Impact on Hydrogel Properties. Overall, a good formulation strategy is crucial in the formulation of phytosome-chitosan hydrogel with high stability, drug delivery efficiency and therapeutic responses when applied in derma.

Table 1: Formulation Variables and Their Impact on Hydrogel Properties

S.No.	Formulation Variable	Parameter/Component	Impact on Properties	Outcome in Drug Delivery
1	**Polymer Selection**	Chitosan, Derivatives	Affects gel formation, adhesion	Improved skin retention
2	**Lipid Composition**	Phospholipids (Phytosome)	Enhances drug encapsulation	Increased bioavailability
3	**Drug-to-Lipid Ratio**	Phytoconstituent loading	Influences entrapment efficiency	Controlled drug release
4	**Polymer Concentration**	Chitosan amount	Alters viscosity and gel strength	Better stability and spreadability
5	**Cross-linking Density**	TPP, Genipin, etc.	Controls network structure	Sustained drug release
6	**Additives**	Plasticizers, Penetration enhancers	Improves flexibility and permeation	Enhanced drug delivery

4. Preparation Methods of Phytosome–Chitosan Hydrogels

Phytosome complexes are incorporated into a polymeric hydrogel framework to form phytosome-chitosan hydrogels which is a carefully designed process of incorporating the phytosome complexes into a hydrogel polymer to improve drug delivery with topical use. The integration of the phytosomes into the hydrogel structure is one of the basic strategies, which entails the dispersal of the pre-formed phytosomes complex consisting of phospholipid-bound phytoconstituents in a chitosan solution. The process allows the bioactive compounds to maintain their increased solubility and permeability properties and they are encased into a gel network that gives them sustained release and better skin retention. At this stage, the issue of dispersion and homogenization is of high importance to ensure that the distribution of phytosomes is evenly distributed throughout the hydrogel, which would directly affect the uniformity of the release of phytosomes and therapy. The three-dimensional structure of the hydrogel is commonly formed with the help of ionic gelation, as well as cross-linking. In ionic gelation, the chitosan is a positively charged polysaccharide which reacts with negatively charged cross-linkage reagents i.e. sodium tripolyphosphate (TPP) to form a stable gel network by electrostatic interactions. It is useful due to its simplicity, mild conditions of processing and the

possibility to work with sensitive bioactive compounds. It is also possible to use chemical cross-linking technique which involves the use of such reagents as genipin or glutaraldehyde to form covalent bonds between the polymer chains, thus enhancing mechanical strength, stability and rationalization of drug release. The intensity of cross-linking is an important factor in deciding the porosity, swelling, and release kinetics of the hydrogel. Alongside the traditional ones, novel strategies of the fabrication are being applied in the development of nanostructured phytosomes-chitosan hydrogel with enhanced functionality. These are nano-gel formation, microfluidics, and 3D printing, whereby close control of the particle size, structure, and distribution of drugs in the hydrogel matrix can be achieved. Specifically, nano-gel systems offer a higher surface area and an improved interaction with the biological tissue leading to an improved penetration and targeting of the drug in questions. The innovative methods also allow the creation of personalized and response-to-stimulus systems in a particular therapeutic use. The general steps that may be taken as shown in Figure 2: Preparation Process of Phytosome Chitosan Hydrogels entail the creation of the phytosome complexes, its entrapment in the chitosan matrix, and cross-linking to create a stable hydrogel system. Selection of a preparation technique will be influenced by issues like drug nature, preferred release profile and use necessity. In general, these preparation methods present a versatile and effective way of designing phytosome-chitosan hydrogels with high stability, drug delivery rate, and better curing effects in skin-care uses.



5. Characterization of Formulations

A phytosomes-chitosan hydrogel formation is a crucial step in determining the quality, stability and therapeutic functioning of the formation especially in topical drug delivery. An all-inclusive analysis entails the determination of physicochemical characteristics, drug concentration and entrapment ability, in vitro drug release and permeation characteristics, among other factors all of which individually define the efficacy of the formulation. Physicochemical characterization involves parameters like pH, viscosity and spreadability, which are critical towards making sure that they are compatible with the skin and spread easily. The pH of the hydrogel must lie in the physiological range of the skin (usually 5.07.0) in order to prevent irritation and preserve the skin integrity. The viscosity is important to the formulation in that it affects its consistency and stability in terms of being able to stay where it is needed without flowing out too much. It is generally quantified with the help of

viscometers or rheometers, which allows information about the flow properties of the gel and its structural strength. Another parameter is spreadability, which measures the ease with which the hydrogel may be cast out uniformly on the skin surface; this is normally measured by assessing the time or effort needed to distribute a given amount of gel. Besides these properties, the presence and content of the drug and entrapment efficiency is key in determination of the loading capacity and even distribution of phytoconstituents in the phytosome-chitosan hydrogel system. Drug content analysis is done to ensure that the formulation contains the required quantity of active compound which is normally determined by the use of analytical procedures like the UV-visible spectroscopy or high-performance liquid chromatography (HPLC). On the other hand, entrapment efficiency is the measure of the percentage of drug that has been effectively encapsulated into the phytosome complexes and retained in the hydrogel matrix and that indicates the efficiency of the formulation process. The entrapment efficiency should be high because it increases the therapeutic efficacy and helps to maintain the release of the drug. Moreover, in vitro release and permeation research on drugs are fundamental to the study of the release dynamics and penetration pattern of the drug by the hydrogel system. The diffusion cell or dialysis is normally used to study the drug release whereby the quantity of drug released at a given time is measured to establish the release profile and mechanism. The studies assist in determining whether the release is diffusion-controlled, swelling-controlled or combined. The permeation studies are usually conducted on excised animal or synthetic membranes, which measure how well the drug enters the skin layers with an insight in its bioavailability and therapeutic effect. These parameters are strongly dependent on factors like the concentration of the polymer, its cross-linking density, and its phytosome properties. In general, comprehensive characterization of phytosome-chitosan gels allows achieving the production of stable, efficient, and patient-friendly preparations with the optimal performance in drug delivery during dermatological application.

6. Stability and Storage Considerations

The issue of stability and storage is very important in determining the effectiveness and safety as well as shelf-life of phytosomechitosan hydrogel formulations, especially in topical drug delivery processes. Physical and chemical stability testing is done to test how the formulation sustains itself in terms of structure, drug content, and performance in various environmental conditions with time. The physical stability of a hydrogel is monitored by observing the appearance, color, phase separation, viscosity, and consistency of the hydrogel. Any modifications in these properties can be evidence of degradation, instability or incompatibility of the formulation components. As an example, changes in viscosity might influence the behavior of spread ability and drug release, and phase separation might result in the dispersion of drugs. Chemical stability is concerned with the integrity of active phytoconstituents and phospholipid complex of phytosome system. Biodegradation of bioactive compounds by oxidation, hydrolysis or light and temperature exposure may greatly decrease therapeutic efficacy. Thus, analytical methods like UV spectroscopy, HPLC and stability-indicating test are quite frequently employed to control drug content and degradation products with time. The reaction among chitosan, phytosomes, and cross-linking substances should also be determined in order to be sure that there are no negative chemical reactions in the course of the storage. Shelf-life determination is an imperative part of stability study and is usually determined by accelerated and real-time stability testing as per the regulatory guidelines. Accelerated stability experiments entail storing the formulation at high temperature and humidity conditions (e.g. 40 C and 75 percent RH) to determine long-term stability, whereas real-time experiments evaluate stability at normal storing conditions over the long term. These tests are used in establishing the expiry date of the product and the storage conditions it should be kept in. The packaging is also important to stabilize

phytosomechitosan hydrogel in the environment by keeping it stable in regards to moisture, oxygen, and light. Appropriate packaging material including airtight containers, laminated tubes, or amber-colored jars are used to reduce the exposure to degrading conditions. It is also important that they are well sealed and labeled to maintain product integrity and safety to the users. Different parameters (that is, pH, viscosity, drug content and microbial stability) are systematically tested through standardized techniques to achieve the same product quality as listed in Table 2: Stability Parameters and Evaluation Methods. All in all, stability and storage conditions must be given serious attention to the development of phytosome- chitosan hydrogels with high reliability in performance, long shelf-life and good therapeutic results.

Table 2: Stability Parameters and Evaluation Methods

S.No.	Stability Parameter	Evaluation Method	Purpose
1	**Appearance &Color**	Visual inspection	Detect physical changes
2	**pH**	pH meter	Ensure skin compatibility
3	**Viscosity**	Rheometer/Viscometer	Assess consistency & stability
4	**Drug Content**	UV/HPLC analysis	Monitor chemical stability
5	**Entrapment Efficiency**	Centrifugation + analysis	Evaluate drug retention
6	**Phase Separation**	Storage observation	Check formulation integrity
7	**Microbial Stability**	Microbial testing	Ensure safety & sterility
8	**Accelerated Stability**	Temperature/Humidity chambers	Predict shelf-life

7. Uses in Dermatological Therapy.

Phytosomechitosan hydrogels are currently of great interest in the dermatological therapy since they can be used to achieve greater drug delivery in addition to biocompatibility and multifunctional therapeutic properties. These hybrid systems offer the optimal moist environment that stimulates tissue restoration, collagen production, and cellular growth in the wound healing and skin restoration process. Chitosan is known to possess intrinsically antimicrobial and hemostatic activities, and it inhibits infections and promotes an accelerated wound healing process. Concurrently, phytosome-delivered herbal bioactives e.g. flavonoids and polyphenols increases antioxidant and oxidative stress and inflammation at the wound site. Such synergy action is very effective in enhancing healing, especially in long-term wounds and burns. Phytosome-chitosan hydrogels have a high potential to be used in the anti-inflammatory and anti-aging fields since they are useful to deliver bioactive compounds into the deepest layers of the skin where they regulate inflammatory pathways and neutralize free radicals. Such systems mostly come in handy in the treatment of the redness, irritation, and photoaging as they enhance skin hydration, elasticity and the overall skin texture. The sustained therapeutic action of the product due to the controlled release properties ensures that the product required frequent application, which improves the adherence of patients. Moreover, antioxidants that are delivered using phytosomes assist in the prevention of early aging by ensuring that the skin cells are not damaged by oxidation. Phytosome-chitosan hydrogels provide a target and efficient delivery of drugs during the treatment of chronic skin diseases like psoriasis, eczema and acne. The increased permeability of phytosomes permits active compounds to enter the stratum corneum and access

deeper layers whereas the hydrogel matrix guarantees a long-lasting retention of active compounds in the site of action. This translates into better treatment outcome and decreased side effects of the drug on systems. In addition, antimicrobial and anti-inflammatory effects of chitosan and anti-inflammatory effect of herbal bioactives help in minimizing itchiness, scaling and inflammation. All in all, these state-of-the-art hydrogel systems offer a flexible and efficient platform to a diverse set of dermatological applications and enhance patient outcomes and their efficacy.

8. Advantages and Limitations

There are a number of strengths associated with the phytosomes- chitosan hydrogels which render them one of the most suitable ones to use in the development of an advanced topical drug delivery system. Their increased bioavailability due to the phytosome complex that increases the solubility and permeability of herbal bioactives is one of the major advantages. The chitosan hydrogel matrix further enhances drug retention and controlled and sustained release of drug, resulting in a high therapeutic action. The systems are non-toxic, biocompatible and biodegradable thus safe to use in long term dermatology. Their mucoadhesive characteristics enhance the plastering of the skin-surface, and their capability to retain a wet atmosphere facilitates wound healing and skin moistness. Phytosomes-chitosan hydrogels can also be made to be stimuli-responsive, enabling targeted delivery of drugs, which is dependent on the environmental conditions that include the pH or temperature. Although these are merits, there are some limitations and challenges. The development of a certain formulation may become complex as the optimization of many parameters should be done including polymer concentration, lipid ratio, and cross-linking conditions. This complexity may escalate the production costs and restrict the large-scale production. Shelf-life may also be affected by stability problems, especially those associated with the breakdown of phytoconstituents and phospholipids. Moreover, herbal raw materials may change, and this may cause inconsistency in the formulation performance. The regulatory issues, as well as the absence of standardized guidelines on such hybrids, may slow down the product approval and commercialization. The effective translation of such systems into clinical practice requires the resolution of these restrictions.

9. Prospects and Future Innovations.

Due to the development of nanotechnology and material science, the future of phytosomechitosan hydrogel in dermatological treatment is very bright. Controlled release of drugs is being achieved by the development of smart hybrid hydrogel systems in response to certain physiological stimuli including pH, temperature, and enzymatic activity. These systems have the ability to selectively administer drugs to skin areas that are diseased or inflamed thus enhancing better therapeutic effects with reduced side effects. Formulations based on nanotechnology are also increasing the functionality of these hydrogels with nanoparticles, nanofibers, and other hi-tech materials that enhance mechanical strength, drug loading capacity and stability. With the help of such innovations, it is possible to create multifunctional systems that have antimicrobial, anti-inflammatory, and regenerative properties. Individualized dermatological treatments are another new trend, in which the compound is descriptively made according to the specific patient criteria, such as skin type, genetic composition, and the severity of the disease. New technologies of artificial intelligence and biomarker analysis are helping in designing individualized treatment plans that ensure the highest level of efficacy with the minimum side effects. Moreover, there is also the inclusion of eco-sustainable and green materials in designing the next-generation formulations. In general, the constant study and the further development of new applications are likely to increase the usage of phytosome-chitosan hydrogels to be a foundation of contemporary dermatological drugs delivery.

10. Conclusion

The phytosomes chitosan hydrogels are a new technology of topical drug delivery that offers the benefits of both Phyto solute and chitosan-based hydrogels. Such hybrid system provides better solubility, stability, bioavailability of herbal Bioactives as well as controlled and sustained drug release. Their biocompatibility, biodegradability and skin penetration increase properties make them ideal in a broad array of dermatological applications, such as wound healing, anti-inflammatory treatment and treating chronic skin conditions. Despite the challenges in terms of complexity of formulation, stability and regulatory approval has been addressed with continued developments in nanotechnology and material science overcoming these associated limitations. It is probable that further improvements will be made on smart, responsive, and personalized systems of hydrogel to enhance their therapeutic potential. Overall, phytosomes-chitosan hydrogels have a great potential as the next generations of drug delivery systems, innovative, safe and patient friendly to deliver effective dermatology therapy.

References

1. Bombardelli, E., Curri, S. B., Della Loggia, R., Del Negro, P., &Tubaro, A. (1989). Phytosome complexes of plant extracts. *Fitoterapia, 60*(1), 1–9.
2. Semalty, A., Semalty, M., Rawat, B. S., & Singh, D. (2010). Phytosome technology: A review. *Journal of Pharmacy Research, 3*(6), 1387–1391.
3. Kidd, P. M. (2009). Bioavailability of phytosome complexes. *Alternative Medicine Review, 14*(3), 226–246.
4. Maiti, K., Mukherjee, K., Gantait, A., Saha, B. P., & Mukherjee, P. K. (2007). Curcumin–phospholipid complex. *International Journal of Pharmaceutics, 334*(1–2), 37–42.
5. Lu, M., Qiu, Q., Luo, X., et al. (2019). Phytosome drug delivery systems. *Drug Delivery, 26*(1), 214–224.
6. Rinaudo, M. (2006). Chitosan properties and applications. *Progress in Polymer Science, 31*(7), 603–632.
7. Dash, M., Chiellini, F., Ottenbrite, R. M., & Chiellini, E. (2011). Chitosan biomaterials. *Progress in Polymer Science, 36*(8), 981–1014.
8. Agnihotri, S. A., Mallikarjuna, N. N., &Aminabhavi, T. M. (2004). Chitosan drug delivery systems. *Journal of Controlled Release, 100*(1), 5–28.
9. Bernkop-Schnürch, A., &Dünnhaupt, S. (2012). Chitosan-based delivery systems. *European Journal of Pharmaceutics and Biopharmaceutics, 81*(3), 463–469.
10. Hoare, T. R., &Kohane, D. S. (2008). Hydrogels in drug delivery. *Polymer, 49*(8), 1993–2007.
11. Caló, E., &Khutoryanskiy, V. V. (2015). Biomedical hydrogels. *European Polymer Journal, 65*, 252–267.
12. Peppas, N. A., et al. (2000). Hydrogels in pharmaceutical applications. *European Journal of Pharmaceutics and Biopharmaceutics, 50*(1), 27–46.
13. Ahmed, E. M. (2015). Hydrogel preparation and applications. *Journal of Advanced Research, 6*(2), 105–121.
14. Koetting, M. C., Peters, J. T., Steichen, S. D., & Peppas, N. A. (2015). Stimuli-responsive hydrogels. *Materials Science and Engineering: R, 93*, 1–49.
15. Qiu, Y., & Park, K. (2001). Environment-sensitive hydrogels. *Advanced Drug Delivery Reviews, 53*(3), 321–339.
16. Grenha, A. (2012). Chitosan nanoparticles preparation. *Journal of Drug Targeting, 20*(4), 291–300.
17. Mohammed, M. A., Syeda, J. T. M., Wasan, K. M., & Wasan, E. K. (2017). Chitosan nanoparticles overview. *International Journal of Nanomedicine, 12*, 765–782.

18. Boateng, J., Matthews, K., Stevens, H., & Eccleston, G. (2008). Wound healing dressings. *Journal of Pharmaceutical Sciences, 97*(8), 2892–2923.
19. Puglia, C., & Bonina, F. (2012). Lipid nanoparticles in dermatology. *Advanced Drug Delivery Reviews, 64*(Suppl), 118–131.
20. Torchilin, V. P. (2006). Nanocarriers in drug delivery. *Nature Reviews Drug Discovery, 5*(2), 145–160.
21. Patel, A., Patel, M., Yang, X., & Mitra, A. K. (2010). Lipid-based drug delivery systems. *Drug Development and Industrial Pharmacy, 36*(10), 1231–1242.
22. Kean, T., & Thanou, M. (2010). Biodegradation and toxicity of chitosan. *Advanced Drug Delivery Reviews, 62*(1), 3–11.
23. World Health Organization. (2013). *Guidelines on good manufacturing practices (GMP)*. WHO Press.
24. U.S. Food and Drug Administration. (2020). *Guidance for industry: Drug products*. FDA.
25. European Medicines Agency. (2018). *Guideline on nanotechnology-based medicinal products*. EMA.

Chapter 8: Characterization Techniques of Nanohydrogel Systems

Kabhi Khanna*, Ansh Kumar Bhuva[1],Tazmeen Shafi[2]

[*]Adesh Institute of Pharmacy and Biomedical Sciences, Adesh University, Bathinda, Punjab

[1]Adesh Institute of Pharmacy and Biomedical Sciences, Adesh University, Bathinda, Punjab Email-anshpatel072@gmail.com

[2]Adesh Institute of Pharmacy and Biomedical Sciences, Adesh University, Bathinda, Punjab Email-tazmeenshafi568@gmail.com

Abstract

The application of nanohydrogel system in drug delivery has become an innovative drug delivery platform due to its unique physicochemical properties, water content, and ability to facilitate the delivery of drugs in controlled and sustained releases. To ensure good therapeutic outcomes, it is necessary to comprehensively characterize them in terms of their structure, stability, and performance. Physicochemical, chemical, mechanical, and biological tests, drug loading and drug release studies are the main types of characterization, which are highlighted in this chapter. In-depth information on the behavior of nanohydrogel at both molecular and nanoscale can be provided by such complex analytical techniques as spectroscopy, microscopy and real-time surveillance equipment. Stability and storage tests also ensure long term effectiveness and safety of the formulation. Although the characterization is not easy as the character is complex and dynamic, recent advances in nanotechnology have been able to improve the accuracy and reliability of analysis to a significant extent. In general, it is observed that characterization techniques are important to maximize the use of nanohydrogel systems in biomedical and dermatological applications.

Keywords: Nanohydrogels, Characterization, Drug delivery, Physicochemical analysis, Nanotechnology, Controlled release, Biomedical applications.

1. Introduction

Nanohydrogel systems have been developed as novel drug delivery systems that possess the characteristic features of hydrogels combined with nanoscale characteristics, delivering a better drug loading capacity, controlled drug release and increased contact with the bio tissue especially in dermatological and biomedical applications. These systems are made of three-dimensional and cross-linked networks of polymer at the nanoscale that can entrap a broad range of therapeutic agents such as small molecules, proteins, peptides, and herbal bioactives. These make them very suitable in topical, transdermal, and targeted drug delivery because of their high water content, tunable physicochemical properties and their biocompatibility. The nanoscale morphology of nanohydrogels gives it a high surface area and a high diffusion rate of drugs as well as an enhanced capability to penetrate biological barriers like the stratum corneum. With these benefits, nanohydrogels have become very popular in the contemporary pharmaceutical research as multi-purpose vectors that can be developed to achieve targeted therapeutic functions. Characterization is crucial in the nanohydrogel systems and it is rather difficult to overrate its significance in the quality, performance stability and safety of the nanohydrogel system. The extensive characterization will guarantee that the formulation is developed to the desirable requirements concerning particle size, morphology, mechanical strength,

drug loading capacity, and drug release behavior. Dynamic light scattering, electron microscopy, spectroscopy, and thermal analysis are among the techniques that are normally used to determine these parameters. Proper characterization is paramount in maximizing the formulation variables, reproducibility and in vivo performance. It also assists in the compliance with regulations since it presents the scientific evidence of the safety and effectiveness of the formulation. Besides, characterization aids the interpretation of the interface between the nanohydrogel and biological systems such as the drug release processes, permeability, and biocompatibility, which are essential to deliver successful treatment results. Efforts notwithstanding, nanohydrogels are complex and dynamic in nature, and their characterization poses a number of challenges associated with the latest progress in analytical methods. Among the most important is the precise quantification of nanoscale characteristics of the nanoparticle size and distribution that may be affected by the environmental conditions and methods of sampling preparation. It is also challenging to get clear and consistent imaging results with heterogeneous and soft structure of hydrogel because of the use of the material in imaging techniques, especially electron microscopy. The high water content may also be an inconvenience to some analysis procedures where special procedures or sample preparation steps have to be followed. The other problem is that drug release and diffusion are difficult to assess since they depend on a variety of factors such as the polymer composition, the density of the cross-linking, and the environment. The reproducibility and consistency of characterization outcomes are also an important issue, especially the production on large scale. Furthermore, the absence of standardized protocols in the characterization of nanohydrogel can cause inconsistency in the interpretation of the data and prevent approval by the regulators. All in all, nanohydrogel systems have tremendous potential in drug delivery, but characterization in all its forms is crucial to their successful development, optimization, and use in the clinic.

2. Physicochemical Characterization

One of the most important aspects of evaluating the stability of nanohydrogel systems is its physicochemical characterization which provides detailed features in terms of structures and surface characterizations at the nanoscale. Particle size and size distribution is one of the most important parameters and determinant of drug loading capacity, release behavior and penetration through biological barriers like the skin. The diameter of the nanohydrogels varies between a few and several hundred nanometers and the distribution of the size must be uniform or the size distribution invariably becomes non-uniform and lacks the property of uniform distribution. Dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA). The most typical methods to quantify particle size and polydispersity index include dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA), which give information on the homogeneity of the system. A smaller particle size is likely to cause an increase in the surface area and penetration of the tissue but narrow size distribution is reliable in providing therapeutic effects. Another important parameter that determines the stability of nanohydrogel dispersions and interaction between them and the biological membranes is the zeta potential and surface charge. The electrical charge on the particle surface is indicated by the zeta potential and the measure of zeta is usually done through the light scattering of electrophoresis. The absolute value of the zeta potential values is large, which implies that the particles have strong repulsive electrostatic forces that prevent aggregation and hence enhances colloidal stability. Besides, the positively charged nanohydrogels are more likely to be more effective in cellular uptake and bioadhesion since surface charge has got a role to play in determining whether the positively charged nanohydrogels can interact with negatively charged cell membranes and the skin surfaces with a higher degree of penetration. Morphology and structural analysis also give the necessary data concerning the shape and surface properties as well as the inside structure of nanohydrogels. This is

through advanced imaging techniques such as scanning electron microscopy (SEM), transmission electron microscopy (TEM) and atomic force microscopy (AFM). SEM can provide comprehensive surface images that can be used to observe the texture and porosity of the hydrogel network; TEM can be used to see the internal structures and nanoscale organization. The topographical analysis capabilities of high resolution and mechanical property measurements at nanoscale will provide information about the stiffness and elasticity of the hydrogel. All these techniques will help in establishing the establishment of the stable nanohydrogel regime and the nature of structural features which influence the process of loading and unloading drugs. The combination of particle size analysis, measurement of surface charge and morphological analysis as shown in Figure 1: Physicochemical Characterization of Nanohydrogel Systems give a complete picture of the system physicochemical behavior. In general, detailed physicochemical characterization plays a crucial role in optimizing the formulations of nanohydrogel, improving stability, and performance of nanohydrogel in specific and targeted delivery of drugs locally and systemically.



Figure 1: Physicochemical Characterization of Nanohydrogel Systems

3. Chemical and Structural Characterization

Nanohydrogel systems: Chemical and structural characterization of nanohydrogel systems is important to determine the molecular interaction, modification in the functional groups, crystallinity, and thermal behavior of the formulation, which directly affect the drug loading, stability, and drug release performance. Fourier Transform Infrared Spectroscopy (FTIR) has been one of the applications that are most prevalent in the determination of functional group and validation of the chemical interaction of the polymer, drug, and cross-linking agents in the nanohydrogel system. FTIR analysis gives typical absorption peaks of certain chemical bonds that enable a researcher to identify any changes or shifts that will confirm successful encapsulation of drugs or chemical alterations during formulation. Nuclear Magnetic Resonance (NMR) spectroscopy also supplements FTIR as it will give detailed information regarding the molecular structure, chemical environment, and dynamics of the components in the hydrogel system. NMR is especially applicable in establishing the presence of polymer network, assessment of degree of cross-linking, and also in determining the interactions

between phytoconstituents and polymer matrices. Another essential method in determining the crystalline or amorphous state of nanohydrogels and the drugs that are incorporated is the X-ray Diffraction (XRD). The method aids the identification of the presence of the drug in a crystalline form or has been transformed into an amorphous form during formulation, which is in most cases linked with high solubility and bioavailability. The usual indication of successful drug incorporation into the hydrogel matrix is a reduction or loss of typical crystalline peaks in the XRD patterns. Differential Scanning Calorimetry (DSC) is useful in understanding the thermal properties and stability of nanohydrogel systems as it measures heat flow as a result of a phase change like melting, crystallization, and glass transition. DSC analysis aids in establishing the compatibility of components of formulations and whether some interaction can occur that can alter stability. It is also helpful to assess the physical condition of the drug in the hydrogel and ensure its dispersion in the molecular scale. All these methods of characterization will give a complete picture of the chemical composition and structural integrity of nanohydrogels. As can be summarized in Table 1: Chemical Characterization Techniques and Their Applications, each of the techniques provides certain insights that would be useful in optimizing and validating the formulation. All in all, chemical and structural characterization is critical towards guaranteeing the establishment of stable, effective, and reproducible nanohydrogel systems in the application of advanced drug delivery platforms.

Table 1: Chemical Characterization Techniques and Their Applications

S.No.	Technique	Principle	Key Information Obtained	Application in Nanohydrogels
1	**FTIR** (Fourier Transform Infrared Spectroscopy)	Absorption of IR radiation by functional groups	Identification of chemical bonds and interactions	Confirms drug–polymer interaction and cross-linking
2	**NMR** (Nuclear Magnetic Resonance)	Magnetic behavior of atomic nuclei	Molecular structure and chemical environment	Determines polymer structure and network formation
3	**XRD** (X-ray Diffraction)	Diffraction of X-rays by crystalline materials	Crystallinity and phase structure	Identifies crystalline/amorphous nature of drug
4	**DSC** (Differential Scanning Calorimetry)	Heat flow during thermal transitions	Thermal stability and phase transitions	Evaluates compatibility and physical state of drug

4. Mechanical and Rheological Properties

The parameters are the mechanical and rheological properties of the nanohydrogel systems, which are critical in defining the performance of the system, its stability and applicability in drug delivery, especially in topical and transdermal delivery. These properties determine how the hydrogel will behave under stress, how the hydrogel is to diffuse on the skin, and how the hydrogel is to absorb and deliver therapeutic agents to the skin. The rheological properties of greatest interest are the viscosity and flow behavior since they influence the ease of delivery, spread and residence time of the hydrogel at the administration site. In most nanohydrogels, it is usual to have shear-thinning, a non-Newtonian behavior, where the viscosity of the gel decreases with the shear rate such that a gel may become less viscous during use and then it recovers its shape after the end of use. This makes the property highly

desired in topical formulations, as it causes the formulas to become more readily applied to the skin and much more adherence of the formula to the skin. They are usually measured with the help of rheometers and viscometers which provide data on the profile of the flow, and integrity of the hydrogel system. Elasticity and gel strength are also extremely vital since they determine how the hydrogel can sustain its structure when it is subjected to some mechanical forces and external stress. Elasticity is the ability of the hydrogel to be recovered to its original shape after deformation with gel strength being the degree of firmness and strength of the polymer network. Some of the factors that control these properties include polymer concentration, cross-linking density and additives. Balanced gel strength will ensure that the hydrogel is neither too hard nor too soft and it can maintain its structure without being too hard and hence making it very easy to use. These properties are measured using mechanical testing methods which include compression and oscillatory rheology and are used to optimize formulation parameters. The ability of nanohydrogels to swell and the property of the hydrogel to retain water is also a significant property of the gel since it directly affects the kinetics of drug release and the ability of the hydrogel to keep the environment moist, which is also a critical property of wound healing and skin hydration. Swelling due to absorption of water in the hydrogel leads to growth and formation of channels in the polymer network that allows diffusion of drugs. The degree of swelling is dependent on the hydrophilicity of polymer, cross-linking density and environmental factors, e.g. pH and temperature. The hydrogel has a high water retention capacity, which increases the capacity of the hydrogel to maintain the application site moist promoting better therapeutic effects and comfort to the patients. These parameters are all that determine the functional performance of nanohydrogel systems as shown in Figure 2: Mechanical and Rheological Properties of Nanohydrogels. Research in the field of viscosity, elasticity, gel strength and swelling behavior is required to develop highly effective, stable and patient friendly formulations of nanohydrogel in the development of the advanced drug delivery system.



Figure 2: Mechanical and Rheological Properties of Nanohydrogels

5. Drug Loading and Release Studies

Nano-hydrogel loading and release investigation is part of characterization of the nanohydrogel systems because it directly influences the therapeutic efficacy, dose precision, and control delivery profile of the drug entrained. The main criteria to assess the effectiveness of the active pharmaceutical

ingredient incorporation into the nanohydrogel matrix are drug content and entrapment efficiency. Drug content is the actual dose of drug in the formulation and is usually determined through such means of analysis like UV- visible spectroscopy or high-performance liquid chromatography (HPLC) to guarantee the consistency of doses and accuracy of formulations. Entrapment efficiency, conversely, is the percentage of drug that was successfully entrapped in the hydrogel network in relation to the total amount of drug employed in the formulation. The entrapment efficiency is high meaning good incorporation and low loss of drugs, a factor that is important towards delivery of drugs in a sustained and targeted manner. These parameters are highly dependent on factors like polymer concentration, density of cross-linking, solubility of the drug, and method of preparation. The in vitro drug release kinetics will give an insight in the manner the drug is released off the nanohydrogel system with time under lab conditions. These experiments are normally performed under diffusion cell, dialysis membrane, or Franz diffusion apparatus wherein the formulation undergoes diffusion in a donor compartment and the volume of drug released into a receptor medium is quantified at a set time period. An analysis of the release data is then conducted on several kinetic models including zero order, first-order, Higuchi models or Korsmeyer-Peppas models to establish the mechanism of drug release. Nanohydrogels tend to have controllable and prolonged release characteristics because of their cross-link network polymeric framework, which controls the diffusion of drugs molecules via the framework. Factors that may affect the release behavior include swelling, polymer matrix degradation and environmental elements like pH and temperature. Diffusion and permeation analyses also determine the capacity of the drug to permeable biological barriers especially the skin during topical use. The experiments are typically conducted on animal or human skin that has been excised, synthetic membrane or cell culture model to replicate in vivo. The parameters that can be calculated to quantify the efficiency of drug transportal through the membrane are the permeation rate, flux and permeability coefficient. Nanohydrogels are also beneficial in terms of their solubility, being in close contact with the skin, and being able to release drugs at the targeted site. Also, it can be penetrated by adding nanoscale structures and functional additives. Overall, the drug loading and release study enables a profound understanding of the behavior of the nanohydrogel systems in terms of drugs delivery and optimization of the formulation factors to enhance therapeutic efficacy and drug delivery in the practice of biomedical and dermatological care.

6. Surface and Thermal Analysis

Surface and thermal profiles of nanohydrogel systems play a vital role in achieving structural integrity, drug loading capacity, stability and general functionality of such systems in drug delivery systems. The surface area and porosity of the nanohydrogels can be studied to determine the internal structure of the nanohydrogels since the surface area and porosity of the nanohydrogels can be directly linked to the encapsulation, diffusion and release behaviour of the aforementioned drugs. Surface area is normally calculated through methods such as Brunauer Emmett Teller (BET) analysis and also porosity and pore size distribution are determined using techniques, such as mercury intrusion porosimetry or gas adsorption techniques. High surface area and well defined porous structure increases the drug loading capacity as it has more active sites to adsorb, and bind with the drug in the hydrogel network. Also, the size and distribution of the pores will greatly affect the rate of release of the drug since large and interconnected pores will result in faster diffusion and other small pores will result in a controlled release and a sustained one. Surface morphology and porosity also help enhance contacting with biological tissues to enhance adhesion and permeability in topical applications. The thermal stability and degradation studies are also necessary in deciding the stability and suitability of the nanohydrogel systems in various environmental conditions.Thermal behavior such as phase transitions, melting temperature, and degradation patterns are common methods of

assessing thermal behavior by the use of Differential Scanning Calorimetry (DSC) and Thermogravimetric Analysis (TGA). DSC will provide information on how the formulation constituents are compatible and the physical state of the drug in the hydrogel matrix, and TGA will provide information on how the formulation constituents are compatible and the physical state of the drug in the hydrogel matrix. These experiments can be utilized to determine how stable nanohydrogels are in storage, processing and application. Knowing thermal properties is especially significant in making sure that the formulation does not degrade prematurely in different temperatures and that it is also stable under different temperatures. As shown in Table 2: Thermal and Surface Characterization Parameters, the parameters that need to be looked into in the process of formulations include surface area, pore size, thermal transitions and degradation temperature; all of which are systematically measured with the assistance of advanced analytical techniques to bring out the best in the performance of the formulation. In most situations, surface and thermal characterization can give appreciable information on the physical and chemical stability of the nanohydrogels that are useful in designing strong, efficient and reliable drug delivery systems in biomedical and dermatological research.

Table 2: Thermal and Surface Characterization Parameters

S.No.	Parameter	Technique Used	Key Information Obtained	Application in Nanohydrogels
1	**Surface Area**	BET Analysis	Specific surface area	Enhances drug loading capacity
2	**Porosity & Pore Size**	Mercury porosimetry / Gas adsorption	Pore distribution and volume	Controls drug release rate
3	**Surface Morphology**	SEM / AFM	Surface texture and structure	Improves adhesion and interaction
4	**Thermal Transitions**	DSC	Melting point, glass transition	Determines compatibility and stability
5	**Thermal Stability**	TGA	Decomposition temperature	Evaluates heat resistance
6	**Degradation Profile**	TGA / DSC	Weight loss patterns	Predicts shelf-life and storage stability

7. Biological Evaluation

A biological assessment of nanohydrogel systems is an essential part of the safety, compatibility, and therapeutic efficacy of biomedical and dermatological nanohydrogel systems. The basis of cytotoxicity studies and biocompatibility studies is to determine whether the formulation is safe to use on the biological tissues. These investigations are generally performed with the aid of cell culture models in vitro (keratinocytes or fibroblasts) in which the cell viability is assessed with the help of such assays as MTT, Alamar Blue, or Live/ Dead staining. Having a large number of viable cells implies that nanohydrogel is non-toxic and can be used therapeutically. Biocompatibility is also the assessment of the interactions of the hydrogel and biological systems, such as protein adsorption and cell adhesion and proliferation, which may be utilized in wound healing and tissue regeneration.

Sensitization tests and skin irritation tests will also be used to determine the safety of nanohydrogels when used topically. In vivo animal models or other in vitro reconstructed human skin models are used to test them to determine the likelihood of irritation, redness, or allergic response on their application. The parameters that are monitored, like erythema, edema, and histopathological change are done very closely to make sure that the formulation does not lead to adverse skin reactions. Besides safety analysis, the antimicrobial and anti-inflammatory properties of nanohydrogels are also important in its therapeutic efficacy, especially in the treatment of the skin infection and inflammatory diseases. Antimicrobial activity is commonly determined by techniques such as agar diffusion, minimum inhibitory concentration (MIC) or zone of inhibition against usual pathogens such as Staphylococcus aureus and Escherichia coli. In cell-based or animal models, anti-inflammatory activity is determined by the decrease in the level of inflammatory markers or cytokines. These properties are improved by incorporation of bioactive components, including herbal extracts or nanoparticles, and nanohydrogels are very effective in healing and inflammation prevention. In general, biological assessment guarantees that the nanohydrogel systems are safe, effective and that they can be employed in clinical use.

8. Stability and Storage Investigations.

Nanohydrogel system storage and stability studies are needed to ensure that the nanohydrogel systems can perform, be safe, and reliable in different environmental conditions in the long run. Physical stability entails testing variations in appearance, color, viscosity, phase of separation and consistency with time. Any change in these parameters can be viewed as a sign of the unsteadiness or even deterioration of the hydrogel system. As an example, increase or decrease in viscosity can influence the spreadability and drug release pattern whereas phase separation can result in unbalanced distribution of drugs. They are normally monitored in conditions that are different in terms of storage conditions such as different temperatures and humidity to determine the strength of the formulation. The chemical stability is concerned with the integrity of drug and polymer in the nanohydrogel system. Detecting any degradation of the active compound or chemical interactions between formulation components are detected by use of an analytical method, whereby HPLC, UV spectroscopy, or FTIR are the analytical methods used. Oxidation, hydrolysis, and light or heat exposure may have a strong effect on the stability of chemicals, resulting in lower therapeutic effect. Thus, it should be kept in mind that the formulation should be able to retain its chemical composition during the desired shelf-life. Shelf-life analysis is done by using both accelerated and real time stability tests. Accelerated tests are tests in which the formulation is subjected to higher temperature and humidity conditions (e.g. 40C and 75 percent RH) to examine long-term stability whereas real-time tests are tests that examine stability during normal storage conditions over time. Through these studies, it is possible to calculate the expiry date, storage conditions and packaging of the product. The formulation is then aimed with proper packaging material (airtight and light resistant containers) to avoid the effects of the environment. In general, the stability and storage research are critical in maintaining a uniform quality, safety, and effectiveness of products across the product lifecycle.

9. Developed and Novel Characterization Techniques.

Development of nanotechnology and analytical science has led to invention of very elaborate characterization methods which are used in providing further insights about the structure, behaviour and performance of the nanohydrogel systems. The size, distribution, and surface properties of particles in the nanoscale are accurately measured using analytical methods (nanoparticle tracking analysis, nanoparticle dynamics light scattering) and analytical spectroscopy. All these methods are more accurate and sensitive than traditional methods and help to understand and optimize the

nanohydrogel formulations. Nanohydrogels have also been greatly characterised by imaging and spectroscopic inventions. High-resolution techniques, such as cryo-electron microscopy (cryo-EM), confocal laser scanning microscopy (CLSM), and super-resolution microscopy can be used to visualize the structure of a hydrogel and the distribution of drugs within the matrix at that level never before. The spectroscopies, e.g., Raman spectroscopy and advanced NMR, give information on a molecular scale, e.g. chemical reaction and structural organization. The other useful development is the real-time monitoring that will allow to continuously monitor the release of the drug, its degradation and its effects on the biological systems. These methods involve in situ imaging, biosensors and microfluidic systems which apoyse physiological environments which enable dynamic assessment of nanohydrogel functionality. Not only do these innovations enhance the level of accuracy in the characterization, but also contribute to the development and simplification of complicated drug delivery devices.

10. Conclusion

A good example of a new kind of advanced drug delivery systems with a tremendous potential in biomedical and dermatological practice is nanohydrogel systems. They should be understood and maximized performance is achieved through comprehensive characterization, i.e., physicochemical, mechanical, chemical, biological and stability tests. The critical information about drug loading, release, stability and its interaction with biological systems, which can be used to create safe and effective formulations, can be obtained by these analyses. Nevertheless, in spite of the difficulties that this complicated structure and active nature introduce to them, new methods of analysis and nanotechnology is constantly developing to increase the accuracy and reliability of the characterization methods. It is anticipated that innovative tools and methodologies that are integrated will lead to further enhancement of designing and optimizing and clinical translation of nanohydrogel systems. Overall, the detailed characterization is one of the pillars of the successful creation of nanohydrogels and the route towards their widespread use in the modern sphere of drug delivery and treatment approaches is opened.

References

1. Zhang, X., & Wang, Y. (2021). Nanohydrogels for biomedical applications. *Advanced Functional Materials, 31*(15), 2007845. https://doi.org/10.1002/adfm.202007845
2. Li, J., Mooney, D. J. (2016). Designing hydrogels for controlled drug delivery. *Nature Reviews Materials, 1*(12), 16071. https://doi.org/10.1038/natrevmats.2016.71
3. Buwalda, S. J., Boere, K. W. M., Dijkstra, P. J., et al. (2014). Hydrogels in therapeutic applications. *Journal of Controlled Release, 190*, 254–273.
4. Kopeček, J. (2007). Hydrogel biomaterials: A smart future? *Biomaterials, 28*(34), 5185–5192.
5. Thoniyot, P., Tan, M. J., Karim, A. A., et al. (2015). Nanoparticle–hydrogel composites. *Advanced Science, 2*(1–2), 1400010.
6. Narayanaswamy, R., &Torchilin, V. P. (2019). Hydrogels and their applications. *Molecules, 24*(3), 603.
7. Varaprasad, K., Jayaramudu, T., & Sadiku, E. R. (2020). A mini review on hydrogels. *International Journal of Biological Macromolecules, 164*, 1354–1361.
8. Sood, N., Bhardwaj, A., Mehta, S., & Mehta, A. (2016). Stimuli-responsive hydrogels. *Drug Delivery, 23*(3), 748–763.
9. Hoang Thi, T. T., et al. (2020). Nanogels as carriers. *Gels, 6*(4), 36.
10. Karimi, M., et al. (2016). Smart micro/nanogels in drug delivery. *Chemical Society Reviews, 45*(5), 1457–1501.

11. Albanese, A., Tang, P. S., & Chan, W. C. W. (2012). Nanoparticle size effects. *Annual Review of Biomedical Engineering, 14*, 1–16.
12. Wilhelm, S., et al. (2016). Nanoparticle delivery efficiency. *Nature Reviews Materials, 1*(5), 16014.
13. Giri, J., et al. (2011). Nanomaterial properties and drug delivery. *Journal of Nanoscience and Nanotechnology, 11*(6), 4680–4690.
14. Pelton, R. (2000). Temperature-sensitive microgels. *Advances in Colloid and Interface Science, 85*(1), 1–33.
15. Lyon, L. A., & Fernandez-Nieves, A. (2012). Microgel colloids. *Annual Review of Physical Chemistry, 63*, 25–43.
16. Richtering, W., & Pich, A. (2012). Responsive microgels. *Soft Matter, 8*(44), 11423–11430.
17. Karg, M., & Hellweg, T. (2009). Thermoresponsive microgels. *Current Opinion in Colloid & Interface Science, 14*(6), 438–450.
18. Chai, Q., Jiao, Y., & Yu, X. (2017). Hydrogels for biomedical applications. *Gels, 3*(1), 6.
19. Kwon, I. K., et al. (2013). Hydrogels for tissue engineering. *Biomaterials Research, 17*(1), 1–13.
20. Nichols, S. P., Koh, A., Storm, W. L., Shin, J. H., &Schoenfisch, M. H. (2012). Biocompatible hydrogels. *Biomaterials, 33*(29), 7507–7520.
21. De Jong, W. H., & Borm, P. J. A. (2008). Drug delivery and nanoparticles. *International Journal of Nanomedicine, 3*(2), 133–149.
22. Ruel-Gariépy, E., & Leroux, J. C. (2004). Injectable hydrogels. *European Journal of Pharmaceutics and Biopharmaceutics, 58*(2), 409–426.
23. Langer, R. (1998). Drug delivery and targeting. *Nature, 392*(6679), 5–10.
24. Siepmann, J., & Peppas, N. A. (2011). Modeling drug release. *International Journal of Pharmaceutics, 418*(1), 6–12.
25. Torchilin, V. P. (2014). Multifunctional nanocarriers. *European Journal of Pharmaceutics and Biopharmaceutics, 87*(3), 467–483.

Chapter 9: Advanced Evaluation Strategies (In Vitro, Ex Vivo & Kinetic Modeling)

Johny Lakra*Kirti[1], Ritika Saini[2]

Research Scholar, MM College of Pharmacy, Maharishi Markandeshwar Deemed to be University, Mullana-Ambala, Haryana, India Email- lakrajohny@gmail.com

[1]Assistant Professor, Department of Pharmacy, Amritsar Group of Colleges, Amritsar, Punjab, India

[2]Assistant Professor, Department of Pharmacy, Amritsar Group of Colleges, Amritsar, Punjab, India

Abstract

Improved assessment strategies, including in vitro, ex vivo, and kinetic modelling strategies are required to optimize modern drug delivery systems. The techniques can provide valuable information on the behavior of drug release, permeation, retention, and drug interaction to the biological barriers, particularly in topical and transdermal systems. In vitro methods offer a controlled, reproducible environment in which the study of release kinetics can be done, and ex vivo experiments can be used to provide physiologically relevant data in the utilization of biological tissues. Kinetic modeling is also capable of enhancing the understanding of the mechanisms of the release as well as predicting the performance in vivo. With the new technologies of artificial intelligence, microfluidic systems and real-time tracking tools, the evaluation is becoming more precise and efficient despite the biological variability and limitations of the models. These developments enable the safe, successful and selective in vivo delivery of drugs and reduce the necessity to perform large-scale in vivo experiments.

Keywords: In vitro analysis, Ex vivo, Drug release kinetics, IVIVC, Nanohydrogels, Drug permeation, Predictive modeling.

1. Introduction

The use of advanced evaluation strategies is essential in designing and improving the contemporary drug delivery system, especially nanocarrier and hydrogel-based ones, as they offer detailed information about their efficacy, safety, and effective therapy results. Drug delivery evaluation strategies include extensive variety of experimental and analytical techniques that are used to determine the behavior of drug release, permeation, stability, and interaction with biological systems. Among them, in vitro and ex vivo research are key instruments that enable the researcher to model and predict the in vivo behavior of formulations under regulated conditions. In vitro assessment procedures e.g. drug release assessment by the use of dialysis membranes or Franz diffusion cells offer essential data on rate and mechanism of drug release of the formulation. Such studies aid in the comprehension of how a formulation variable can affect drug delivery and are able to optimise release profiles to produce sustained or targeted therapy. Ex vivo experiments are, however, those which use excised tissue in an animal or human being, especially the skin, to test drug permeation, retention and deposition under a more biologically realistic condition. These techniques fill the force between in vitro testing and in vivo research since they provide more realistic information regarding the contact between drugs and biological obstacles, particularly in topical and transdermal systems. In vitro and

ex vivo studies are important because they will be used to reduce dependence on using animals to conduct tests, cutting the cost of conducting experiments, and screening many formulations in a short period during the development process. They also assist with regulatory needs through the creation of reproducible and scientifically approved data about formulation performance. Moreover, besides experimental analysis, kinetic modelling is crucial in the interpretation of data on drug release and the principles that dictate the mechanism of drug transport. The most common mathematical models that are used to study the equations of release kinetics to decide whether diffusion, erosion, or both rules the drug release are the zero-order, first-order, Higuchi, and Korsmeyer-Peppas equations. Kinetic modelling is not only useful in modelling the release behavior of drugs in various conditions but it is also useful in the rational design of formulations with desired release behavior. Moreover, experimental data combined with kinetic models can be used to better create correlations among in vitro, ex vivo, and in vivo performance which is critical in achieving successful clinical translation. Although these evaluation strategies have their benefits, they also have issues with variability in biological samples, modelling, and complexity of physiological conditions, and also standardized protocols. However, sophisticated assessment strategies with the use of in vitro, ex vivo, and kinetic modelling technologies are still irreplaceable instruments in the creation of effective, safe, and targeted drug delivery systems.

2. In Vitro Evaluation Techniques

The in vitro evaluation techniques are fundamental in the determination of performance, release quality and permeability characteristics of advanced drug delivery systems, especially nanohydrogels and topical preparations since they allow the controlled and reproducible environments to study drug transfers. One of the most significant in vitro studies that are commonly performed by dialysis membrane technique or Franz diffusion cells that imitate diffusion of drug molecules in the formulation to a receptor media. In the dialysis method, the formulation is put in a semi-permeable membrane that allows the drug to escape into the atmosphere over time, the kinetics of release can be determined. The Franz diffusion cell which is extensively used in topical and transdermal research studies is used to see the formulation of drug into the donor compartment and the drug diffuses across a membrane into the receptor fluid under controlled temperature and stirring conditions. Such configurations enable the accurate measurement of the drug release rates and mechanisms which are critical in maximizing the formulation design. These experimental models offer a systematic method in assessing the diffusion behavior and release profile as seen in Figure 1: In Vitro Drug Release and Diffusion Setup.



Figure 1: Ex Vivo Skin Permeation and Retention Studies

The other important parameters to determine the effectiveness of drug incorporation in the delivery system are drug content and entrapment efficiency. Drug content analysis guarantees homogenization of the active pharmaceutical ingredient and is normally tested by methods of analytical chemistry like UV- visible spectroscopy or high-performance liquid chromatography (HPLC). Entrapment efficiency is the percentage of drug effectively entrapped in the nanohydrogel matrix in relation to the amount of drug utilized in the formulation, which is the efficiency of the preparation procedure. The entrapment efficiency should be high because this would guarantee sustained release and reduce the wastage of the drug. These parameters are dependent on factors including polymer concentration, cross-linking density, and drug-polymer interactions. The research on permeation and diffusion also considers the capacity of the drug to penetrate biological or synthetic membranes, and it gives some understanding of the possible bioavailability and therapeutic attributes. These experiments are normally performed in Franz diffusion cells with synthetic membranes or excised biological tissue, where the flux, permeability coefficient, and cumulative drug permeation are determined. The results help determine the effects of the formulation variables on the transport of the drug across such barriers as strain corneum. In addition, the diffusion studies also specify the diffusion mechanism, either Fickian diffusion, anomalous transport, or erosion-controllable release. Environmental factors that are critical in determining the manner in which permeation will behave are the pH, temperature, and properties of membranes. Altogether, the in vitro assessment methods provide a universal methodology to study the drug release, encapsulation efficiency, and permeation properties, which makes it possible to optimize drug delivery systems to achieve a better effect of drug therapy and comply with regulatory norms.

3. Ex Vivo Evaluation Methods

Ex vivo approaches to drug delivery system evaluation are critical in determining how the drug delivery system performs in an environment that is as close to the physiological environment as possible, specifically in topical and transdermal delivery systems where the skin forms the major barrier. They are based on the use of excised animal or human skin to examine drug permeation, retention and interaction with biological tissues and allow more realistic observations than in vitro models. Franz diffusion cells, in which excised skin is placed between the receptor and donor

compartments and the excised skin is covered with the formulation on the epidermal side are commonly used to conduct skin permeation studies. The drug penetrates into the receptor media through the skin layers, and the values of permeation rate, flux, and permeability coefficient, can be measured. Such studies assist in determining the degree to which the drug enters the stratum corneum and progresses to other deeper layers of the skin which is vital in determining the level of therapeutic efficacy. Retention and deposition studies are also additional to permeation analysis since the study is used to establish how much drug is retained at various skin layers i.e. epidermis and dermis. Once the experiment of permeation is concluded, the skin is normally washed, sectioned and analyzed in order to measure the distribution of the drug in the tissue. Localized therapy would prefer high retention within specific layers because it would provide the localized effects of the drugs that would be localized to the area of treatment and systemic exposure would be minimal. These papers offer useful data on how nanohydrogels can be used to increase the local drug delivery and subsequent improvement in the treatment outcomes. Ex vivo evaluation also includes a histopathological and imaging analysis, which provides a detailed report of the structural and morphological modification of skin tissues after treatment. Histopathological analysis entails the use of staining and eyeing through the microscope of skin sections to determine whether there is any evidence of irritation, inflammation or the damage of tissues and guaranteeing safety of the formulation. Confocal laser scanning microscopy (CLSM) and fluorescence microscopy are also imaging techniques that are employed in visualizing drug penetration and drug distribution within the skin layers, and give qualitative and quantitative data about drug localization. These combined methods, as shown in Figure 2: Ex Vivo Skin Permeation and Retention Studies, provide a holistic analysis of transport, distribution, and interaction of drugs with biological tissues. Altogether, ex vivo testing systems can be considered a crucial interface between in vitro and in vivo testing, and allow to predict the performance of the formulation and realistically predict the development of safe and effective drug delivery systems.



Figure 2: Ex Vivo Skin Permeation and Retention Studies

4. Drug Release Kinetics and Modeling

Kinetics and modeling of drug release: To understand and predict the release profile of drugs in nanohydrogel systems, drug release kinetics and modeling are fundamentally important to develop formulations with controlled and targeted release profiles. Mathematical modeling offers a mechanistic manner in which experimental release data can be interpreted and the mechanisms that govern drug transport can be determined. Zero-order kinetics defines the system in which the drug is being released at the same rate regardless of the concentration. This form of release is most suitable in terms of a constant therapeutic value, and can be common in the controlled diffusion systems or reservoir type systems. Conversely, first-order kinetics is a release that is concentration-dependent, that is, the speed with which a drug releases decreases with time as the drug concentration within the system reduces. This model is usually linked with matrices based systems in which diffusion is a dominant factor. The Higuchi model is a mathematical model that is most common in the description of drug release through porous matrices like hydrogels. It presupposes diffusion controlled drug release as a square root time dependence, which comprises a constant release rate over time. The model is especially effective in the situation when the drug is evenly distributed in the polymer system. The KorsmeyerPeppas or power law model is a more generalized equation that can be used to study the drug release of polymeric systems and where the process is not well defined or includes many processes. It adds release exponent (n value) which is used in determining the nature of release mechanism which could be Fickian diffusion, non-Fickian transport, or case II transport. Mechanism-based drug release interpretation combines these models to gain a better comprehension on how drugs are discharged out of nanohydrogels taking into account aspects like diffusion, swelling, relaxation of polymer, and polymer degradation. By comparing experimental data to these models, scientists can identify the prevailing release mechanism and maximise formulation parameters respectively. In summary, as Table 1: Drug Release Kinetic Models and their Equations illustrates, each of the models has certain understanding about kinetics of drug release and is chosen depending on the properties of the formulation and experimental data. Altogether, kinetic modeling can be a strong predictive of the release profile of drugs, formulation design, and consistent therapeutic performance of sophisticated drug delivery systems.

Table 1: Drug Release Kinetic Models and Their Equations

S.No.	Model	Equation	Key Feature	Interpretation
1	**Zero-Order Kinetics**	$Q_t = Q_0 + k_0 t$	Constant release rate	Ideal for controlled drug delivery
2	**First-Order Kinetics**	$\log Q_t = \log Q_0 - \frac{k_1 t}{2.303}$	Concentration-dependent release	Release rate decreases over time
3	**Higuchi Model**	$Q_t = k_H \sqrt{t}$	Diffusion-controlled release	Drug release from matrix systems
4	**Korsmeyer–Peppas Model**	$\frac{M_t}{M_\infty} = kt^n$	Empirical model	Determines release mechanism (n value)

5. Diffusion and Transport Mechanisms

The mechanisms of diffusion and transportation are critical to acquiring knowledge of how drugs escape nanohydrogel systems into biological barriers, especially skin, which is a highly selective and protective barrier. The main theoretical model that rules the diffusion of drugs is the laws of diffusion introduced by Fick on the diffusion of a substance away and into areas of increased and decreased concentration respectively. According to the first law of diffusion, the concentration gradient is inversely proportional to the rate of diffusion and therefore a steep gradient causes the drug to move across the membrane more rapidly. The second law of diffusion describes the temporal variations in diffusion, especially when the situation is non-steady-state, and is necessary to model drug release and permeation of controlled delivery systems including nanohydrogels. Such laws have been extensively used to examine the drug penetration by the stratum corneum, the outermost layer of the skin, which is the main barrier to the penetration of a drug. The skin barrier consists of several layers which are stratum corneum, epidermis, and dermis, and each of them differs in its role to transmit drugs. The stratum corneum, commonly referred to as a brick-and-mortar structure, is made up of corneocytes (also embedded into a lipid matrix) which limits the movement of most hydrophilic and large molecules. The drugs may enter the skin by three principal routes: transcellular (through the cells), intercellular (between the cells), and transappendageal (using the hair follicles and the sweat glands). Of these, the most common route of drug diffusion is the intercellular pathway which is mainly employed by lipophilic drugs, whereas transappendageal route may be used by hydrophilic drugs. Nanohydrogel systems help increase drug movement effectiveness in terms of increasing hydration of stratum corneum, destabilizing lipid organization, and controlled release of the drug at the skin surface. The factors that influence drug permeation across the skin are many and encompass physicochemical properties of drug, properties of the formulation and environment. Molecular size, solubility, lipophilicity and ionization state are drug-related factors that have an important effect on permeability and typically, smaller and moderately lipophilic molecules have desirable skin penetration. Polymer composition, cross-linking density and the addition of penetration enhancers are also critical in the modulation of drug release and transport. The environment, i.e., temperature, humidity, and pH, might also affect the skin permeability by modifying the stratum corneum structure and its level of hydration. A combination of these mechanisms and pathways as illustrated in Figure 3: Drug Diffusion and Transport Pathways in Skin, can provide a complete picture on how drugs are transported through the skin barrier. In general, the detailed study of the diffusion and transport processes is necessary to develop the most efficient nanohydrogel-based drug delivery system with the best permeation and therapeutic properties.



Figure 3: Drug Diffusion and Transport Pathways in Skin

6. Correlation Between In Vitro, Ex Vivo, and In Vivo Data (IVIVC)

In vitro-ex vivo-in vivo Correlation Correlation between in vitro, ex vivo and in vivo data, commonly referred to as IVIVC (In Vitro–In Vivo Correlation), is a critical aspect in the development and evaluation of drug delivery systems, as it allows prediction of in vivo drug performance based on laboratory and preclinical studies. IVIVC models are established by developing a mathematical and statistical relationship between the profiles of drug release in in vitro experiments and the pharmacokinetic responses observed to the drug in vivo. The correlation is especially useful with controlled and sustained release systems like nanohydrogels, where the relationship between release behavior and systemic absorption is important in order to maximize the therapeutic effect. IVIVC is typically divided into different levels, such as Level A (point-to-point correlation), Level B (statistical moment analysis), and Level C (single-point correlation), each of which has a different degree of predictability and regulatory acceptance. Among them, Level A correlation is believed to be the most informative as it offers a direct and linear association between in vitro dissolution and in vivo absorption profiles. Ex vivo experiments take an intermediate position as they fill the gap between in vitro and in vivo data using excised tissues. These works aid in the refinement of IVIVC models by taking into account physiological barriers, e.g. skin, to better predict the results. Drug delivery predictive models go further to use mathematical models, computational modeling, and statistical software to predict the behavior of drugs under varying conditions. Simulation of the absorption, distribution, metabolism, and elimination of drugs are increasingly simulated using techniques such as compartmental modeling, physiologically based pharmacokinetic (PBPK) modeling, and machine learning approaches. These models can be used to optimize the formulation parameters, reduce the necessity of conducting extensive animal or human research, and speed up the drug development process. The main parameters, including dissolution rate, permeation flux, bioavailability, and pharmacokinetic constants are systematically analyzed to draw valid correlations. Variability in biological systems, differences in experimental conditions, and characteristics of formulation can affect the accuracy of IVIVC, underscoring the need to adopt standardized procedures and employ sound validation methods. Regulatory authorities also attach importance to the role of IVIVC in

promoting biowaivers and maintaining the same level of product quality. In sum, IVIVC is an effective approach to correlating laboratory results with clinical performance to enable rational design, optimization, and regulatory approval of advanced drug delivery systems.

Table 2: Correlation Parameters and Evaluation Methods

S.No.	Parameter	Evaluation Method	Significance in IVIVC	Application
1	**Drug Release Rate**	In vitro dissolution studies	Indicates release kinetics	Predicts drug availability
2	**Permeation Flux**	Franz diffusion cell (ex vivo)	Measures drug transport across skin	Links in vitro to biological systems
3	**Permeability Coefficient**	Diffusion studies	Quantifies membrane penetration	Supports formulation optimization
4	**Bioavailability (Cmax, Tmax)**	In vivo pharmacokinetic studies	Reflects systemic drug absorption	Validates IVIVC models
5	**Area Under Curve (AUC)**	PK analysis	Measures overall drug exposure	Correlates release with absorption
6	**Correlation Coefficient (R^2)**	Statistical modeling	Indicates strength of correlation	Validates predictive models

7. Advanced Analytical and Imaging Techniques

Modern drug delivery systems have been investigated using advanced methods of analysis and appearance that allow them to provide in-depth analysis of the structural, functional and dynamic processes of these systems at micro and nanoscale. Confocal microscopy and fluorescence imaging can be said to be one of the most powerful ones used to visualize the distribution, penetration and localization of the drug within the biological tissues, particularly in dermatology. A technique that can provide three dimensional images of the layers of the skin with a high resolution and has allowed the researchers to trace the route of the fluorescently labeled drugs or nanocarriers as it sinks into the stratum corneum, epidermis and dermis. The technique is especially effective in estimating the extent of penetration and spatial distribution of a solution such as nanohydrogels and it provides both qualitative and quantitative data. This analysis is also augmented by fluorescence imaging which is able to provide real time images of drug movements and accumulation in the desirable areas in order to facilitate optimization of the delivery system to enhance the therapeutic efficiency. In addition to imaging, the process of spectroscopic scrutiny and thermal scrutiny are also essential to determine the stability of the drug delivery systems and its physicochemical characteristic. The details of the chemical interactions, functional groups and the structural integrity of the formulation at the molecular level are presented in Fourier Transform Infrared Spectroscopy (FTIR), Raman spectroscopy and Nuclear Magnetic Resonance (NMR) techniques. These processes help to check on the incorporation of drugs, compatibility of ingredients, chemical reactions that might arise during the formulation or storage. Thermal analysis techniques like Differential Scanning Calorimetry (DSC) and the Thermogravimetric Analysis (TGA) determine thermal stability, phase changes and

degradation behavior and are important in determining the product stability and shelf-life. A combination of spectroscopic and thermal analyses provides an in-depth detail of composition and stability of nanohydrogel systems. The real-time monitoring techniques are a rapidly emerging area of drug delivery evaluation which enables constant investigations into the drug release, diffusion as well as interaction with biological environments under physiological simulated conditions. Dynamically tracking drug behavior without disrupting the experimental process can be done using microfluidic platforms, biosensors and in situ imaging platforms. They can be capable of simulating more complex biological conditions, e.g. fluid flow, pH change, temperature change and make more accurate predictions of their behavior in vivo. In addition, there are other advanced imaging methods including live-cell imaging and optical coherence tomography (OCT) that can also be used to non-invasively monitor drug delivery processes in real time. This combination of these sophisticated methods of analysis and imaging does not just enhance the accuracy and reliability of evaluation, but also increases the development and optimization of formulation. All these technologies are transforming the situation of the drug delivery since they offer precise, real-time and multi-dimensional study of complex systems that ultimately results in the development of safer, more efficient and more focused therapeutic solutions.

8. Challenges and Limitations

Although there is strong progress in the assessment methods of the drug delivery systems, there are a number of threats and constraints that may interfere with the reliability and translatability of the findings. Among the primary concerns is the variability of biological models, which can be different in ex vivo and in vivo experiments, as the skin thickness, lipid composition, hydration and metabolic activity can vary, and the findings are variable. The discrepancy between the animal models, and the human tissues, also makes the interpretation of the data more complex, and it reduces the direct relevance of the research to the clinical cases. Moreover, the in vitro and ex vivo models, which are however useful in initial screening, have no capacity to regularly recapitulate the complexity of the physiological conditions, such as dynamic blood circulation, immune responses, and metabolism. Such constraint can result in discrepancies in the laboratory and real performance in vivo. An example is that use of synthetic membranes in diffusion studies cannot be representative of the human skin barrier properties and hence drug permeation can be overestimated or underestimated. The other critical issue is related to the model validation since the problem of the establishment of correct correlations between the in vitro, ex vivo and in vivo data remains. It can also influence the predictive model such as IVIVC because of such factors as the conditions of the experiment, variability of formulation and analysis inconsistencies. In addition, absence of standard protocols and regulatory systems of some of the more sophisticated evaluation techniques can pose a hindrance to reproducibility and cross study comparisons. These constraints underscore the importance of better experimental methodologies, standard experimental techniques and incorporation of new technologies to increase predictability and reliability of drug delivery assessment systems.

9. The Future Outlook and developments.

The future of the drug delivery assessment is rapidly changing, as new technologies, including artificial intelligence (AI), machine learning, and microengineering strategies, are quickly embraced, and are likely to greatly enhance the predictive accuracy and efficiency. The analysis of complex data, the determination of patterns and predicting drug behavior, such as release kinetics, permeability and pharmacokinetics, are also increasingly analyzed using AI and machine learning algorithms. The technology allows building strong predictive models that can optimally design formulations and eliminate the use of large-scale experimental trials. Microfluidic systems and organ-on-chip

technologies are also becoming an influential tool in modeling physiological conditions and having them simulated under controlled conditions. The platforms are capable of recapitulating important biological processes of the human tissues, including fluid dynamics, cellular interactions, and barrier functions, and are able to give more precise and more reproducible data than conventional in vitro models. As an illustration, skin-on-chip models permit real-time imaging of drug penetration and reaction with living cells, to overcome the discrepancy between laboratory research and clinical research. There is also increased interest in personalized drug evaluation methodology in which factors that are particular to patients, including genetic profile, skin type, and the disease condition, are taken into account to optimize drug delivery system in order to produce the best therapeutic effects. This paradigm shift to precision medicine is bound to improve the effectiveness of treatment and decrease side effects. On the whole, these innovations are changing the sphere of drug delivery assessment as they allow making it more accurate, efficient, and patient-centered.

10. Conclusion

High level of assessment models like in vitro, ex vivo and kinetics modelling strategies are significant in development and optimization of modern drug delivery systems especially nanohydrogels as well as other complex formulations. These methods will provide in-depth insights into the release, permeation, stability and interaction of drugs to the biological systems to enable the development of effective and specific therapeutic solutions. Even though when combined with kinetic modeling, the workings of drug transport can be understood better and can make use of in vivo performance prediction, when combined with in vitro and ex vivo tests, a controllable and cost effective analysis platform can be found. But, despite the difficulties which the biological variability, the modeling constraints and the validation issues entail, the reliability and the predictive ability of the assessment options continue to increase because of the constant development of the methods of analysis and the computation models. The emergence of novel technologies such as AI, machine learning, organ-on-chip systems, and many others improve the process of simulation of the physiological conditions, as well as optimization of the drug delivery systems. Besides making the research and development process speedier, these innovations enable to comply with regulations and lessen reliance on animal research. Lastly, it is important to have a well integrated assessment system that incorporates both experimental and computational techniques towards the safety, efficacy and clinical success of the novel drug delivery systems.

References

1. Dressman, J. B., & Reppas, C. (2000). In vitro–in vivo correlations. *European Journal of Pharmaceutical Sciences, 11*(S2), S73–S80.
2. Amidon, G. L., Lennernäs, H., Shah, V. P., &Crison, J. R. (1995). Biopharmaceutics classification system. *Pharmaceutical Research, 12*(3), 413–420.
3. Shah, V. P., et al. (1998). In vitro dissolution profile comparison. *Pharmaceutical Research, 15*(6), 889–896.
4. Cardot, J. M., &Beyssac, E. (2012). In vitro–in vivo correlation. *Dissolution Technologies, 19*(1), 15–19.
5. Kostewicz, E. S., et al. (2014). Biorelevant dissolution methods. *European Journal of Pharmaceutical Sciences, 57*, 342–366.
6. Mitragotri, S. (2005). Modeling skin permeability. *Nature Reviews Drug Discovery, 4*(6), 517–528.
7. Prausnitz, M. R., & Langer, R. (2008). Transdermal drug delivery. *Nature Biotechnology, 26*(11), 1261–1268.

8. Hadgraft, J. (2004). Skin barrier and transdermal delivery. *International Journal of Pharmaceutics, 284*(1–2), 1–6.
9. Benson, H. A. E. (2005). Transdermal drug delivery principles. *Current Drug Delivery, 2*(1), 23–33.
10. Franz, T. J. (1978). Skin permeation studies relevance. *Journal of Investigative Dermatology, 70*(3), 173–176.
11. OECD. (2004). *Guidelines for the testing of chemicals: Skin absorption*. OECD Publishing.
12. Ng, S. F., Rouse, J. J., Sanderson, F. D., & Eccleston, G. M. (2010). Validation of Franz diffusion cell. *AAPS PharmSciTech, 11*(3), 1432–1441.
13. Wagner, J. G. (1971). Biopharmaceutics and pharmacokinetics. *Journal of Pharmaceutical Sciences, 60*(1), 1–17.
14. Gibaldi, M., & Perrier, D. (1982). *Pharmacokinetics*. Marcel Dekker.
15. Levy, G. (1967). Pharmacokinetics of drug absorption. *Clinical Pharmacology & Therapeutics, 8*(5), 698–705.
16. Siepmann, J., Siepmann, F., & Peppas, N. A. (2012). Modeling drug release systems. *International Journal of Pharmaceutics, 453*(1), 12–24.
17. Costa, P., & Lobo, J. M. S. (2001). Modeling and comparison of dissolution profiles. *European Journal of Pharmaceutical Sciences, 13*(2), 123–133.
18. Grassi, M., Grassi, G., Lapasin, R., & Colombo, I. (2007). *Understanding drug release*. CRC Press.
19. Crank, J. (1975). *The mathematics of diffusion*. Oxford University Press.
20. Guy, R. H. (2010). Transdermal drug delivery systems. *International Journal of Pharmaceutics, 393*(1–2), 3–5.
21. Bouwstra, J. A., & Honeywell-Nguyen, P. L. (2002). Skin structure and permeability. *Advanced Drug Delivery Reviews, 54*(S1), S41–S55.
22. Müller, R. H., & Keck, C. M. (2004). Challenges in nanocarrier drug delivery. *Advanced Drug Delivery Reviews, 56*(9), 1317–1334.
23. Ferrari, M. (2005). Cancer nanotechnology and drug delivery. *Nature Reviews Cancer, 5*(3), 161–171.
24. Whitesides, G. M. (2006). Microfluidics in drug delivery. *Nature, 442*(7101), 368–373.
25. Huh, D., et al. (2011). Organ-on-chip systems. *Science, 328*(5986), 1662–1668.

Chapter 10: Translational Advances in Nano Dermatology (In Vivo Assessment, Clinical Integration & Future Innovations)

Garima Gupta*, Sumit Singh Rajput[1] Dr.Ahamadi Tabasum.M[2]

***Chhatrapati Shahu Ji Maharaj University, Kanpur, Uttar Pradesh, India**

gg507385@gmail.com

[1]Chhatrapati Shahu Ji Maharaj University, Kanpur, Uttar Pradesh, India

ps1708005@gmail.com

[2]Pharmacovigilance Associate,Bangalore medical College and Research Institute,Bangalore,India

Abstract

Nano dermatology Translational innovation in Nano dermatology has greatly influenced the creation of new drug delivery systems to effectively treat skin conditions. Using nanotechnology with dermatological science, nanoscale carriers, such as nanoparticles, liposomes, phytosomes, and nanohydrogels, improve drug solubility, stability, penetration, and targeted delivery across the skin barrier. Translational research narrows the gap between laboratory discoveries and clinical implementation by means of systematic, in vitro, ex vivo, in vivo and clinical studies to ensure safety, efficacy and scalability. In vivo experiments provide important information on pharmacokinetics, biodistribution, and therapeutic efficacy, and clinical trials confirming safety, patient compliance, and efficacy. Although artificial intelligence, personalized medicine, and intelligent delivery systems have their challenges like scalability, various regulations, and cost, recent developments in these areas offer hopeful solutions. These innovations aid in the creation of more accurate, patient-centered therapies, which ultimately enhances clinical outcomes and quality of life in dermatological care.

Keywords:

Nano dermatology, Translational research, Nanocarriers, In vivo evaluation, Clinical trials, Drug delivery, Personalized medicine

1. Introduction

Nano dermatology has become a new and emerging discipline, which combines nanotechnology with the science of dermatology in order to come up with new drug delivery systems that can be useful in improving therapy in skin-related diseases. This information will be applied in interdisciplinary research on the design and use of nanoscale carriers, including nanoparticles, nanohydrogels, liposomes, phytosomes, and nanoemulsions, to enhance the solubility, stability, permeability, and targeted delivery of drugs throughout the layers of the skin. Nano dermatology circumvents the drawbacks of traditional topical and transdermal preparations, allowing effective and efficient penetration across the stratum corneum and controlled and slow release of a drug, and is therefore of special value to the management of chronic illnesses such as psoriasis, eczema, acne, and skin infections. This is due to the fact that translational research can be used to close the gap between laboratory findings and clinical practices, such that promising nanocarrier systems discovered at the research stage can be incorporated effectively in actual therapeutic practice. Translational research is a methodological procedure that entails in vitro analysis, ex vivo analysis, in vivo analysis, and clinical examination that are supposed to confirm the safety, efficacy as well as scalability of the formulation.

It is very instrumental in optimization of the formulation parameters, learning about the pharmacokinetics and actual distribution, and in regulatory compliance. Also, translational methods can save time and money related to drug development by detecting possible difficulties in the initial phase of the process and making decisions. The trip between the bench and the bedside is however not a simple one and has a number of obstacles and opportunities. Scalability of nanocarrier systems can be considered one of the greatest challenges because the same formulations that functioned successfully when the laboratory scale was used may present challenges when it comes to large-scale production because of the factors of reproducibility, stability, and cost. Regulatory barriers are also a major challenge since the absence of uniform rules regarding the regulation of products of nanotechnology may slow down the process of approval and commercialization. Moreover, biological responses may vary and not be predictable by preclinical models and physiology of human beings. Despite these concerns, nano dermatology has numerous prospects to evolve further with the assistance of the newest technologies such as artificial intelligence, individual approach to treatment, and other effective ways of imaging. These innovations can make the drug administration systems more accurate, effective, and flexible and can also make the process of treatment of a patient more individual, based on specific characteristics of a patient. Overall, the advances in translational nano dermatology can transform the world of the treatment of dermatological diseases through the provision of safer, more effective, and patient-focused interventions that ultimately result in the clinical outcomes and life quality.

2. In Vivo Evaluation of Nano Dermatological Systems

Nano dermatological systems. In vivo testing of nano dermatological systems is a significant process in the translation of the laboratory-based formulations to clinically viable therapies, by providing a comprehensive insight into their pharmacological properties, safety and therapeutic effectiveness in a living biological system. Animal models have become a fundamental part of this process to offer some control yet a physiologically relevant setting, to study drug behavior. The rodents, mice, rats, guinea pigs and other large animals such as pigs are the popular models and whose skin is highly similar to that of the human being in its thickness and structure. Such models are applied to determine the factors such as the skin penetration, the possibility of being irritated, the wound healing performance, and the activity of anti-inflammatories. The disease-specific effects (psoriasis or dermatitis) may also be studied using them, which helps to determine the specific therapeutic influence of nanocarrier systems. Pharmacokinetics and biodistribution Pharmacokinetics and biodistribution Pharmacokinetics and biodistribution research can further enhance the knowledge of the behavior of nanodermatological formulations after administration. The pharmacokinetic analysis involves analyzing the absorption, distribution, metabolism and elimination parameters of the drug (ADME) to provide some insight into the systemic exposure and the duration of the drug remainance in the body. The purpose of Biodistribution Research is to track the localization of nanocarriers and drugs in various tissues, e.g., different layers of the skin, systemic organs, etc. typically with a sophisticated imaging approach, such as fluorescence labelling or radiolabelling. Such trials are crucial in determining whether or not the drug remains localized at the site of action or it is recirculated in other body systems, which may affect the efficacy or safety. In vivo efficacy and safety testing is another essential aspect since it determines therapeutic outcome and adverse reactions of the formulation to the actual biological conditions. Measures of efficacy usually involve the observation of clinical endpoints like the decrease of inflammation, rate of healing or lesion size depending on the type of dermatological disease under mutation. Safety assessment entails the presence of symptoms of toxicity, irritation, allergic reactions as well as histopathological changes in skin tissues. These tests allow the effectiveness and safety of further clinical development of the formulation. The mechanism,

as depicted in Figure 1: In Vivo Evaluation and Drug Distribution Pathways, is application of the nano dermatological formulation, which was disseminated throughout the skin layers and possibly systemic circulation, and the resultant measurement of the pharmacokinetics, biodistribution, and therapeutic response. Overall, in vivo testing provides the abstract image of the actual workings of nano dermatological systems in real time, and therefore, it is a major step between preclinical and clinical practice and the development of safe, effective and targeted dermatological therapies.



Figure 1: In Vivo Evaluation and Drug Distribution Pathways

3. Clinical Integration and Human Studies

Another area where nano dermatological systems have been applied successfully is clinical integration and human studies, where it is essential to translate experimental findings in the operation of nano dermatological systems into real-life therapeutic applications by having safe, effective, and acceptable formulations. The phases of clinical trials in dermatology are logically structured to test the functionality of new drug delivery systems in human beings, with Phase I trials firstly testing the safety, tolerability and possible adverse effects of the new system in a limited number of healthy volunteers or patients. Phase II trials are aimed at assessing therapeutic effectiveness, dose-effectiveness, and short-term side effects using a larger patient population and especially in those with a particular dermatological issue such as psoriasis, eczema, or acne. Phase III trials are large scale trials that are done to establish efficacy, long-term safety, and compare the new formulation to other standard treatments and in the end provide evidence that will lead to regulatory approval. Phase IV post-marketing surveillance is in other occasions done to determine the safety and effectiveness of the product when used in a larger population. The main factors of the success of dermatological interventions, especially topical and transdermal agents, are patient compliance and therapeutic outcomes. Nano dermatological system has considerable benefits in this aspect by enhancing drug penetration, lowering dosing rate, and side effects, which in combination increases adherence to treatment plan by patients. Facilities like convenience of use, lack of oiliness, and less irritation, and prolonged release characteristics bring high patient contentment and enhanced clinical performance.

The clinical endpoints that are commonly used to evaluate the therapeutic outcomes include the reduction of lesion size, the improvement of skin condition, reduction of inflammation, and general quality of life indicators. These results give meaningful information about the functionality of the formulation in the real world and its effect on patient health. The pathways of regulatory approval are important to make sure that nanodermatological products are of high quality, safe, and effective before they are made available in the market. The pharmacokinetics, toxicity, and stability of the product require complete information of preclinical and clinical trials provided by regulatory bodies like FDA, EMA, and CDSCO to assess the risk benefit profile of the product. Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), and standardized documentation are also part of adherence to assure the process of approval to the product consistency and reliability. According to a summary of clinical evaluation parameters and endpoints as illustrated in Table 1: Clinical Evaluation Parameters and Endpoints, the key parameters that are systematically measured in clinical trials to enable regulatory decision-making include the safety profiles, efficacy outcomes, patient compliance, and pharmacokinetic data. Although this may be a complicated procedure, effective clinical introduction of nano dermatological systems has massive potentials to transform the dermatological therapy process by providing effective, patient-oriented, and targeted treatment opportunities.

Table 1: Clinical Evaluation Parameters and Endpoints

S.No.	Parameter	Evaluation Method	Clinical Endpoint	Significance
1	**Safety & Tolerability**	Phase I clinical trials, adverse event monitoring	Absence of severe toxicity, irritation	Ensures formulation safety
2	**Efficacy**	Phase II & III trials, clinical scoring systems (PASI, EASI)	Reduction in lesion severity, symptom improvement	Confirms therapeutic effectiveness
3	**Dose Optimization**	Dose-response studies	Optimal therapeutic dose with minimal side effects	Improves treatment outcomes
4	**Pharmacokinetics (PK)**	Blood/plasma analysis (Cmax, Tmax, AUC)	Drug absorption and distribution profile	Supports dosing regimen design
5	**Patient Compliance**	Patient-reported outcomes, adherence studies	Improved adherence and satisfaction	Enhances real-world effectiveness
6	**Quality of Life (QoL)**	Dermatology Life Quality Index (DLQI)	Improvement in patient well-being	Measures clinical benefit
7	**Long-Term Safety**	Phase IV/post-marketing surveillance	Detection of delayed adverse effects	Ensures continued safety
8	**Comparative Effectiveness**	Controlled clinical trials vs standard therapy	Superiority or non-inferiority outcomes	Supports product positioning

4. Safety, Toxicity, and Regulatory Considerations

They are fundamental components of clinical evaluation parameters and endpoints in the measurement of the safety, efficacy and performance of nanodermatological drug delivery systems in human studies and present an organized and quantifiable outcome to lead to clinical decision-making and regulatory acceptance. The main concern of early-phase clinical trials and especially Phase I trials is safety and tolerability as the formulas also undergo testing to assess their potential adverse effects including skin irritation, erythema, edema, or systemic toxicity. The constant occurrence of the adverse events will ensure that the formulation is not of a significant risk to the patients. The emphasis in Phase II and Phase III trials lies in efficacy measurement, through either standardized clinical scoring systems like the Psoriasis Area and Severity Index (PASI), Eczema Area and Severity Index (EASI), or lesion count reduction in acne. These endpoints will provide quantitative information on the effectiveness of the treatment and will help to determine whether the formulation has a significant clinical benefit over the current therapies. The other very important parameter is dose optimization that involves management of optimum drug concentration that causes the most therapeutic effect and the least side effects. This is usually measured by dose response studies, which are done to narrow down dosing regimens to achieve better patient outcomes. Pharmacokinetic analysis is a significant facet of drug absorption, distribution, metabolism and elimination among human beings. Systemic exposure and drug bioavailability is determined by analyzing such parameters as maximum plasma concentration (Cmax), time to reach maximum concentration (Tmax) and area under the curve (AUC). Such data are of crucial value in making sure the topical or transdermal formulations can have localized effects without unwanted systemic absorption. The adherence to therapy is a decisive factor in determining the success of the treatment, and in the sphere of dermatology, the patients may need to adhere to the treatment for a long period of time. The factors such as ease of application, formulations texture, frequency of application and non-irritating properties are the key factors influencing the patient adherence. The increased compliance level is directly connected with the better therapeutic results and patient satisfaction. Quality of life (QoL) scale as rated by some like the Dermatology Life Quality Index (DLQI) can be very informative in terms of how treatment impact the daily life of patients, physical comfort, psycho-emotional well being and social functioning. The study of the safety over an extended period of time that is usually conducted during the Phase IV post-marketing trials is highly important in the identification of delayed or unusual adverse effect, which may not be noticeable during the previous trials. Comparative effectiveness studies go an extra step to compare the effectiveness of the new formulation to the standard treatments and determine whether the new formulation is better or not worse in the clinical practice. As it can be observed in Table 1: Clinical Evaluation Parameters and Endpoints, all these parameters are a complete set of parameters to evaluate nanodermatology systems, which are currently demanded to attain the desired standard levels of safety, efficacy and patient acceptability. Overall, systematic clinical appraisal is priceless in the context of translating innovative drug delivery systems into effective therapeutic products that may help to improve patient outcomes and quality of life.

5. Translational Challenges in Nanodermatology

The problem with translating nanodermatological research into clinical and commercially viable products is a bottleneck to this translation due to the numerous technical, regulatory and economic factors involved in this transformation. The scale-up and manufacturing problems are among the key problems as the formulations that are tested at a controlled laboratory level may be problematic when manufactured on a larger scale. The size of the particles, encapsulation efficiency, uniformity and stability which are typically complicated by variations in the processing conditions and equipment constraints are some of the parameters that require to be regularly taken care of during large-scale

production. The procedures that may be used on a small scale such as solvent evaporation or nano-precipitation may have to be altered or optimized on large scale to create the complexity and cost increment. The other factors of difficulty are reproducibility and standardization since nanodermatological systems are extremely sensitive to formulation factors, including polymer composition, cross-linking density, and processing parameters. Even slight variations may lead to drastic alterations in the release behaviour, permeability and therapeutic behaviour. The fact that there are no standardized protocols and characterization techniques universally accepted also contributes to the necessity to have a batch-to-batch consistency and even to be able to compare the results of various studies or manufacturing arrangements. Such discrepancy may make it difficult to pass regulatory approval, since agencies expect strong and repeatable data that will guarantee the quality and safety of the products. Also, cost and commercialization issues are important to restrict the broad use of nanodermatological technologies. Systems based on nanocarriers can be very expensive to design and produce because the materials used, equipment and methods of analysis are often very expensive and may increase the final product price. The high cost of production could be a constraint to access, especially in low and middle-income areas, and also the competitiveness of the markets with traditional formulations. Further, commercialization is associated with compliance with rigid regulatory frameworks, intellectual property concerns and extensive clinical testing, which is expensive in terms of both money and time. In order to address these challenges, a multidisciplinary approach that consists of optimization of processes, establishment of practices that can be scaled, use of standardized evaluation procedures, and inclusion of cost-effective production methods is required as summed up in Table 2: Translational Challenges and Possible Solutions. The potential solutions to enhanced scalability and reproducibility have emerged tools on automation, continuous manufacturing, and quality-by-design (QbD) solutions. It is also necessary to have collaborative work between academia, industry and regulatory bodies to make the translation process streamlined and to have a firm guideline on the products based on nanotechnology. All of these translational concerns are vital to the key unlocking the potential of nanodermatology and ensuring the effective, safe, and innovative delivery of treatments to patients.

Table 2: Translational Challenges and Possible Solutions

S.No.	Challenge	Description	Possible Solution	Impact
1	**Scale-Up Issues**	Difficulty in maintaining consistency during large-scale production	Process optimization, continuous manufacturing	Improves industrial feasibility
2	**Manufacturing Complexity**	Use of advanced techniques and sensitive parameters	Automation and advanced equipment	Enhances production efficiency
3	**Reproducibility Issues**	Batch-to-batch variability	Standardized protocols and quality control	Ensures product consistency
4	**Lack of Standardization**	Absence of uniform guidelines	Regulatory harmonization and validation methods	Facilitates approval process
5	**High Cost of**	Expensive materials and	Cost-effective materials and scalable	Improves

	Production	technologies	methods	affordability
6	**Commercialization Barriers**	Regulatory, financial, and market challenges	Industry-academia collaboration, funding support	Accelerates market entry

6. Advanced Drug Delivery Approaches

The application of nano dermatology in advanced drug delivery methods is changing the picture of the therapeutic agent delivery to the skin by providing precise targeting, controlled release, and higher treatment responses. The targeted and controlled nanocarrier systems are intended to administer drugs to affected areas of the skin or cellular targets and contain minimal systemic exposure, minimizing the side effects. These systems comprise nanoparticles, liposomes, phytosomes, nanoemulsions, and nanohydrogels, which may be designed to bind a particular receptor or a biological structure in the skin. A targeting protocol can be passive targeting, as the nanocarrier will be concentrated in diseased tissues because of an increase in permeability, or active targeting, which involves the conjugation of ligands such as antibodies or peptides onto the carrier surface to identify specific cellular markers. Controlled release systems also have an additional benefit of achieving improved therapeutic effects due to the ability to maintain a constant drug concentration at the site of action, lower drug dosing, and patient adherence. Another important development is stimuli-responsive and smart nanomaterials, which may react to a particular stimulus e.g. pH, temperature, light, or enzymatic activity. These intelligent systems can release the drug under a controlled way only when they are subjected to certain conditions, and this increases accuracy and reduces off-target effects. An example is the pH-sensitive hydrogels, where drugs can be released in swollen or infected areas of the skin where the pH is different than under normal conditions, and thermoresponsive hydrogels where drugs can be released or withheld depending on the temperatures. These smarter delivery systems promise a lot when it comes to the treatment of complicated dermatological conditions with very high specificity and efficiency. The possibilities of nano dermatology are further extended by combination and hybrid delivery systems which combine various technologies or therapeutic agents in one platform. These systems can include nanocarriers together with hydrogels, microneedles or any other device of drug delivery to increase its penetration and retention. The phytosome systems, like phytosome-chitosan hydrogel, take advantage of the lipid-based and polymer-based carriers to enhance the solubility of drugs, their stability and release control. Moreover, with combination therapy using many drugs or bioactive compounds, synergies can be achieved, enhancing the overall treatment results of such conditions as chronic inflammation, infections, and skin disorders. These novel strategies combine targeting systems, intelligent responsiveness and the hybrid technologies to develop very effective and versatile drug delivery systems as shown in Figure 2: Advanced Nano dermatology Drug Delivery Platforms. In general, enhanced drug delivery approaches in nano dermatology can be seen as a dramatic advancement in the direction of highly specific, active, and patient-centered therapies, which can be expected to become the next-generation approach to dermatological treatment.



Figure 2: Advanced Nano Dermatology Drug Delivery Platforms

7. Personalized and Precision Dermatology.

Personalized and precision dermatology is revolutionizing the treatment of skin disorders by combining personalized biological, genetic, and clinical information to develop a specific treatment plan. The genomics and biomarkers have a key role in this approach because the development of molecular biology has made it possible to identify genetic variations, inflammatory markers, and disease-specific pathways in dermatological diseases, including psoriasis, eczema, and melanoma. Biomarkers are useful in early detection, classification of the disease, and predicting the response to treatment, and this enables clinicians to choose the most suitable treatment for any patient. This is also improved by tailored drug delivery systems, which are used to personalize formulations according to the needs of each patient, such as the type of skin, disease severity and sensitivity. Nanoparticles, hydrogels, and liposomes are all nanocarrier-based systems that can be designed to deliver drugs to a particular location at a specific release profile, resulting in minimal side effects and enhanced therapeutic effects. Lifestyle factors, environmental exposure, and comorbid conditions are also taken into account in the process of patient-specific treatment, which provides a comprehensive approach to treatment. This changes the previous paradigm of a one-size-fits-all model to individualized treatment, resulting in a new era of effectiveness and compliance in treatment as well as the overall quality of life, something that was never seen before in dermatology.

8. New Technology and Innovations.

Nanodermatology is rapidly growing with the help of modern technologies and innovations, which offer new devices and methods that can enhance the delivery of drugs, diagnosing, and monitoring treatment. Automatic analysis of images, recognition of diseases, and treatment outcomes are all aspects of dermatology that the phenomenon of artificial intelligence (AI) is making a splash in. Machine learning algorithms can work with mass data including clinical images and patient recordings to help with the proper diagnosis and individual treatment plans. The other emerging technology is nanorobotics and intelligent delivery systems whereby nanobot-based systems are

developed to deliver drugs to specific sites in the skin in response to a specific biological stimulus (pH or temperature). Such systems are providing a chance of highly regulated and efficient administration of drugs with minimal side effects. Also, 3D bioprinting and the production of the latest models of skin are transforming the research and testing by offering realistic and human-like tissue structure testing the efficacy of drugs and their safety. Such models do not imply the use of animals and allow the further, even higher, accuracy of the simulation of the conditions of the human skin. All these new technologies have been transforming the future of dermatological research and curing, and even offer some new solutions to some difficult skin conditions.

9. Future Perspectives

The potential of nanodermatology in the future is enormous as it will be integrated into a multidisciplinary approach, sustainable practice and be expanded to more clinical applications. It involves uniting such disciplines like nanotechnology, biotechnology, materials science and clinical medicine in coming up with new drug delivery systems that would prove to be effective and safe. These systems will be optimized and even designed with the help of the integration of computational modeling, the utilization of artificial intelligence, and more enhanced imaging techniques. Also gaining relevance with the emphasis being laid on adoption of environmentally friendly materials, biodegradable polymer and less energy consuming manufacturing processes to ensure that the impact made on the environment is minimal. This strategy is in line with the trend of achieving sustainability across the globe and at the same time ensuring a high level of quality and safety of its products. It is also broadening of clinical applications of nanodermatology to include the treatment of simple skin diseases in addition to novel and advanced treatment of skin cancer, regenerative medicine, and cosmetic. It is anticipated that the detailed description of the multifunctional nanocarriers that will be able to deliver over one therapeutic agent at a time will assist in improving the outcome of treatment in case of intra-complicated conditions. Overall, nanodermatology can be characterized as a huge potential of innovation and clinical improvement in the future.

10. Conclusion

The field of nanodermatology translation has provided the new opportunities to the development of novel drug delivery methods, providing innovative opportunities in the treatment of various skin diseases. With the combination of the best formulation technologies and the application of in vitro, ex vivo, and in vivo assessment strategies, scientists have been able to come up with systems that have the potential to deliver drugs in targeted, controlled and efficient manner. Incorporation of nanotechnology has enhanced the solubility, stability and penetration of drugs, and solved numerous limitations of the traditional dermatology treatment. There are challenges to overcome that are to do with the issue of scalability, regulatory acceptance, and the cost but the methods of analytical analysis, computational modeling and manufacture processes are continuously being improved and are helping in overcoming the obstacles. Nanodermatology can offer highly effective treatments, personalized to patients, which is further enhanced with the introduction of personalized medicine, artificial intelligence, and smart delivery systems. The use of sustainable and green technology is also being implemented; this makes future developments to be aligned with the environment and the issue of ethics. In general, the field of nanodermatology is a perspective and rapidly developing area that can bridge the science and practice of dermatology in the future and offer safer, more effective, and patient-centered treatment.

References

1. Patra, J. K., Das, G., Fraceto, L. F., et al. (2018). Nano based drug delivery systems. *Journal of Nanobiotechnology, 16*(1), 71.
2. Nohynek, G. J., Dufour, E. K., & Roberts, M. S. (2008). Nanotechnology in cosmetics and dermatology. *Critical Reviews in Toxicology, 38*(3), 251–277.
3. Lademann, J., et al. (2013). Penetration of nanoparticles into human skin. *Skin Pharmacology and Physiology, 26*(4–6), 227–233.
4. Prow, T. W., et al. (2011). Nanoparticles and microparticles for skin delivery. *Advanced Drug Delivery Reviews, 63*(6), 470–491.
5. Barry, B. W. (2001). Novel mechanisms of drug delivery. *European Journal of Pharmaceutical Sciences, 14*(2), 101–114.
6. Benson, H. A. E., & Watkinson, A. C. (2012). *Topical and transdermal drug delivery*. Wiley.
7. Bouwstra, J. A., Ponec, M. (2006). Skin barrier in drug delivery. *Advanced Drug Delivery Reviews, 58*(1), 3–15.
8. Mitragotri, S., Burke, P. A., & Langer, R. (2014). Overcoming skin barrier. *Nature Reviews Drug Discovery, 13*(9), 655–672.
9. Dragicevic, N., & Maibach, H. I. (2016). *Percutaneous penetration enhancers*. Springer.
10. Singh, R., & Lillard, J. W. (2009). Nanoparticle-based drug delivery. *Experimental and Molecular Pathology, 86*(3), 215–223.
11. Etheridge, M. L., et al. (2013). Clinical translation of nanomedicine. *ACS Nano, 7*(9), 7582–7586.
12. Hare, J. I., et al. (2017). Challenges in nanomedicine translation. *Advanced Drug Delivery Reviews, 108*, 25–38.
13. Bobo, D., et al. (2016). Nanoparticle-based medicines review. *Pharmaceutical Research, 33*(10), 2373–2387.
14. Ventola, C. L. (2017). Progress in nanomedicine. *Pharmacy and Therapeutics, 42*(12), 742–755.
15. Wilhelm, S., et al. (2016). Nanoparticle delivery barriers. *Nature Reviews Materials, 1*, 16014.
16. Anselmo, A. C., & Mitragotri, S. (2019). Nanoparticles in medicine. *Bioengineering & Translational Medicine, 4*(3), e10143.
17. U.S. Food and Drug Administration. (2014). *Guidance for industry: Nanotechnology products*. FDA.
18. European Medicines Agency. (2011). *Reflection paper on nanotechnology-based medicinal products*. EMA.
19. World Health Organization. (2010). *Guidelines for clinical evaluation of drug products*. WHO Press.
20. ICH. (2016). *Guideline for good clinical practice E6(R2)*. International Council for Harmonisation.
21. Roberts, M. S., & Walters, K. A. (2007). *Dermatological and transdermal formulations*. CRC Press.
22. Kim, B. Y. S., Rutka, J. T., & Chan, W. C. W. (2010). Nanomedicine overview. *New England Journal of Medicine, 363*(25), 2434–2443.

23. Duncan, R., & Gaspar, R. (2011). Nanomedicine(s) regulatory challenges. *Molecular Pharmaceutics, 8*(6), 2101–2141.

24. Farokhzad, O. C., & Langer, R. (2009). Impact of nanotechnology in drug delivery. *ACS Nano, 3*(1), 16–20.

25. Jain, K. K. (2012). Nanomedicine clinical applications. *Methods in Molecular Biology, 948*, 1–12.

About Editors

Dr. Nicky Kumar Jaiswal is the Founder and Chief Executive Officer of The Article Architect, a specialized research support platform providing comprehensive assistance to Ph.D. scholars in research planning, scientific writing, journal targeting, and publication strategy. He earned his Doctor of Pharmacy (Pharm.D) degree from Adesh University, Punjab, and has previously served as an Assistant Professor and Course Coordinator at Desh Bhagat University. With extensive expertise in clinical pharmacy, pharmacovigilance, and drug safety monitoring, he has successfully bridged academic knowledge with clinical practice.Dr. Jaiswal has an outstanding publication record, with multiple articles published in reputed national and international journals, including 10 Scopus-indexed research papers in 2025 alone, in journals reaching an impact factor of 6. He is also the author of a Community Pharmacy textbook, a contributor to several book chapters, and the holder of pharmaceutical patents. His research interests include pharmacovigilance, gastroesophageal reflux disease, nanotechnology, infectious diseases, and clinical therapeutics, and he actively serves as a reviewer for international journals.

Anil Sah is the Founder and Chief of Research at Path Lab, Darbhanga, Bihar, a reputed diagnostic center known for accurate testing and quality reporting. He holds an M.Sc. in Chemistry from L.N.M.U., Darbhanga, and a D.M.L.T. from Bihar School of Health Education, and has served as a Senior Scientific Officer in pathology laboratories, gaining extensive experience in diagnostic sciences. Currently pursuing a Pharm.D. from Desh Bhagat University, Mandi Gobindgarh, Punjab, he integrates laboratory expertise with clinical practice to enhance patient care and healthcare outcomes. His research interests include pharmacovigilance, gastroesophageal reflux disease (GERD), infectious diseases, and hepatotoxicity, reflecting his commitment to advancing research and improving healthcare quality

Rimpy Hooda has completed her Bachelor of Pharmacy (B.Pharmacy) from BPS Mahila Vishwavidyalaya, Khanpur Kalan, Haryana, from 2013 to 2017. She further pursued a Master of Pharmacy (M.Pharmacy) with specialization in Pharmaceutical Chemistry from Kurukshetra University, Kurukshetra, in 2017. Currently, she has been pursuing her Doctor of Philosophy (Ph.D.) in Pharmaceutical Chemistry from Kurukshetra University since 2021, focusing on advanced research in drug discovery and computational chemistry. Her research interests primarily include Pharmaceutical Chemistry, Molecular Docking, and Computer-Aided Drug Design (CADD). She has developed expertise in in-silico drug design approaches, protein–ligand interaction studies, structure-based drug design, and virtual screening of bioactive compounds. Her work focuses on understanding drug–target interactions and identifying potential therapeutic compounds using computational tools and molecular docking techniques. She is also experienced in scientific research writing, preparation of research articles, and analysis of pharmaceutical and biomedical data. With a strong academic background and research orientation in computational drug discovery and medicinal chemistry, Rimpy is particularly interested in contributing to the editorial and peer-review process of pharmaceutical and biomedical journals. She is committed to maintaining high standards of scientific accuracy, research integrity, and quality publication in the field of pharmaceutical sciences.

Dr. Firdaus holds a Ph.D. and is currently working as an Assistant Professor in the School of Pharmacy, Sharda University, Greater Noida, Uttar Pradesh, India. She has 6 years of research experience and 3 years of teaching experience. She completed her B. Pharmacy from SHIATS, Allahabad (U.P.), and her M. Pharmacy (Pharmaceutical Chemistry), PGDRA, PGIPR, and Ph.D. from Jamia Hamdard, New Delhi, India. During her doctoral studies, she was awarded the Senior Research Fellowship (SRF) by the Indian Council of Medical Research (ICMR), New Delhi. Dr. Firdaus has published research and review articles in reputed national and international journals. She has also guided one Ph.D. scholar. Her research interests include synthetic chemistry, computational drug design, and herbal research.

Dr Savneet Kaur is an accomplished academician and researcher in the field of Chemistry, currently serving as an Associate Professor in the Department of Applied Sciences at Desh Bhagat University, Mandi Gobindgarh. She holds a Ph.D. in chemistry and has over 8 years of teaching and research experience. Her research expertise includes water quality assessment, heavy metal contamination, environmental chemistry, and antioxidant studies. Dr. Kaur has an impressive publication record in reputed national and international journals and has contributed to several books and book chapters in applied and environmental chemistry. She is also associated with a registered design/patent application, reflecting her innovation and research excellence. Her work involves advanced analytical instruments such as UV-Vis spectrophotometers, ICP-MS, and ion chromatography techniques. She actively supervises PhD scholars and has received multiple accolades, including Best Teacher and Young Scientist awards.

ISBN: 978-81-686-5990-2
e-ISBN

Mantra Publication
An International Publisher

ISBN: 978-81-686-5998-8
p-ISBN